CA2621202A1 - Method for analyzing genes of industrial yeasts - Google Patents

Method for analyzing genes of industrial yeasts Download PDF

Info

Publication number
CA2621202A1
CA2621202A1 CA002621202A CA2621202A CA2621202A1 CA 2621202 A1 CA2621202 A1 CA 2621202A1 CA 002621202 A CA002621202 A CA 002621202A CA 2621202 A CA2621202 A CA 2621202A CA 2621202 A1 CA2621202 A1 CA 2621202A1
Authority
CA
Canada
Prior art keywords
nucleotide sequence
seq
dna
gene
sequence represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002621202A
Other languages
French (fr)
Inventor
Toshihiko Ashikari
Yoshihiro Nakao
Norihisa Nakamura
Yukiko Kodama
Tomoko Fujimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Holdings Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2621202A1 publication Critical patent/CA2621202A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

An object of the present invention is to provide a method for analyzing gene of an industrial yeast. The method of the present invention comprises (a) analyzing the genome sequence of the industrial yeast; and (c-1) selecting a gene of the industrial yeast encoding an amino acid sequence having 70 to 97%
identity to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or (c-2) selecting a gene of the industrial yeast consisting of a nucleotide sequence having 60 to 94% identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae.

Description

DEMANDE OU BREVET VOLUMINEUX

LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:

NOTE POUR LE TOME / VOLUME NOTE:

DESCRIPTION
METHOD FOR ANALYZING GENES OF INDUSTRIAL YEASTS

Technical Field The present invention relates to a method analyzing genes of an industrial yeast used for the production of an alcoholic beverage such as beer or sake, a fuel alcohol, etc. and particularly for genes of brewing yeast used for the production of an alcoholic beverage. More particularly, it relates to a method where, in the production of an alcoholic beverage, DNA sequence information of brewing yeast is compiled in a database so that the gene which involves in increase in productivity and/or improvement in flavor such as stabilization, reinforcement, etc. of the flavor is selected; a method for breeding yeast suitable for the brewing in which expression of a gene is controlled, such as yeast in which the selected gene is disrupted or'yeast in which the gene is overexpressed; and a method for the production of an alcoholic beverage using the bred yeast.

Background Art Development of techniques for production of fuel alcohols, alcoholic beverages such as beer or sake, etc.
has been carried out using industrial yeast. Especially in the production of an alcoholic beverage using brewing yeast, there has been a brisk development in the techniques for increasing productivity and improving flavor such as stabilization or enhancement of flavor of an alcoholic beverage.

The most consumed alcoholic beverage in the world is beer and the amount of beer produced in the world in 2001 was about 140,000,000 kL. Type of beer i,s roughly classified into three depending upon types of yeast and fermentation methods. The three types are, naturally fermented beer where fermentation is carried out utilizing yeast and microorganisms inhabiting in breweries; ale-type beer where fermentation is carried out using a top fermenting yeast belonging to Saccharomyces cerevisiae (hereinafter, abbreviated as S. cerevisiae) at the temperature of 20 to 25 C and the following aging period is shortened; and lager-type beer where fermentation is carried out using a bottom fermenting yeast belonging to Saccharomyces pastorianus at the temperature of 6 to 15 C
and then subjected to a low-temperature aging. At present, not less than 90% of the beer produced in the world is a lager-type beer and, therefore, the bottom fermenting yeast that is used for brewing of the lager-type beer has been most widely used in beer brewing.

In the so-called fermentation production where production is carried out using a microorganism including the above-mentioned brewing yeast, it is important that the fermentation process is optimized and that the useful strain is selected and bred, in order to increase productivity and improve quality of the product.
In the case of optimization of beer brewing, a method where an amount of yeast metabolites such as alcohol (e.g.
ethanol), ester, organic acid, etc. are monitored, and then temperature, quantity of airflow, content of raw material, etc. are controlled, has been conducted. In such a case, material uptake and excretion by yeast cells and metabolism in the cells are handled as a black box and only very superficial control is carried out. In addition, for the purpose of giving, for example, high flavor to an alcoholic*

beverage, a process controling method to suppress the amount of oxygen supply during beer brewing or the like has been tried. In such a method, however, growth rate of the yeast itself is reduced due to insufficient oxygen, and adverse effects such as retardation of fermentation and/or deterioration of beer quality may arise. Accordingly, there has been a limit on the improvement in productivity and quality of beer by means of optimization of fermentation processes.

On the other hand, with regard to a method of breeding useful industrial yeast such as useful beer yeast, a technique for selecting a desirable strain has widely been used rather than actual breeding. Beer brewing per se has been performed since well before the discovery of microorganisms by Pasteur. In the beer brewing, a method of selecting a more suitable strain of beer yeast from many strains of yeast used in the beer brewery has been traditionally carried out while there have been few cases where beer yeast with good traits is positively bred.
As an example of a positive breeding method, there is a method where artificial mutagenesis by chemicals or radioactive rays is used. However, brewing yeast, particularly a bottom fermenting yeast which is widely used in beer brewing, is in many cases a polyploid. In that case, it is not possible to produce a desired mutant unless mutation takes place in all of the alleles to be mutated.
Accordingly, although it is possible to induce a desirable mutation in the case of a haploid laboratory yeast, it is substantially impossible in the case of beer yeast which is a polyploid.

In recent years, a breeding where mutation or cross-breeding is carried out by using spores isolated from bottom fermenting yeast (c.f.., for example, Non-Patent Document 1) has been tried. However, the bottom fermenting yeast is a polyploid, and has complicated chromosome structure. Therefore, isolation of spores having a proliferation ability is difficult, and moreover, it is almost impossible to obtain a strain with good traits from them.

On the other hand, it has recently become possible that desired genes are introduced and expressed in the brewing yeast using a genetic engineering technique, whereby it has become possible to breed yeast with the desired character by using the results of functional analysis of genes and the genes which have been functionally analyzed. However, as compared with the baker's yeast (S. cerevisiae; c.f., for example, Non-Patent Document 2) of which the whole genome sequence is already clarified, the genome sequence of the bottom fermenting yeast has not been clarified and there have been only a very few findings about the bottomfermenting yeast specific gene involved in brewing character specific to bottom fermenting yeast and about the function of the said gene during beer brewing.

In recent years, transcriptome analysis has been conducted using DNA array where DNA fragments or nucleotide oligomers, each of which has a partial sequence of structural genes or internal regions of the chromosomes are fixed on solid support. For example, Olesen, et al.
conducted a comprehensive genetic expression analysis of bottom fermenting yeast during the brewing using GeneFilters (manufactured by Research Genetics Co.)(c.f., for example, Non-Patent Document 3). However, since the genome sequence of bottom fermenting yeast has not been clarified yet, it is ambiguous that which gene is monitored for its expression precisely. Thus, the information about bottom fermenting yeast is quite insufficient to apply to metabolic analysis, and to breeding of useful yeast, and to control of beer brewing process.

At present, the whole genome sequences of more than 100 species of microorganisms have been determined (c.f., for example, Non-Patent Document 6) including S.

cerevisiae, Escherichia coli (c.f., for example, Non-Patent Document 4) and Mycobacterium tuberculosis (c.f., for example, Non-Patent Document 5). On the basis of the determined DNA sequences, genes of these microorganisms are identified and function of an enormous number of genes have been predicted without conducting genetic, biochemical or molecular biological experiments. However, industrial yeast such as brewing yeast which has high ploidy and a complicated chromosome structure, and thus an assembly (an operation for connecting the DNA sequences) is presumed to be difficult. Therefore, the genome sequence of bottom fermenting yeast which contains two different types of genome (c.f., for example, Non-Patent Document 7) has not been reported yet.

In the production of specific alcohols or alcoholic beverages, there is a technique to increase concentration of sulfite in the product for the control of flavor.

Sulfite is known as a compound which has anti-oxidative activity, and has been widely used as an antioxidant in the fields of food, beverage and pharmaceuticals, and also in an alcoholic beverage. For example, in the case of wine that requires a long aging period, sulfite plays an important role for the preservation of its quality. It is also known that, in beer brewing, the quality preservation period becomes long in accordance with the increase in concentration of sulfite contained in the product. Thus, when the amount of sulfite in the product is increased, it is possible to prepare a product that has excellent flavor stability and a long quality preservation period.

The simplest way to increase the amount of sulfite in the product is addition of sulfite. In Japan, so far as wine is concerned, it is permitted by the Ministry of Health, Labor and Welfare to add sulfite to an extent of not more than 350 ppm in terms of residual sulfite concentration. In that case, however, since sulfite is categorized as,food additives, it is not desirable to add sulfite to beer when a negative image of consumers to food additives is taken into consideration.

However, the yeast used in brewing produces hydrogen sulfide by the reduction of sulfate in the medium in order to synthesize sulfur-containing metabolites such as sulfur-containing amino acids. Sulfite is an intermediate metabolite of this pathway. If sulfite is efficiently excreted outside of the cells during fermentation period, it is possible to increase the amount of sulfite both in the wort and in the product.

There are two methods for increasing sulfite concentration in the wort during fermentation. One is to control a fermentation process and another is to breed brewing yeast. As for the control of fermentation process, the amount of sulfite produced during fermentation is inversely proportional to the concentration of dissolved oxygen and, therefore, there has been an attempt of a method where the concentration of dissolved oxygen is reduced so that the amount of sulfite is increased and at the same time the oxidation of sulfite is suppressed.
However, in that method, growth rate of yeast is reduced due to the lack of oxygen, which has negative effects such as retardation of fermentation and deterioration of quality. Therefore that method is not practical.

On the other hand, as mentioned above, a genetic engineering technique has been developed for breeding brewing yeast. For example, there are some reports focused on sulfur metabolism of yeast. Sulfite (S02) is an intermediate product of sulfur-containing amino acid and vitamin synthesis and is produced via a pathway of sulfate ion (S042-) - APS (adenyl sulfate) - PAPS (phosphoadenylyl sulfate )- sulfite ion ( S032- ) where the sulfate ion is incorporated from outside of the cells. There is an attempt in which copy numbers of MET 3 gene participating in the reaction of sulfate ion ( SO4a- 2-APS (adenylyl sulfate) and of MET 14 gene participating in the reaction of APS (adenylyl sulfate) - PAPS (phosphoadenylyl sulfate) are increased to improve the ability of the yeast for the production of sulfite (c.f., for example, Non-Patent Document 8). There is another example of an attempt where reduction of sulfite ion (S032-) is inhibited by the disruption of MET 10 gene whereby amount of sulfite produced by the yeast is increased (c.f., for example, Non-Patent Document 9). According to such attempts, the amount of sulfite produced by an MET 10 gene disruptant is increased to an extent of not less than ten-fold of the parental strain , but on the other hand, some retardation in fermentation and increase in the amounts of acetaldehyde and 1-propanol in the beer are noted, which has become a problem for the practical use.
Accordingly, although~development of breeding methods for industrial yeast such as brewing yeast using genetic engineering have been in progress, it is the current status that, due to insufficient genomic information of brewing yeast, selection of the brewing yeast specific gene ----involved in a brewing character of brewing yeast, analysis of function of protein encoded by the gene and utilization of those findings for breeding have not been sufficiently carried out.

Thus, a method for breeding yeast which shows the desired character without deterioration of fermentation speed and product quality has not been established yet and there has been a big demand for the development of such a method not only in the brewing industry but also in the industries where the yeast is used.

(Non-Patent Document 1) C. Gjermansen: "Construction of a hybrid brewing strain of Saccharomyces carlsbergensis by mating of ineiotic segregants", Carlsberg Res. Commun., volume 46, pages 1 to 11 (1981).

(Non-Patent Document 2) A. Goffeau, et al.: "The Yeast Genome Directory", Nature, volume 387, pages 5 to 105 (1997).

(Non-Patent Document 3) K. Olesen, et al.: "The dynamics of the Saccharomyces carlsbergensis brewing yeast transcriptome during a production-scale lager beer fermentation", FEMS Yeast Research, volume 2, pages 563 to 573 (2000).
(Non-Patent Document 4) F. R. Blattner, et al.: "The Complete Genome Sequence of Escherichia coli K-12", Science, volume 277, pages 1453-1462 (1997).

(Non-Patent Document 5) S. T. Cole, et al.;

"Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence", Nature, volume 393, pages 537-544 (1998).

(Non-Patent Document 6) The National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov/PMGifs/Genomes/micr.html.
(Non-Patent Document 7) Y. Tamai et al.:"Co-existence of two types of chromosome in the fermenting yeast, Sacchaomyces cerevisiae", Yeast, volume 10, pages 923-933 (1998).

(Non-Patent Document 8) C. Korch, et al.: Proc. Eur.
Brew. Conv. Congress, Lisbon, pages 201-208 (1991).
(Non-Patent Document 9) J. Hansen, et al.:

"Inactivation of MET 10 in brewer's yeast specifically increases SO2 formation during beer production", Nature Biotech., volume 14, pages 1587-1591 (1996).

(Non-Patent Document 10) T. Sijen, et al.:
"Transcriptional and posttranscriptional gene silencing are mechanistically related", Curr. Biol., volume 11, pages 436-440 (2001).

(Non-Patent Document 11) N. Goto, et al.: "SSU1-R, a sulphite resistance gene of wine yeast, is an allele of SSU
1 with a different upstream sequence", J. Ferment. Bioeng., volume 86, pages 427-433 (1998).

(Non-Patent Document 12) D. Avram, et al.: "SSU 1 encodes a plasma membrane protein with a central role in a network of proteins conferring sulfite tolerance in Saccharomyces cerevisiae", J. Bacteriol., volume 179, pages 5971-5974 (1997).

(Non-Patent Document 13) H. Park, et al.; "SSU 1 mediates sulphite efflux in Saccharomyces cerevisiae", Yeast, volume 16, pages 881-888 (2000).

Disclosure of the Invention An object of the present invention is to provide a method of analyzing and selecting genes relating to the desired brewing characters, which is achieved in such a manner that a database compiling the genome sequence (hereinafter, may be abbreviated as genomic DB) of industrial yeast, particularly brewing yeast used for an alcoholic beverage such as beer, is prepared; gene that the brewing yeast possesses is selected from the database;
functional analysis of the gene may be carried out by disruption or overexpression. Another object of the present invention is to provide a DNA array which is useful for an analyzing method of genes of an industrial yeast.
Further object is to provide a breeding method of the yeast showing the brewing character which the said gene is relating to and also a method of producing an alcohol or an alcoholic beverage where productivity and quality are improved using the said yeast. Still another object is to provide genes mentioned above and peptides encoded by the said genes.

It has been known that brewing yeast widely used for industrial purpose is a polyploid and especially, bottom fermenting yeast is an allopolyploid which is composed of at least two kinds of genomes. One of the genomes is thought to be a genome derived from S. cerevisiae of which the whole genome sequence has been clarified, while the source of another genome(s) has not been clarified yet.

The present inventors have analyzed the genome sequence of the bottom fermenting yeast in order to find unidentified genes displaying essential functions for excellent brewing. The amino acid sequences of the bottom fermenting yeast were then compared with those registered in the genomic DB for S. cerevisiae, and functions of proteins encoded by genes of the brewing yeast were estimated. As a result, it has been clarified that the genes of the bottom fermenting yeast are roughly classified into Sc type genes showing nearly 100% amino acid identity to those of S. cerevisiae and non-Sc type genes showing around 70 to 97% amino acid identify (this corresponds to around 60 to 94% identity in nucleotide level). Moreover, it has been clarified that the bottom fermenting yeast has a complicated chromosome structure consists of Sc-type chromosomes, non-Sc-type chromosomes and Sc/non-Sc-type chimera chromosomes. Structure of the whole chromosomes of the bottom fermenting yeast is shown in Fig. 1. On the basis of genomic information clarified by the present invention, the present inventors have found such an unexpectedly complicated structure of chromosomes, and developed a screening method for the genes of bottom fermenting yeast.

To be more specific, the inventors have achieved a method for analyzing gene of an industrial yeast comprising (a) analyzing nucleotide sequence of the genome of the industrial yeast, particularly bottom fermenting yeast which is one of the brewing yeasts,; and (c-1) selecting a gene of the industrial yeast encoding an amino acid sequence having 70 to 97% identity to an amino acid.sequence encoded by the gene of Saccharomyces cerevisiae, or (c-2) selecting a gene of the industrial yeast consisting of a nucleotide sequence having 60 to 94%
identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae.

Preferably, the method of the present invention comprises, (b)= comparing the genome sequence with the genome sequence of Saccharomyces cerevisiae after the step (a) and before the step (c-1) or (c-2).
Preferably, the analyzing method of the present invention comprises, (d) carrying out functional analysis of the selected gene, after the step (c-1) or (c-2), whereby the brewing character given to the yeast by the genes are identified. The present inventors have repeatedly carried out intensive investigations on the basis of those findings and accomplished the present invention.

Thus, the present invention includes the following embodiments:

1. A method for analyzing gene of an industrial yeast comprising (a) analyzing nucleotide sequence of the genome sequence of the industrial yeast; and (c-i) selecting a gene of the industrial yeast encoding an amino acid sequence having 70 to 97% identity to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or (c-2) selecting a gene of the industrial yeast consisting of a nucleotide sequence having 60 to 94%
identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae.

2. The analyzing method according to Embodiment 1, comprising, (b) comparing the genome sequence of the industrial yeast with that pf the genome sequence of Saccharomyces cerevisiae after the step (a) and before the step (c-1) or (c-2).

3. The analyzing method according to Embodiment 1 or 2, comprising (d) carrying out functional analysis of the selected gene after the step (c-1) or (c-2).

4. The analyzing method according to Embodiment 3, which comprises screening genes involved in increase of productivity and/or improvement in flavor in the production of an alcohol or an alcoholic beverage by the functional analysis of the step (d).

5. The analyzing method according to Embodiment 3 or 4, wherein the functional analysis is performed by disruption of a gene or overexpression of a gene.

6. The analyzing method according to any of Embodiments 1-5, wherein the industrial yeast is a brewing yeast.

7. The analyzing method according to Embodiment 6, wherein the brewing yeast is a beer yeast.

8. The analyzing method according to Embodiment 7, wherein the beer yeast is a bottom fermenting yeast.

9. A gene of the industrial yeast encoding an amino acid sequence having 70 to 97% identity to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or consisting of a nucleotide sequence having 60 to 94%
identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae, which is obtained by the analyzing method according to any one of Embodiments 1-8.
10. A gene library comprising one or more of genes of the industrial yeast each of which encodes an amino acid sequence having 70 to 97% identity to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or consists of a nucleotide sequence having 60 to 94%
identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae, which is obtained by the analyzing method according to any one of Embodiments 1-8.
11. The gene library according to Embodiment 10, wherein the gene of the industrial yeast is comprised in, consists of or has any nucleotide sequence selected from SEQ ID NOs:33 to 6236, SEQ ID NOs:166154 to 166181, SEQ ID

NOs:166490 to 167042 and SEQ ID NOs:173125 to 174603.
12. A DNA array comprising one or more of DNAs, wherein each DNA is selected from at least one group of (1) to (4):

(1) DNA consisting of a nucleotide sequence of an open reading frame of the genome sequence of an industrial yeast which encodes an amino acid sequence having 70 to 97%
identity to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or a nucleotide sequence complementary to the above nucleotide sequence, or a nucleotide sequence of continuous 10 or more nucleotides selected from the above nucleotide sequences;

(2) DNA consisting of a nucleotide sequence of the genome sequence of an industrial yeast other than from open reading frames which consists of a nucleotide sequence having 60 to 94% identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae, or a nucleotide sequence complementary to the above nucleotide sequence, or a nucleotide sequence of continuous 10 or more nucleotides selected from the above nucleotide sequences;

(3) DNA having a nucleotide sequence of any of SEQ ID
NOs:166490 to 167042, or DNA having a nucleotide sequence of any of SEQ ID NOs:167043 to 173124;and (4) DNA having a nucleotide sequence of any of SEQ ID
NOs:173125 to 174603, or DNA having a nucleotide sequence of any of SEQ ID NOs:174604 to 190810.
13. The DNA array according to Embodiment 12 comprising DNAs wherein at least one DNA is selected from every group of (1) to (4).
14. The DNA array according to Embodiment 12 or 13, wherein the DNAs of (1) is comprised in, consists of or has any nucleotide sequence selected from SEQ ID NOs:33 to 6236, SEQ ID NOs:166154 to 166181, SEQ ID NOs:6237 to 75336 and SEQ ID NOs:166182 to 166489.
15. The DNA array according to any one of Embodiments 12-14, which further comprises, in addition to at least one group of DNAs selected from (1) to (4), DNAs of the following (5) and/or (6),:

(5) DNA consisting of a nucleotide sequence of an open reading frame of the genome sequence of an industrial yeast which encodes an amino acid sequence having identity of more than 97% to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or a nucleotide sequence complementary to the above nucleotide sequence, or a nucleotide sequence of continuous 10 or more nucleotides selected from the above nucleotide sequences; and (6) DNA consisting of a nucleotide sequence of the genome sequence of an industrial yeast other than from open reading frames which consists of a nucleotide sequence having identity of more than 94% to the nucleotide sequence of the gene of Saccharomyces cerevisiae, or a nucleotide sequence complementary to the above nucleotide sequence, or a nucleotide sequence of continuous 10 or more nucleotides selected from the above nucleotide sequences, and optionally comprises DNAs of the following (5') and/or (6'):

(5') DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (5), or a nucleotide sequence complementary to the above nucleotide sequence; and (6') DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (6), or a nucleotide sequence complementary to the above nucleotide sequence.
16. The DNA array according to Embodiment 15, wherein the DNAs of (5) has a nucleotide sequence of any one of SEQ
ID NOs:75337 to 82784, or SEQ ID NOs:82785 to 166153.
17. The DNA array according to any one of Embodiments 12-16, which comprises, in addition to at least one group of DNAs selected from (1) to (4), DNAs selected from at least one of (7) to (10):

(7) DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (1), or a nucleotide sequence complementary to the above nucleotide sequence;

(8) DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (2), or a nucleotide sequence complementary to the above nucleotide sequence;
(9) DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (3), or a nucleotide sequence complementary to the above nucleotide sequence; and (10) DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (4), or a nucleotide sequence complementary to the above nucleotide sequence.

18. The DNA array according to Embodiment 17, which comprises, in addition to at least one group of DNAs selected from (1) to (4), DNAs selected from at least one of (7-1) to (10-1):

(7-1) DNA consisting of a nucleotide sequence which contains mismatch of 1 base to the DNA of (1), or a nucleotide sequence complementary to the above nucleotide sequence;

(8-1) DNA consisting of a nucleotide sequence which contains mismatch of 1 base to the DNA of (2), or a nucleotide sequence complementary to the above nucleotide sequence;

(9-1) DNA consisting of a nucleotide sequence which contains mismatch of 1 base to the DNA of (3), or a nucleotide sequence complementary to the above nucleotide sequence; and (10-1) DNA consisting of a nucleotide sequence which contains mismatch of 1 base to the DNA of (4), or a nucleotide sequence complementary to the above nucleotide sequence.
19. The DNA array according to any one of Embodiments 12-18, which comprises at least one group of DNAs selected from (1) to (4), at least one group of DNAs selected from (7) to (10), DNAs of (5) and/or (6) and DNAs of (5') and/or (6').
20. The DNA array according to any one of Embodiments 12-19, wherein the DNAs are oligonucleotides consisting of 10-30 nucleotides.
21. Use of the DNA array according to any one of Embodiments 12-20 as an analyzing method of genes of an industrial yeast.
22. A method for classifying an industrial yeast comprising (a) hybridizing genomic DNA prepared from the industrial yeast to the DNA array of any one of Embodiments 15-20 and (b) calculating hybridization ratio to any of (1) to (4), and hybridization ratio to (5) and/or (6).
23. The method for classification according to Embodiment 22, wherein the DNA array of Embodiment 19 is used, and percentage of genes which hybridize to DNAs of (1) and/or (2), but not to DNAs of (7) and/or (8) is determined as hybridization ratio to any of (1) to (4), and percentage of genes which hybridize to DNAs of (5) and/or (6), but not to DNAs of (5') and/or (6') is determined as hybridization ratio to any of (5) and/or (6).
24. A method for detecting nucleotide polymorphism in genome of an industrial yeast comprising (a) hybridizing genomic DNA prepared from the industrial yeast to the DNA array of any one of Embodiments 17-20; and (b) selecting a gene wherein hybridization intensity to the DNAs of any of (7) to (10) is higher than hybridization intensity to the DNAs of any of (1) to (4).
25. A method for screening a useful strain of industrial yeast, comprising (a) hybridizing genomic DNA prepared from the industrial yeast strain to the DNA array of any one of Embodiments 12-20; and (b) determining the industrial yeast strain as useful when the strain contain 1 or more genes wherein hybridization intensity thereof is 1.5 times higher, or 2/3 or less compared to an average hybridization intensity to the DNAs of any of (1) to (4).
26. A method for screening a gene olf an industrial yeast, comprising (a) hybridizing genomic DNA prepared from the industrial yeast strain to the DNA array of any one of Embodiments 12-20; and (b) selecting a gene wherein hybridization intensity thereof is 1.5 times higher, or 2/3 or less compared to an average hybridization intensity to the DNAs of any of (1) to (4).

. 27. A method for screening a gene of an industrial yeast, comprising (a-1) hybridizing genomic DNA, cDNA or cRNA prepared from the industrial yeast to the DNA array of any one of Embodiments 12-20;

(a-2) independently from the step (a-1), hybridizing genomic DNA, cDNA or cRNA prepared from another industrial yeast of any one of Embodiments 12-20; and (b) selecting a gene wherein hybridization intensity thereof to the DNAs of any of (1) to (4) in the step (a-1) is significantly different from hybridization intensity thereof in the step (a-2).

28. A method for screening a gene of an industrial yeast, comprising (a-1) hybridizing cDNA or cRNA prepared from the industrial yeast to the DNA array of any one of Embodiments 12-20;

(a-2) independently from the step (a-1), hybridizing cDNA
or cRNA prepared from the industrial yeast to the DNA array of any one of Embodiments 12-20, wherein the industrial yeast of (a-2) has been cultured in a different condition from the culture condition for the industrial yeast of (a-1); and (b) selecting a gene wherein hybridization intensity thereof to the DNAs of any of (1) to (4) at the step (a-1) is significantly different from hybridization intensity thereof at the step (a-2).

29. A gene obtained by the screening method of any one of Embodiments 26-28.

30. The gene according to Embodiment 9 or 29 characterized in that concentration of sulfite in a culture medium of an industrial yeast increases when the gene is expressed in the yeast.

31. A nucleic acid encoding a polypeptide of any one of the following i) and ii):

i) a polypeptide having the amino acid sequence represented by SEQ ID NO:3, and ii) a polypeptide having an amino acid sequence wherein one or more amino acid residue(s) is deleted from, substituted for and/or added to the amino acid sequence represented by SEQ ID NO:3, and having an activity to increase concentration of sulfite in a culture medium of an industrial yeast when the gene is expressed in the yeast.

32. The nucleic acid according to Embodiment 31, which is selected from the following a) and b):

(a) a nucleic acid having the nucleotide sequence represented by SEQ ID NO:1; and (b) a nucleic acid having a nucleotide sequence which hybridizes to the nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:1 under a stringent condition, and encodes a polypeptide having an activity to increase concentration of sulfite in a culture medium of an industrial yeast when the gene is expressed in the yeast.

33. A recombinant vector containing the gene of Embodiment 9 or Embodiments 29-30, or the nucleic acid of Embodiment 31-32.

34. A transformant comprising the recombinant vector of Embodiment 33.

35. The transformant according to Embodiment 34, which is a yeast of genus Saccharomyces.

36. A polypeptide of any one of the following i) and ii):

i) a polypeptide having the amino acid sequence represented by SEQ ID NO:3; and ii) a polypaptide having an amino acid sequence wherein one or more amino acid residue(s) is deleted from, substituted for and/or added to the amino acid sequence represented by SEQ ID N:3, and having an activity to increase concentration of sulfite in a culture medium of an industrial yeast when the gene is expressed in the yeast.

37. The polypeptide according to Embodiment 36, which is encoded by a nucleic acid selected from the following a) and b):

(a) a nucleic acid having the nucleotide sequence represented by SEQ ID NO:1; and (b) a nucleic acid having a nucleotide sequence which hybridizes to the nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID No.1 under a stringent condition, and encodes a polypeptide having an activity to increase concentration of sulfite in a culture medium of an industrial yeast when the gene is expressed in the yeast.

38. A method for producing an alcohol or an alcoholic beverage, using the transformant of Embodiment 34 or 35.

39. A breeding method of yeast which is suitable for \the production of an alcohol or an alcoholic beverage, characterized in that, expression of the gene of Embodiment 9 or Embodiments 29-30, or the nucleic acid of Embodiments 31-32 is controlled.

40. The breeding method according to Embodiment 39, wherein the yeast belongs to the genus Saccharomyces.

41. Yeast obtained by the breeding method of Embodiment 39 or 40.

42. A method for producing an alcohol or an alcoholic beverage using the yeast mentioned in Embodiment 41.

43. An alcohol or an alcoholic beverage which is produced by the producing method of Embodiment 42.

44. A method for analyzing gene of an industrial yeast comprising (c-i) selecting a gene of the industrial yeast encoding an amino acid sequence having 70 to 97% identity to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or (c-2) selecting a gene of the industrial yeast consisting of a nucleotide sequence having 60 to 94%
identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae.

Brief Description of the Drawing Fig. 1 shows total chromosome structures of bottom fermenting yeast. A white bar represents an Sc type chromosome while a black bar represents a non-Sc type chromosome. An ellipse represents a centromere. Roman numerals show chromosome numbers for the corresponding S.
cerevisiae. In a drawing which shows a non-Sc chromosome, a part marked out in black shows that ligation takes place at the region. For example, in nonScII-nonScIV, it is shown that nonSciI and nonScIV are ligated at the part marked out in black (300 kb).

Fig. 2 shows a distribution of identify of the DNA
sequence at both ends of 3648 cosmids prepared from the genomic DNA of strain 34/70 with the genome sequence of S.

cerevisiae. The X-axis shows the identity to S. cerevisiae and, for example, 84% on the X-axis shows an identity of more than 82% and not more than 84%. The Y-axis shows the numbers of cosmid end sequences showing the identity.

Fig. 3 shows a mapping example of cosmid and shotgun clones to genome sequence of S. cerevisiae. (1) and (2) show genes existing on Watson strand and Crick strand on the chromosome XVI of S. cerevisiae, respectively. (3)and (4) show Sc type and non-Sc type DNA fragments inserted in cosmid clones, respectively. (5) and (6) show Sc type and non-Sc type DNA fragments inserted in shotgun clones, respectively.

Fig. 4 shows a mapping example of contigs to the genome sequence of S. cerevisiae. (A) is a schematic depiction of Chromosome XVI of S. cerevisiae. (B) is a drawing where the parts of 857 to 886 kb of the Chromosome XVI of S. cerevisiae is enlarged. Y-axis indicates %
identity of contigs with S. cerevisiae genome sequence. X-axis indicates position of contigs against S.cerevisiae genome sequence. Contigs (solid lines) are connected with the forward-reverse links (dot lines) from the shotgun and cosmid reads, respectively.

Fig. 5 shows the result of DNA array-based comparative genomic hybridization. The genomic DNA of strain 34/70 was hybridized to a DNA array (Affymetrix Gene Chip Yeast Genome S98 Array) and the signal of each ORF (open reading frame) was normalized to that of the haploid strain S288C
and shown as Signal Log Ratio (2n). Signal Log Ratios were lined following gene order in Chromosome XVI. The non-Sc type genes do not hybridize to this Sc type array, therefore, the points (indicated by arrows) where the Signal Log Ratios show vigorous changes were considered to be translocation sites.

Fig. 6 shows the structure of the Chromosome XVI of strain 34/70 deduced from DNA array and PCR analysis.
Fig. 7 shows the fermentation profiles of SSU1 disruptants and parental strain (BH96). a) shows yeast growth(OD 600), b) shows the change of apparent extract (w/w %) and c) shows sulfite concentration(ppm).

Fig. 8 shows the fermentation profiles of SSU1 overexpressed strains and parental strain (BH225). a) shows yeast growth(OD 600), b) shows the change of apparent extract (w/w %) and c) shows sulfite concentration(ppm).
Fig. 9 shows the change of sulfite concentration during fermentation using MET14 overexpressed strains and parental strains (KN009F and FOY227).
Fig. 10 shows DNA sequences of ScSSUl and non-ScSSUl.
Fig. 11 shows DNA sequences of ScMET14 and non-ScMET14.

Fig. 12 shows the fermentation profiles of strain 34/70. a) shows yeast growth(OD 600) and b) shows the change of apparent extract (w/w %).

Embodiments for Carrying Out the Invention I. A method for analyzing gene of an industrial yeast The present invention provides a method for analyzing gene of an industrial yeast. The present method comprises (c-1) selecting a gene of the industrial yeast encoding an amino acid sequence having 70 to 97% identity to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or (c-2) selecting a gene of the industrial yeast consisting of a nucleotide sequence having 60 to 94%
identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae.

In a preferred ambodiment, the method of the present invention omprises, (a) analyzing nucleotide sequence of the genome sequence of the industrial yeast, before the step (c-1) or (c-2).In a preferred embodiment, the method of the present invention comprises, (b) comparing the genome sequence with the genome sequence of Saccharomyces cerevisiae, after the step (a), if any, and before the step (c-1) or (c-2).
In a preferred embodiment, the analyzing method of the present invention further comprises the step of d) carrying out functional analysis of the selected gene, after the step (c-1) or (c-2).

With regard to the industrial yeast in the present invention, brewing yeast for beer, wine, sake, etc. and yeasts used for the production of fuel alcohols are exemplified. To be more specific, yeast of genus Saccharomyces, etc. may be listed, and in the present invention beer yeasts such as Saccharomyces pastorianus Weihenstephan 34/70, NCYC456, NBRC 1951, NBRC 1952, NBRC
1953, NBRC 1954, etc. may be used. It is also possible to use whisky yeasts such as S. cerevisiae NCYC 90, etc., wine yeasts such as Kyokai wine yeast No. 1, No. 3, No. 4, etc., sake yeasts such as Kyokai sake yeast No. 7, No. 9, etc.
and the like.

Preferably, the industrial yeast of the present invention is a brewing yeast, more preferably, a beer yeast. Most preferably, the industrial yeast of the present invention is a bottom fermenting yeast. The bottom fermenting yeast means a yeast used for the lager beer production. Some strains of beer yeasts, such as Saccharomyces pastorianus Weihenstephan 34/70, NCYC456 or the like are classified as bottom fermenting yeasts. The strain used in the following Examples is one of the bottom fermenting yeasts commonly used for the lager beer production. The most of the bottom fermenting yeasts seem to have almost the same genome with that of strain 34/70.
It is also possible to breed yeast having an excellent brewing character when the gene obtained by the method of the present invention is used for carrying out an expression control in such a way that the gene is overexpressed in the yeast, and/or the gene is disrupted.
Accordingly, the gene which is obtained by the method of the present invention, peptide which is encoded by the gene, a breeding method of an industrial yeast using the gene, yeast which is obtained by the breeding method, and a method for the production of an alcohol or an alcoholic beverage using the yeast are also within a scope of the present invention.

(A) Analysis of nucleotide sequence of the genome sequence of industrial yeast If the genome sequence of a target industrial yeast is not determined, "anayzing" at the step (a) can maen determining the genome sequence of industrial yeast. In the present specification, the "genome sequence" means the whole genome sequence or a part of the genome sequence.

If the genome sequence of a target industrial yeast is determined, "anayzing" in step (a) can mean obtaining information regarding the genome sequence of a target industrial yeast from an appropriate source, for example, from a publicly available database.

Determination of the genome sequence of an industrial yeast can be achieved by any conventional methods. For example, it includes the steps of (a) genomic DNA is prepared from yeast, (b) shotgun library and (c) cosmid library are prepared from those genomic DNA, (d) DNA
fragments to be used for determination of DNA sequence are prepared from those library clones, (e) DNA sequence of the library DNA fragments is determined by a sequence reaction and (f) the sequences of those DNA fragments are assembled to reconstruct the genome sequence. Both or either one of (b) shotgun library and (c) cosmid library may be prepared for this purpose.

There is no particular limitation for the methods used for (a) to (f) and the method may be conducted according to the known means, while preferred method for each of them is mentioned below.

(a) Preparation such as extraction, purification, etc.
of the genomic DNA is preferably carried out in accordance with the known methods, for example, in "Yeast, a practical approach (IRL Press, 6.2.1, p. 228)" and "Seibutukagakujikkennhou, No. 39, Experiments in Yeast Molecular Genetics (edited by Yasuharu Oshima, Gakkai Shuppan Center, pages 84 to 85, 1996)". The specific examples of the preferred method for the preparation of DNA
are mentioned below.

Yeast cells for the preparation of genomic DNA are cultured by a common method. With regard to a medium, any of natural and synthetic media may be used so far as the medium contains carbon source, nitrogen source, inorganic salt, etc. which are able to be metabolized by the yeast, whereby cultivation of the microorganism can be efficiently carried out. For example, YPD medium (2% (w/w) glucose, 1%

(w/w) yeast extract and 2% (w/w) polypeptone) may be used.
With regard to a method of incubation, incubation by shaking at about 25 to 35 C through the night is recommended.

After the cultivation, cells are recovered from the culture medium by centrifugation. The resulting cell pellet is washed with a washing solution. Example of the washing solution is buffer A (50 mM sodium phosphate, 25 mM
EDTA and 1% (v/v) (3-mercaptoethanol; pH 7.5), etc.

Preparation of the genomic DNA from the washed cells may be carried out according to a common preparation method of genomic DNA where cell walls are lysed using Zymolyase and SDS; protein, etc. are removed using a phenol and phenol/chloroform solution; and genomic DNA is precipitated using ethanol or the like. To be more specific, the following method may be exemplified.

Cultivated cells are washed and resuspended in buffer A, then about 5 to 10 mg of Zymolyase 100T (Seikagaku Kogyo) are added and the mixture is gently shaken at about 25 to 40 C for about 30 minutes to 2 hours. After the shaking, buffer containing SDS such as buffer B (0.2 M
Tris-HC1, 80 mM EDTA and 1% SDS; pH 9.5) is added thereto and the mixture is allowed to stand at about 60 to 70 C for about 30 minutes to lyse the cells. After that, the cell lysate is cooled on ice, mixed with 5 M potassium acetate and allowed to stand on ice for about 60 minutes further.
The resulting solution is centrifuged (for example, at 5,000 g for 10 minutes at 15 C) to take supernatant. The same volume of ethanol is added to the supernatant to precipitate DNA and the mixture is immediately centrifuged (for example, at 5,000 g for 10 minutes at 15 C) to obtain DNA. The resulting precipitate is washed with 70% (v/v) ethanol, subjected to natural drying and dissolved in a solution such as TE buffer (10 mM Tris-HC1 and 1 mM EDTA;
pH 8.0) to give a crude genomic DNA solution. Cesium chloride and bisbenzimide are added to and dissolved in the crude genomic DNA solution, the mixed solution is subjected to an ultracentrifugal separation (for example, at 100,000 g for 17 hours at 25 C), irradiation with UV light is conducted so that the DNA bands are visualized and the lower band is recovered. Bisbenzimide is removed by extracting the recovered DNA solution with isopropanol which is saturated with cesium chloride solution, then 4-fold by volume of 0.3 M sodium acetate are added to the recovered aqueous layer followed by mixing and the DNA is precipitated by ethanol and recovered by centrifugation.
The recovered DNA is treated with RNase and extracted with phenol/chloroform and DNA is purified from the recovered aqueous layer by precipitation with ethanol again. The precipitate recovered by centrifugation is washed with 70%
(v/v) ethanol, subjected to natural drying and dissolved in a TE buffer to prepare the genomic DNA solution.

(b) Preparation of a shotgun library As to a method for the preparation of a genomic DNA
library using the genomic DNA of yeast prepared in the above (a), a method mentioned in "Molecular Cloning, A

Laboratory Manual, Third Edition (2001)" (hereinafter, abbreviated as "Molecular Cloning, Third Edition") may be used and, with regard to a method for the preparation of a shotgun library which is particularly suitable for the determination of the genome sequence, the following method may be exemplified.

A TE buffer is added to the genomic DNA prepared in (a) and the genomic DNA is fragmented using Hydroshear (manufactured by GeneMachines) or the like. Terminal of the genome fragment is blunted using a DNA Blunting Kit (manufactured by Takara Shuzo) or the like, and fractionated by means of an agarose gel electrophoresis.
Then, genome fragments of about 1.5 to 2.5 kb are excised from the gel and a buffer for the elution of DNA such as an MG-elution buffer (0.5 mol/L ammonium acetate, 10 mmol/L
magnesium acetate, 1 mmol/L EDTA and 0.1% SDS) or the like is added to the gel followed by shaking at about 25 to 40 C
through the night to elute DNA. The DNA eluate is treated with phenol/chloroform and precipitated with ethanol to give a genomic library insert. All of the above-mentioned insert and an appropriate vector such as pUC 18 SmaI/BAP
(manufactured by Amersham Biosciences) are subjected to ligation using T4 ligase (manufactured by Takara Shuzo) at about 10 to 20 C for about 20 to 50 hours. The ligation reaction product is precipitated with ethanol and the resulting recombinant vector DNA is dissolved in an appropriate amount of TE buffer. By means of electroporation or the like, the recombinant vector DNA is transformed to Escherichia coli such as an Electro Cell DH5a strain (manufactured by Takara Shuzo). It is recommended that the electroporation is carried out under the condition mentioned in the attached experimental manual.

The transformants into which recombinant vector containing the genomic DNA fragments is inserted are selected on an appropriate selective medium. For example, when pUC 18 SmaI/BAP is used as a vector, the transformants form white colonies on an LB plate medium (an LB medium (10 g/L of bactotryptone, 5 g/L of yeast extract and 10 g/L of sodium chloride; pH 7.0) which contains 1.6% of agar) containing about 0.01 to 0.1 mg/mL of ampicillin, about 0.1 mg/mL of X-gal and about 1 mmol/L of isopropyl-(3-D-thiogalactopyranoside (IPTG) upon incubation through the night at about 30 to 37 C and, therefore, the selection is easy. The transformants are cultured in LB medium containing about 0.1 mg/mL of ampicillin through the night at about 30 to 37 C using a 384-well titer plate, a 50%

aqueous solution of glycerol in the same volume as the LB
is added thereto and the mixture is stirred to give a glycerol stock. Usually, the glycerol stock can be preserved at about -80 C.

(c) Preparation of a cosmid library The genomic DNA prepared in (a) is subjected to a partial digestion using an appropriate restriction enzyme such as Sau3AI (manufactured by Takara Shuzo). It is possible to insert the DNA fragment digested by Sau3AI into a BamHI site of a cosmid vector such as Super CosI vector (manufactured by Stratagene). The treatment with the restriction enzyme and the ligation may be carried out according to the protocol attached thereto. The ligated product obtained by such a method is subjected to a packaging using, for example, Gigapack III Gold (manufactured by Stratagene), and according to the manual for the experimental procedure attached thereto, it is introduced into Escherichia coli such as an XL1-Blue MR

strain (manufactured by Stratagene). That is spread on an LB plate medium containing ampicillin and incubated through the night at about 30 to 37 C to get transformants. The resultant transformants are cultured in LB medium containing about 0.1 mg/mL of ampicillin through the night at about 30 to 37 C using a 96-well titer plate, a 50%
aqueous solution of glycerol in the same volume as the LB
is added thereto and the mixture is stirred to give a glycerol stock. Usually, the glycerol stock can be preserved at about -80 C.

(d) Preparation of DNA fragment for determination of DNA sequence The genome sequence of industrial yeast can be determined mainly using the genome shotgun method. The DNA
fragment of which DNA sequence is determined can be prepared by a PCR using the shotgun library prepared in the above (b). To be specific, clone of the genome shotgun library is inoculated using a replicator (manufactured by Gene Solution) to a 384-well titer plate where about 50p.l each of an ampicillin-containing LB medium is placed to each well and cultured without shaking through the night at about 30 to 37 C. The culture is transferred using a replicator (manufactured by Gene Solution) or the like to a 384-well reaction plate (manufactured by AB Gene) where about 10p1 each of a reaction solution for PCR (TaKaRa Ex Taq manufactured by Takara Shuzo) is placed, and PCR is carried out according to a protocol by Makino, et al. (DNA
Research, volume 5, pages 1 to 9 (1998)) or the like using a GeneAmp PCR System 9700 (manufactured by Applied Biosystems) or the like, whereupon amplification of the inserted fragment is carried out.

Excessive primer and nucleotide are removed using a kit for the purification of PCR products (manufactured by Amersham Bioscience), etc. and a sequence reaction is carried out using the sample as a template.
Determination of the genome sequence can also be performed by preparing and using a cosmid library. Cosmid DNA from the cosmid library of (c) can be prepared by the following method. That is, clone derived from cosmid library is inoculated to each well of a 96-well plate where about 1.0 mL each of an ampicillin-containing appropriate medium such as a 2 x YT medium (1.6% bactotryptone, 1%
yeast extract and 0.5% sodium chloride; pH 7.0) is placed and cultured with shaking through the night at about 30 to 37 C. Cosmid DNA from the said culture can be prepared using KURABO PI-1100 AUTOMATIC DNA ISOLATION SYSTEM
(manufactured by KURABO) according to a manual of KURABO or the like, and they can be used as templates for sequencing reaction.

(e) Sequencing reaction A Sequencing reaction can be carried out using a commercially available sequence kit, etc. Preferred examples of the present invention are shown below.

A sequence reaction mixture can be prepared as follows. The PCR product or cosmid DNA prepared in the above (d) is mixed with about 2Rl of DYEnamic ET

Terminator Sequencing Kit (manufactured by Amersham Bioscience) and appropriate primers to give about 8 1 of reaction mixture. An M13 forward (M13-21) primer and an M13 reverse (M13RV) primer (manufactured by Takara Bio), etc.
are used for the sequence reaction of a PCR product derived from shotgun DNA, while a forward primer such as SS-cos F.1 (SEQ ID NO: 7) and a reverse primer such as SS-cos R.1 (SEQ
ID NO: 8), etc. are used for cosmid DNA. Amounts of the primer and the DNA fragment are about 1 to 4 pmole and about 50 to 200 ng, respectively.

A dye terminator sequence reaction of about 50 to 70 cycles can be carried out using the reaction solution and GeneAmp PCR System 9700 (manufactured by Applied Biosciences). When a commercially available kit such as DYEnamic ET Terminator Sequencing Kit is used, a cycle parameter follows a manual attached thereto. Purification of the sample is carried out according to the manual of Millipore using MultiScreen HV plate (manufactured by Millipore), etc. The purified reaction product is precipitated with ethanol and the resulting precipitate is dried and stored in a dark place of about 4 C. The dried product is analyzed using commercially available sequencer and analyzer such as MegaBACE 1000 Sequencing System (manufactured by Amersham Bioscience) and ABI PRISM 3700 DNA Analyzer (manufactured by Applied Biosystems), etc.
according to the manuals attached thereto.

(f) Reconstruction of genome sequence by means of assembly (A process whereby the order of multiple sequenced DNA fragments is determined) Reconstruction of genomic DNA may be carried out from sequence information of DNA fragments obtained in the above (e). All operations of the reconstruction of genomic DNA
sequence can be carried out on an UNIX platform. Base call can be conducted by a software such as phred (The University of Washington) or the like, masking of vector sequence can be carried out by a software such as Cross Match (The University of Washington) or the like and assembly can be carried out by a software such as Phrap (The University of Washington) or the like. Contig obtained as a result of assembly can be analyzed using a graphical editor such as consed, a graphical editor (The University of Washington) or the like. A series of works from base call to assembly can be carried out en bloc utilizing phredPhrap, a script attached to the consed.

(B) Comparison of the genome sequence of the industrial yeast with that of S. cerevisiae Optionally, comparison of the genome sequence obtained in (A) with that of S. cerevisiae can be carried out by any known means for comparing two sequences. It may include (g) Preparation of a comparative database compiling the comparison data of each of DNA sequences of both ends of cosmid and shotgun clone and contig with S. cerevisiae genome sequence, and mapping of them on S. cerevisiae genome sequence.

Widely used industrial yeast such as bottom fermenting yeast (S. pastorianus) has been regarded as a natural hybrid of S. cerevisiae and its closely related species (such as S. bayanus) "Int. J. Syst. Bacteriol. volume 35, pages 508-511 (1985)". In this view, DNA sequences of the both ends of cosmid clone prepared in (e) are subjected to a homology searching against S. cerevisiae genome sequence by a homology searching algorithm, whereupon the homologous region and the identity of each DNA sequence to S.
cerevisiae genome sequence can be determined, thus database can be prepared.

The S. cerevisiae genome sequences are accessible from public available data bank, such as, Saccharomyces Genome Database (SGD: http://genome-www.stanford.edu/Saccharomyces/).The percent identity of two amino acid or two nucleic acid sequences can be determined by visual inspection and mathematical calculation, or more preferably, the comparison is done by comparing sequence information using a computer program.
An exemplary, preferred computer program is the Genetics Computer Group (GCG; Madison, WI) Wisconsin package version 10.0 program, 'GAP' (Devereux et al., 1984, Nuci. Acids Res. 12: 387). The preferred default parameters for the 'GAP' program includes: (1) The GCG implementation of a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) for nucleotides, and the weighted amino acid comparison matrix of Gribskov and Burgess, Nucl. Acids Res. 14:6745, 1986, as described by Schwartz and Dayhoff, eds., Atlas of Polypeptide Sequence and Structure, National Biomedical Research Foundation, pp. 353-358, 1979; or other comparable comparison matrices;
(2) a penalty of 30 for each gap and an additional penalty of 1 for each symbol in each gap for amino acid sequences, or penalty of 50 for each gap and an additional penalty of 3 for each symbol in each gap for nucleotide sequences; (3) no penalty for end gaps; and (4) no maximum penalty for long gaps. Other programs used by those skilled in the art of sequence comparison can also be used, such as, for example, the BLASTN program version 2Ø9, available for use via the National Library of Medicine website ncbi.nlm.nih.gov/gorf/wblast2.cgi, or the WU-BLAST 2.0 algorithm. Standard default parameter settings for WU-BLAST 2.0 are described at the following Internet site:
sapiens.wustl.edu/blast/blast/#Features. In addition, the BLAST algorithm uses the BLOSUM62 amino acid scoring matix, and optional parameters that can be used are as follows:
(A) inclusion of a filter to mask segments of the query sequence that have low compositional complexity (as determined by the SEG program of Wootton and Federhen (Computers and Chemistry, 1993); also see Wootton and Federhen, 1996, Analysis of compositionally biased regions in sequence databases, Methods Enzymol. 266: 554-71) or segments consisting of short-periodicity internal repeats (as determined by the XNU program of Claverie and States (Computers and Chemistry, 1993)), and (B) a statistical significance threshold for reporting matches against database sequences, or E-score (the expected probability of matches being found merely by chance, according to the stochastic model of Karlin and Altschul (1990); if the statistical significance ascribed to a match is greater than this E-score threshold, the match will not be reported.); preferred E-score threshold values are 0.5, or in order of increasing preference, 0.25, 0.1, 0.05, 0.01, 0.001, 0.0001, le-5, 1e-10, le-15, le-20, le-25, le-30, le-40, le-50, le-75, or le-100.

An example of identity percentages distribution graph of cosmid DNA sequence corresponding to S. cerevisiae genomic DNA sequence is shown in Fig. 2. The DNA sequence of cosmid is roughly classified into a DNA sequence group showing more than 94% identity to S. cerevisiae genome sequence and a DNA sequence group showing around 84%
identity thereto. Accordingly, a DNA sequence having identity of more than 94% to the nucleotide sequence of the gene of Saccharomyces cerevisiae is named an Sc-type DNA
sequence derived from S. cerevisiae. While a DNA sequence having 94% or less identity, more preferably,60 to 94%

i.dentity, most preferably around 84% identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae is named a non-Sc-type DNA sequence derived from a closely-related species of S. cerevisiae. A gene with the Sc type DNA sequence or the non-Sc type DNA sequence is named Sc type gene or non-Sc type gene, respectively.

Similarly, a comparative database of the DNA sequence of both ends of shotgun clone prepared in (e) with genomic DNA sequence of S. cerevisiae is prepared. On the basis of the information obtained from the prepared comparative database, a mapping of cosmid clone and shotgun clone on S.
cerevisiae genome sequence is carried out (refer, for example, to Fig. 3). A comparative database of the DNA
sequence of the contig prepared in (f) with S. cerevisiae genome sequence is also prepared and mapping is carried out. Although the mapping technique is nearly the same as that mentioned above, when contigs linked by paired forward-reverse DNA sequence from the same cosmid and shotgun clone, those contigs are linked (refer, for example, to Fig. 4).
(C) (C-1) Selection of a gene of the industrial yeast encoding an amino acid sequence having 70 to 97% identity to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, and (C-2) selection of a gene of the industrial yeast consisting of a nucleotide sequence having 60 to 94%

identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae.

A stage for the selection of the gene of bottom fermenting yeast encoding an amino acid sequence having 70 to 97% identity to an amino acid sequence encoded by the gene of S. cerevisiae may include (h) a process of identification of ORF (open reading frame) and assignment of function.

(h) Identification of ORF and assignment of its function Identification of ORF in the DNA sequence assembled in (f) is carried out. Preferred examples are specifically mentioned below. With regard to a certain length of DNA
sequence (such as not less than 150 base) embraced by 15= initiation codon and termination codon, there can be carried out identification of ORF existing in a DNA
sequence assembled in (f) using a program, such as ORF
finder (http://www.ncbi.nih.gov/gorf/gorf.html) or the like for the identification of ORF for six kinds of reading frames including complementary sequence.

Assignment of function of protein encoded by the identified ORF can be carried out using a homology searching such as BLAST

(http://www.ncbi.nlm.nih.gov/BLAST/) or the like to an amino acid sequence of ORF of S. cerevisiae that has been registered and published in the Saccharomyces Genome Database (SGD: http://genome-www.stanford.edu/Saccharomyces/). If necessary, it is possible to analyze the chromosomal structure of an industrial yeast by DNA array-based comparative genomic hybridization and PCR. In the Example 8 in the present specification, the choromosome structure of the S.

pastorianus strain 34/70 was analyzed by using a DNA array containing the DNA probes of known S. cerevisiae nucleotide sequences.

Yeast genomic DNA is prepared using a Quiagen Genomic Tip 100/G (#10243) and Qiagen Genomic DNA Buffer Set (#19060) according to the manual attached to the kit. The DNA (e.g., 10 Rg) is digested with DNase I (manufactured by Invitrogen) according to a method of Winzeler, et al.
(Science, volume 281, pages 1194-1197 (1998)), biotinylated using a terminal transferase (manufactured by Roche) and hybridized to a DNA array (Affymetrix Gene Chip Yeast Genome S98 Array). The DNA array contains the DNA probes of known S.,cerevisiae nucleotide sequences. Hybridization and detection of the signal intensity of the DNA array are carried out using a Gene Chip Analysis Basic System and analysis soft ware (Microarray Suite 5.0) manufactured by Affymetrix.

The signal of each probe hybridized with the DNA of brewing yeast is normalized to that of the haploid laboratory yeast strain S288C using an analysis soft ware (Microarray Suite 5.0) and shown as signal log ratio (2n).
Signal log ratios were lined following genes order in each chromosome using a spreadsheet program (Microsoft Excel 2000) and the signal log ratios are shown in bar graphs (refer, for example, to Fig. 5). The non-Sc type genes do not hybridize to the S. cerevisiae array, therefore, the Sc type gene dosage affects the signal log ratio and the points where the signal log ratios show vigorous changes are considered to be translocation sites between Sc type and non-Sc type chromosome.

The chimera chromosome structure can be confirmed by PCR, wherein a genomic DNA derived from brewing yeast is used as a template and Sc type and non-Sc type shotgun sequences are used as primers.

PCR may be carried out using a Takara PCR Thermal Cycler SP according to the attached manual using a Takara LA TaqTM and a buffer attached thereto.

As a result of the PCR, it is confirmed by 0.8%

agarose gel electrophoresis, for example, that a certain length of DNA fragment is amplified from the brewing yeast.
When a genomic DNA of S. cerevisiae which is a laboratory strain is used as a template for the PCR, no amplification of DNA fragment is detected. If DNA sequences of the both ends of the DNA fragment amplified from the brewing yeast are further confirmed, it is consistent with the genome sequences determined by a shotgun method and it can be confirmed that, within such region, translocation between Sc type and non-Sc type chromosome takes place, whereupon a chimera chromosome is formed.

Alternatively, a gene of the industrial yeast consisting of a nucleotide sequence having 60 to 94%
identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae can be selected. Identity of 60 to 94o in nucleotide sequence level corresponds approximately 70 to 97% in amino acid sequence level. Some nucleotide sequences in non-Sc type chromosome other than open reading frames may have identity of less than 60% to the corresponding nucleotide sequences of Sc type chromosome.

(D) Functional analysis of the selected genes Further, selected genes may optionally be subjected to functional analysis. For example, functional analysis of gene may include (i) selection of the gene, (i') cloning of the gene, (j) functional analysis of the gene by disruption or (k) functional analysis of the gene by overexpression.

(i) Selecting of the gene There is no particular limitation for the methods used for the selection of gene(s) for functional analysis.
While preferred methods are, for example, a method using the assignment of the function obtained in the above (h) and a method using a DNA array as described below.

One of the purposes of the present invention is to identify genes from industrial yeasts involved in increase of productivity'and/or improvement in flavor in the production of an alcohol or an alcoholic beverage. The whole genome sequence of Saccharomyces cerevisiae has been identified, and function of each gene of Saccharomyces cerevisiae has already been identified. As mentioned above for the step (h), functions of proteins encoded by the non-Sc type genes can be assigned by a homology searching.
Non-Sc type genes which are expected from the assignment to have an useful activity, e.g., involved in increase of productivity and/or improvement in flavor in the production of an alcohol or an alcoholrpp:erage, are selected as v~ __ target genes for functional anaYysis.~--'------- -For example, the SSU1 gene and the MET14 gene are known to have the sulfite transporting activity, and the adenylsulfate kinase activity, respectively. Both genes are known to play an important role for stabilizing flavor of beer. Other genes from the Sc gene analysis which are known to play some role in a step of producing beer are listed in Table 2 in the following Example 7. These genes, however, do not exert sufficient activity enough for producing tasty beer. Therefore, without any limitation, for the purpose of identifying genes from industrial yeasts involved in increse of productivity and/or improvement in flavor in the production of an alcohol or an alcoholic beverage, non-Sc genes corresponding to these Sc type genes can be selected.

Alternatively, the method using DNA array is, for example, gene expression analysis to identify genes, which show a characteristic expression profile under some conditions, or comparative genomic hybridization to identify genes, which have different copy numbers or different DNA sequences, by detecting deference of signal intensities of probes.

(i') cloning of the gene Genes selected in the above (i) can be obtained from the bottom fermenting yeast according to a common method mentioned, for example, in Molecular Cloning, Third Edition. That is, oligonucleotides having sequences adjacent to the gene are synthesized and a common PCR
cloning method is carried out using a genomic DNA prepared from a bottom fermenting yeast as a template, whereupon the selected gene can be isolated and obtained. With regard to DNA sequences obtained as such, for example, SEQ ID NO: 1 may be listed.

When the gene is named, for example, a gene(1), the gene (1) or primer for amplifying the gene (1) by a PCR
method may be also synthesized using a polynucleotide synthesizer on the basis of the above-mentioned sequence information.

In addition, gene (1) means not only a DNA fragment having the same DNA sequence as gene (1) but also a DNA
fragment hybridizing to the above gene under stringent condition as is defined in the present specification.
The DNA fragment which hybridizes under stringent condition means a DNA fragment which is obtained by a colony hybridization method, a plaque hybridization method, a southern blot hybridization method or the like, using the DNA fragment containing the sequence of the gene (1) identified in the above as a probe.

The term "under stringent condition" means that two nucleic acid fragments can hybridize under a moderately stringent condition or a highly stringent condition. An artisan can easily choose an appropriate moderately or highly stringent condition.

The basic parameters affecting the choice of hybridization conditions and guidance for devising suitable conditions are set forth by Sambrook,, Fritsch, and Maniatis (2001, Molecular Cloning: A Laboratory Manual, third edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., chapters 6 and 7; and Current Protocols in Molecular Biology, 1995, Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4), and can be readily determined by those having ordinary skill in the art based on, for example, the length and/or base composition of the DNA.

One way of achieving moderately stringent conditions involves the use of a prewashing solution containing 5 x SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0), hybridization buffer of about 50% formamide, 6 x SSC, and a hybridization temperature of about40-55 C (or other similar hybridization solutions, such as one containing about 50% formamide, with a hybridization temperature of about 42 C), and washing conditions of about 60 C, in 0.5 x SSC, 0.1% SDS.
Preferably, a moderately stringent condition may include hybridization at about 50 C and 2 X SSC.

Highly stringent conditions can also be appropriately selected based on factors like length of DNAs to be hybridized. Generally, such conditions include hybridization and/or washing at higher temperature and/or lower salt concentration (such as hybridization at about 65 C, 6 X SCC-0.2 X SSC, preferably, 6 X SCC, more preferably 2 X SSC, most preferably, 0.2 X SSC), compared to the moderately stringent condition. For example, highly stringent conditions may include hybridization as defined above, and washing at approximately 68 C, 0.2 x SSC, 0.1%
SDS. SSPE (1xSSPE is 0.15M NaCl, 10 mM NaH2 PO4, and 1.25 mM EDTA, pH 7.4) can be substituted for SSC (1xSSC
is 0.15M NaCl and 15 mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

It should be understood that the wash temperature and wash salt concentration can be adjusted as necessary to achieve a desired degree of stringency by applying the basic principles that govern hybridization reactions and duplex stability, as known to those skilled in the art and described further below (see, e.g., Sambrook et al., 2001).
When hybridizing a nucleic acid to a target nucleic acid of unknown sequence, the hybrid length is assumed to be that of the hybridizing nucleic acid. When nucleic acids of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the nucleic acids and identifying the region or regions of optimal sequence complementarity.

The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5 to 25 C, preferably 5 to 10 C less than the melting temperature (Tm) of the hybrid, where Tm is determined according to the following equations. For hybrids less than 18 base pairs in length, Tm ( C) = 2(number of A + T bases) + 4(number of G + C bases). For hybrids above 18 base pairs in length, Tm ( C) = 81.5 + 16.6(loglo [Na+] ) + 0.41(% G + C) - 0.63(%

formamide - (500/N), where N is the number of bases in the hybrid, and [Na+] is the concentration of sodium ions in the hybridization buffer ([Na+] for 1xSSC = 0.165M).
Preferably, each such hybridizing nucleic acid has a length that is at least 15 nucleotides (or more preferably at least 18 nucleotides, or at least 20 nucleotides, or at least 25 nucleotides, or at least 30 nucleotides, or at least 40 nucleotides, or most preferably at least 50 nucleotides), or at least 25% (more preferably at least 50%, or at least 60%, or at least 70%, and most preferably at least 80%) of the length of the nucleic acid of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5%, or at least 99%, and most preferably at least 99.5%) with the nucleic acid of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing nucleic acids when aligned so as to maximize overlap and identity while minimizing sequence gaps as described in more detail above.

The hybridization may be carried out according to a method mentioned in "Molecular Cloning, Third Edition", "Current Protocols in Molecular Biology, John Wiley & Sons (1987-1997) (hereinafter, abbreviated as Current Protocols in Molecular Biology), "DNA Cloning 1: Core Techniques, A
Practical Approach, Second Edition, Oxford University (1995)", and the like.

To be more specific, shotgun clone containing full-length of the above-mentioned gene (1) can be retrieved using the comparative database obtained in (g) and, on the basis of homology and positional information, etc. When there is no clone containing full-length of the gene in the shotgun library, a DNA fragment encoding the full length of the gene is prepared by a PCR method. For example, a DNA
fragment containing the above-mentioned gene is obtained using synthetic DNA primer pair represented by SEQ ID NO:
13 and SEQ ID NO: 14, etc. Similarly, PCR is carried out using a primer pair designed on the basis of the published information of SGD and using genomic DNA of S. cerevisiae or bottom fermenting yeast as a template, whereupon the full length of the Sc type gene corresponding to the non-Sc type gene is prepared. For example, using synthetic oligonucleotides of SEQ ID NO: 15 and NO: 16 as the primer pair, the DNA fragment containing the Sc type gene can be obtained.

Sc or non-Sc type DNA fragment prepared as mentioned above is inserted into, for example, pCR 2.1-TOPO vector attached to a TA cloning kit (Invitrogen) using a TA

cloning kit or the like, whereupon a recombinant vector TOPO/Sc gene and TOPO/non-Sc gene containing the DNA
fragment having the Sc and the non-Sc type gene, respectively, are able to be prepared. DNA sequences of the Sc and non-Sc type DNA fragments can be comfirmed by Sanger's method "F. Sanger, Science, volume 214, page 1215, 1981".

(j) Functional analysis of the gene by disruption Functional analysis of the selected non-Sc gene may be performed by disruption of the gene, for example.
Functional analysis by disruption of the gene can be done by any known conventional methods. In the present specification, "method for disruption of a gene" includes any methods which stop, block, inhibit or suppress at least part of function of the gene, including deletion of the gene, blocking of the gene by antisense nucleic acid, RNAi method or the like. As an example, we will explain disruption of the non-Sc SSU1 gene, which has been identified by the present invention.

According to a method of the document Goldstein, et al., Yeast, volume 15, page 1541, (1999)", it is possible to prepare a DNA fragment for gene disruption by PCR where a plasmid containing a drug-resistance gene (such as pFA 6a (G418r), pAG 25 (natl)) is used as a template. As a primer pair for the PCR, non-ScSSU1_for (SEQ ID NO: 17)/non-ScSSU1_rv (SEQ ID NO: 18) or the like may be used for the non-ScSSUl disruption. While for the Sc SSU1 disruprion, ScSSU1_for (SEQ ID NO: 19)/ScSSU1_rv (SEQ ID NO: 20) or the like may be used. For the non-Sc type gene disruption, it is also possible to use a plasmid such as pPGAPAUR (AUR1-C) and a primer pair such as non-ScSSUl_for + pGAPAUR (SEQ ID
NO: 21)/non-ScSSU1_rv + AURI-C (SEQ ID NO: 22).

An industrial yeast is transformed with the DNA
fragment for the gene disruption prepared by the above-mentioned method. The transformation may follow a method mentioned in the Japanese Patent Laid-Open Gazette No.
07/303,475, for example. Further, the concentration of the drug for the selection of transformants may be appropriately determined by investigating the sensitivity of the yeast used as a host.

With regard to the transformant prepared here, it is comfirmed whether each of the drug-resistance genes is introduced and the said gene is disrupted correctly using a Southern analysis. To be specific, the genomic DNA

extracted from the parental strain and the transformant are firstly digested by an appropriate restriction enzyme to distinguish Sc and non-Sc type gene (for example, at 37 C
for 18 hours), then fractionated with 1.5% agarose gel electrophoresis and transferred to a membrane. After that, they are hybridized to a probe specific to an Sc-type or a non-Sc type gene for example at 55 C for 18 hours according to a protocolof Alkphos Direct Labelling Reagents (Amersham) and a signal is detected by CDP-Star.

The function of the gene obtained in (i') can be studied by fermentation test using a parental strain and non-Sc SSU1 disruptants prepared in the above (j) and comparison of their fermentation character. Fermentation test can be carried out, for example, using wort under the following condition.

Original extract: about 10 to 15%
Fermentation scale: 1 to 3 liters Dissolved oxygen concentration: about 8 to 10 ppm Fermentation temperature: about 15 C

Pitching rate: about 4 to 6 g of wet yeast cells/ L
Wort is periodically sampled and monitored in the cell growth (OD 600), apparent extract, the concentration of the substance relating to the function of the gene obtained in (i'), etc. then, analyzed.

For example, when the function of the gene obtained in (i') involved in discharge of sulfite, the sulfite concentration in the wort during the fermentation is analyzed. Quantitative analysis of sulfite is carried out in such a manner that sulfite is captured in a hydrogen peroxide solution by means of distillation under an acidic condition and subjected to titration with an alkali (Revised Method for BCOJ Beer Analysis by the Brewing Society of Japan).

As candidates for useful genes involved in increase of productivity and/or improvement in flavor in the production of an alcohol or an alcoholic beverage, we may select genes wherein cell growth, apparent extract, and/or the concentration of the substance relating with the function of the gene were substantially changed by disruption of the gene. Especially, the change in the concentration of the substance participating in the function of the gene is important and should be monitored.

The "substance relating with the function of the gene"
includes, without any limitation, sulfite, ethanol, ester and fusel alcohol or the like. Substances, which are considered to have a negative effect on production of tasty beer, can also be a target of analysis, including diacetyl and phenolic compounds or the like.

(k) Functional analysis of the gene by overexpression Alternatively, functional analysis of a gene can be achieved by overexpression of the gene.

A DNA fragment containing the full-length of the non-Sc type gene is excised by an appropriate restriction enzyme from the plasmid TOPO/non-Sc gene prepared in (i').

The DNA fragment is inserted into a cloning site of a vector for gene expression such as pNI-NUT to construct a vector (pYI-non-Sc type gene) for overexpression of the non-Sc type gene. The vector pNI-NUT contains URA3 as a homologous recombination site and nourseothricin-resistance gene (natl) and ampicillin-resistance gene (Ampr) as selective markers. On the other hand, a vector for overexpression of the Sc type gene (pNI-Sc type gene) has a structure where the above-mentioned pYI-non-Sc type gene is substituted by the corresponding Sc type gene. For overexpression of the Sc or non-Sc type gene introduced here, it is preferred to be driven by promoter and terminator of constitutively expressing gene, for example, glyceraldehyde-3-phosphate dehydrogenase gene (TDH3).

An industrial yeast is transformed using the overexpression vector, which is prepared by the above-mentioned method. The transformation is carried out by the method mentioned in the Japanese Patent Laid-Open Gazette No. 07/303,475 and transformants are selected on an appropriate selective medium. Confirmation of the overexpression may be carried out by RT-PCR method, etc.
Extraction of the total RNA may be carried out using an RNeasy Mini Kit (Qiagen) or the like, according to the manual of "for total RNA isolation from yeast" attached to the kit. Regarding the SSul gene, for example, it is possible to use ScSSUl_for331 (SEQ ID NO: 23)/ScSSUl_982rv (SEQ ID NO: 24) and nonSc-SSU1_for329 (SEQ ID NO:
25)/nonSc-SSU1_981rv (SEQ ID NO: 26) as specific primerpairs for the amplification of Sc and non-ScSSUl gene, respectively.

To amplify a constitutively expressed gene, for example PDA1, as an internal standard, PDA1_forl (SEQ ID NO:
27)/PDA1_730rv (SEQ ID NO: 28) etc. may be used as a specific primer pair. PCR product is fractionated with 1.2% agarose gel electrophoresis and detected with ethidium bromide staining. The overexpression of the said gene in the transformant is confirmed by comparison of quantity of the PCR products.

The functional analysis of the gene obtained in (i') can be carried out by a fermentation test using the parental strain and the overexpressed strain prepared in the above (k). Fermentation test may be carried out under the condition mentioned in (j).

According to the same method mentioned in (j), the wort is periodically sampled and monitored the cell growth 5(OD600), apparent extract and the concentration of the substance relating with the function of the gene obtained in (i').

As candidates for useful genes involved with increase in productivity and/or improvement in flavor in the production of an alcohol or an alcoholic beverage, we may select genes wherein cell growth, apparent extract, and/or the concentration of the substance relating with the function of the gene were substantial:ly changed by overexpression of the gene. Especially, the change in the concentration of the substance relating with the function of the gene is important and should be monitored.

(E) Genes and the gene library The present invention also provides genes obtained by the analyzing method of the present invention. The genes of the present invention include both nucleotides of ORF
encoding proteins, as well as nucleotides from non-coding regions. Nucleotides from non-coding regions may include regulatory regions, such as promoter, enhancer, silencer, terminator or the like, which are important for regulation of expression of a gene.

Specifically, one embodiment of the present invention is a gene of the industrial yeast encoding an amino acid sequence having 70 to 97% identity to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or consisting of a nucleotide sequence having 60 to 94%
identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae, which is obtained by the present analyzing method.

The present invention also provides a gene library comprising one or more of genes of the industrial yeast as described above.

Preferably, the gene of the industrial yeast is comprised in, consists of or has any nucleotide sequence selected from SEQ ID NOs:33 to 6236, SEQ ID Nos:166154 to 166181, SEQ ID Nos:166490 to 167042 and SEQ ID Nos:173125 to 174603.

SEQ ID NOs: 33-6236 represent 6204 DNA sequences of non-Sc type ORFs, which can be preferably used as probes of the microarry.

SEQ ID NOs: 166154-166181 represent 28 DNA sequences of mitochondrial ORFs from 34/70 strain, which can be preferably used as probes of the microarry.

SEQ ID NOs: 166490-167042 represent 553 DNA sequences which have not been identified as the above non-Sc ORFs but have significant similarity to the proteins of S.
cerevisiae using NCBI-BlastX homology searching.

SEQ ID NOs: 173125-174603 represent 1479 DNA sequences ORFs which have not been identified as the above, but have significant similarity to the proteins of S. cerevisiae using NCBI-BlastP homology searching.

The genes of the present invention also include variants of the natural genes, which may include some modification in one or more nucleotide sequence(s) and/or amino acid sequence(s). The genes of the present invention will be described in detail in the section IV of the present specification.

The "gene" and the "gene library" of the present invention can encompass not only genes in the form of chemical substance(s), but also in a form of nucleic acid sequence information recorded in a computer-readable record medium or storage. Therefore, accessing and/or utilizing the nucleic acid seuqnece information of the "gene" and the "gene library" of the present invention are also included in the scope of the present invention.

The "computer-readable record medium or storage"
includes any record medium or storage which is readable and accesible via a computer. This may include, without any limitation, a magnetic record medium such as floppy diskette, hard diskette, and magnetic tape; an optical record medium such as CD-ROM, CD-R, CD-RW, DVD-ROM, DVD-RAM
and DVD-RW; an electronic record medium such as RAM and ROM; as well as a hybrid of the above categories (e.g, a megnetic/optical record medium, such as MO).

II. DNA array Embodiments of the present DNA array The present invention also provides a DNA array which is useful for an analyzing method of genes. "Genes" which can be analyzed by using the DNA array of the present invention may include genomic DNA, cDNA or cRNA or the like of an industrial yeast. The present DNA array can also be applied to the ChIP (Chromatin Immuno-Precipitation)-chip method for analyzing binding between DNA and a protein.
The DNA array of the present invention comprises probe(s) of DNA(s) based on the nucleotide sequences of non-Sc genes which have been identified by the present invention. In the present specification, DNA

oligonucleotide or cDNA which is fixed on a DNA array is sometimes called "probe".

Preferably, the DNA array of the present invention comprises one or more of DNAs, wherein each DNA is selected from at least one group of (1) to (4):

(1) DNA consisting of a nucleotide sequence of an open reading frame of the genome sequence of an industrial yeast which encodes an amino acid sequence having 70 to 97%
identity to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or a nucleotide sequence complementary to the above nucleotide sequence, or a nucleotide sequence of continuous 10 or more nucleotides selected from the above nucleotide sequences;

(2) DNA consisting of a nucleotide sequence of the genome sequence of an industrial yeast other than from open reading frames which consists of a nucleotide sequence having 60 to 94% identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae, or a nucleotide sequence complementary to the above nucleotide sequence, or a nucleotide sequence of continuous 10 or more nucleotides selected from the above nucleotide sequences;

(3) DNA having a nucleotide sequence of any of SEQ ID
Nos.166490 to 167042, or DNA having a nucleotide sequence of any of SEQ ID Nos.167043 to 173124;and (4) DNA having a nucleotide sequence of any of SEQ ID
Nos.173125 to 174603, or DNA having a nucleotide sequence of any of SEQ ID Nos.174604 to 190810. In a preferred embodiment of the present invention, the DNA array comprises DNAs wherein at least one DNA is selected from every group of (1) to (4).

In a preferred embodiments of the present invention, wherein the DNAs of (1) is comprised in, consists of or has any nucleotide sequence selected from SEQ ID NOs:33 to 6236 and SEQ ID NOs:166154 to 166181, and SEQ ID Nos:6237 to 75336 and SEQ ID Nos:166182 to 166489.

SEQ ID NOs:33 to 6236 correspond to ORF encoding non-SC proteins of the present invention. These sequences can be fixed to the DNA array as cDNA probes. SEQ ID NOs:6237 to 75336 are short nucleotide sequences of about 25 continuous nucleotides selected from each of SEQ ID NOs:l to 6236. SEQ ID Nos: 166182-166489 represent sequences of oligonucleotides based on DNA sequences of SEQ ID NOs:

166154 to 166181.

The ORF sequences from yeast in the present specification may include intron. Such intron sequences can be easily recognized for an artisan. The term "comprised in", therefore, means that the nucleotide sequences of the DNA probes on the DNA array can include only exon sequences (without intron) which can be easily selected by referring to the ORF sequences disclosed in the present specification.

The term "have (has)" or "having" means that the nucleotide sequence of the present invention may include additional sequence which does not substantially affect the function of the DNA of the present invention. For example, DNAs encoding ORF may contain an additional signal or tag sequence which can facilitate secretion and/or purification of the protein encoded by the ORF. Alternatively, oligonucleotides may contain additional one or several nucleotide sequences at its terminal which does not affect hybridization specificity of the oligonucleotides.

SEQ ID Nos. 167043-173124 represent sequences of oligonucleotides based on DNA sequences of SEQ ID NOs:
166490-167042. SEQ ID Nos. 174604-190810 represent sequences of oligonucleotides based on DNA sequences of SEQ
ID NOs: 173125-174603. These sequence can be fixed to the DNA array as oligonucleotide probes.

Another embodiment of the DNA array of the present invention is that of further comprising, in addition to at least one group of DNAs selected from (1) to (4), DNAs of the following (5) and/or (6):

(5) DNA consisting of a nucleotide sequence of an open reading frame of the genome sequence of an industrial yeast which encodes an amino acid sequence having identity of more than 97% to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or a nucleotide sequence complementary to the above nucleotide sequence, or a nucleotide sequence of continuous 10 or more nucleotides selected from the above nucleotide sequences; and (6) DNA consisting of a nucleotide sequence of the genome sequence of an industrial yeast other than from open reading frames which consists of a nucleotide sequence having identity of more than 94% to the nucleotide sequence of the gene of Saccharomyces cerevisiae, or a nucleotide sequence complementary to the above nucleotide sequence, or a nucleotide sequence of continuous 10 or more nucleotides selected from the above nucleotide sequences.

DNAs of (5) correspond to ORF of Sc genes, and DNAs of (6) correspond to non-coding regions of Sc genes, respectively. The DNA array comprising DNAs of (5) and/or (6) in addition to DNAs of any of (1) to (4), is useful for a method of classifying an industrial yeast, for example.

In a preferred embodiment, the DNAs of (5) has a nucleotide sequence of any one of SEQ ID NOs: 75337 to 82784, or SEQ ID NOs: 82785 to 166153. SEQ ID NOs: 75337 to 82784 correspond to ORF encoding non-SC proteins of the present invention. SEQ ID NOs: 82785 to 166153 are short nucleotide sequences of about 25 continuous nucleotides selected from each of SEQ ID NOs:33 to 6236.

In a preferred embodiment, the DNA array comprises DNAs selected from the group of (1) and/or (2), together with DNAs selected from the group of (5) and/or (6).
Hybridization intensity of a sample to a DNA probe of (1) is compared to the corresponding DNA probe of (5).
Similarly, hybridization intensity of a sample to a DNA
probe of (2) is compared to the corresponding DNA probe of (6).

Optionally, the present DNA array of this embodiment may further comprise DNAs of the following (5') and/or (6'):

(5') DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (5), or a nucleotide sequence complementary to the above nucleotide sequence; and (6') DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (6), or a nucleotide sequence complementary to the above nucleotide sequence.

As described above, DNAs of (5) correspond to ORF of Sc genes, and DNAs of (6) correspond to non-coding regions of Sc genes, respectively. DNAs of (5') and (6') contain mismatch of one or more base(s), preferably one base to (5) and (6), respectively. In general, a sample of DNAs shows a different hybridization intensity to a probe having mismatch of one or more base(s) in the DNA array hybridization assay. In a preferred embodiment, if a sample DNA hybridizes to a DNA probe of (5) (or (6)) and does not hybridize to the corresponding DNA probe of (5') (or (6')), it can be concluded that the sample DNA is positive as regards the DNA probe of (5) (or (6)) of Sc type gene. On the contrary, if a sample DNA hybridizes to a DNA probe of (5) (or (6)) but also hybridizes to the corresponding DNA probe of (5') (or (6')), it can be concluded that the sample DNA is negative or pseudopositive as regards the DNA probe of (5) (or (6)) of Sc type gene.

Accordingly, DNAs of (5') and/or (6') may be optionally used as DNA probes of the present DNA array for determining and confirming hybridization specificity of a sample to the DNAs of (5) and/or (6).

Still another aspect of the DNA array of the present invention is that of further comprising, in addition to at least one group of DNAs selected from (1) to (4), DNAs selected from at least one group of (7) to (10):

(7) DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (1), or a nucleotide sequence complementary to the above nucleotide sequence;

(8) DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (2), or a nucleotide sequence complementary to the above nucleotide sequence;

(9) DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (3), or a nucleotide sequence complementary to the above nucleotide sequence; and (10) DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (4), or a nucleotide sequence complementary to the above nucleotide sequence.

In general, a sample of DNAs shows a different hybridization intensity to a probe having mismatch of one or more base(s) in the DNA array hybridization assay. This type of DNA array, therefore, is useful for detecting a nucleotide polymorphism in genome of an industrial yeast.
It can also be useful for the method to screen a useful strain of industrial yeast or useful genes themselves.

In a preferred embodiment, the DNAs of (7) to (10) includes mismatch of only one base. That is, the DNAs of (7) and (10) are the following DNAs of (7-1) to (10-1), respectively.

(7-1) DNA consisting of a nucleotide sequence which contains mismatch of 1 base to the DNA of (1), or a nucleotide sequence complementary to the above nucleotide sequence;

(8-1) DNA consisting of a nucleotide sequence which contains mismatch of 1 base to the DNA of (2), or a nucleotide sequence complementary to the above nucleotide sequence;

(9-1) DNA consisting of a nucleotide sequence which contains mismatch of 1 base to the DNA of (3), or a nucleotide sequence complementary to the above nucleotide sequence; and (10-1) DNA consisting of a nucleotide sequence which contains mismatch of 1 base to the DNA of (4), or a nucleotide sequence complementary to the above nucleotide sequence.

Preferably, mismatch of one base is at the center or near the center of each DNA.

One of the most preferred embodiments of the present DNA array comprises at least one group of DNAs selected from (1) to (4) (preferably (1) and/or (2)), at least one group of DNAs selected from (7) to (10) (preferably (7) and/or (8)), DNAs of (5) and/or (6) and DNAs of (5') and/or (6'). The DNA array of this embodiment is especially useful for the present method to classify an industrial yeast, as well as a method to analyze the chromosomal structure of an industrial yeast by DNA array-based comparative genomic hybridization as discussed in the present specification below. Preferably, at least one group of DNAs selected from (7) to (10), and DNAs of (5') and/or (6') has a mismatch of only one base.

Probes which are attached to the DNA arrays of the present invention can be cDNA probes or oligonucleotids.
There is no limitation to the length of cDNA probes, but preferably, no longer than 1,000 bases. Oligonucleotide probes range form about 5 to about 50 nucleotides, preferably, 10-30 nucleotides.

Production of a DNA array of this invention A DNA array of the present invention can be produced based on the DNA sequence information of the ORFs and/or non-coding regions (intergenic DNA sequence between two ORFs) obtained in the above (f). Examples include a DNA

array comprising a solid support to which at least one of a polynucleotide comprising the DNA sequence obtained in the above items ( f ) .

DNA arrays of the present invention include substrates known in the art, such as a DNA microarray, a DNA chip, polynucleotide array and a DNA macroarray, or the like, and comprises a solid support and plural polynucleotides of fragments thereof which are adhered to the surface of the solid support. As the polynucleotides or oligonucleotides adhered to the solid support, the polynucleotides or oligonucleotides of the present invention obtained in the above (f) and (h) can be used.

The analysis described below can be efficiently performed by adhering the polynucleotides or oligonucleotides to the solid support at a high density, though a high fixation density is not always necessary.
Apparatus for achieving a high density, such as an arrayer robot or the like, is commercially available from Takara Shuzo (GMS417 Arrayer), and the commercially available product can be used. Also, the oligonucleotide of the present invention can be synthesized directly on the solid support by the photolithography method or the like (Nat.
Genet. 21, 20-24 (1999)). In this method, a linker having a protective group which can be removed by light irradiation is first adhered to a solid support, such as slide glass or the like. Then, it is irradiated with light through a mask (a photolithograph mask) permeating light exclusively at a definite part of the adhesion part. Next, an oligonucleotide having a protective group which can be removed by light irradiation is added to the part. Thus, a ligation reaction with the nucleotide arises exclusively at the irradiated part.

By repeating this procedure, oligonucleotides each having a desired sequence and different from each other can be synthesized in respective parts. Usually, the oligonucleotides to be synthesized have a length of 10 to 30 nucleotides.

Alternatively, cDNA probes which can be prepared by any known conventional methods based on the nucleotide sequences of mRNA obtained from the industrial yeast can be used. A cDNA probe is fixed to the DNA array after it has been prepared. Examples of general methods for preparing and fixing the cDNA probes to the DNA array are explained in "Science volume 270, pages 467-470 (1995)", for example.
There is no particular limitation for the methods used for the production of DNA array and the method may be conducted according to the known means, while preferred method for each of them is mentioned below.

(1) Production of a DNA array (1)-1 Solid support Any materials of which the polynucleotids or fragments can be adhere to the surface can be used as the solid supports using the invention DNA array. There is no particular limitation for the material and shape used for the solid support, while preferred materials are some resinoids, such as polycarbonate, plastics or the like, as a material and a plate-like and film-like as a solid.

(l)-2 Selection of an oligonucleotide The example of oligonucleotides to be fixed on the plate of a DNA array of this invention are as follows.
Based on the DNA sequences of ORFs obtained in the above (h) and/or intergenic DNA sequences deduced from the above (h), unique and perfect complementary probes (PM Probe;
Perfect Match Probe) against genome sequence of brewing yeast can be designed using a certain method of probe production, such as GeneChip (Affymetrix) technology or the like.

The oligonucleotide probes range form about 5 to about 100 nucleotides, preferabaly about 5 to about 80 nucleotides, preferably about 5 to about 60 nucleotides, more preferably about 5 to about 50 nucleotides, more preferably from about 5 to about 45 nucleotides, still more preferably from about 10 to about 40 nucleotides and most preferably from about 10 to 30 nucletides in length.

Particularly preferred arrays contain probes ranging from about 20 to about 25 oligonucleotides in length. The array may comprise more than 10, preferably more than 50, more preferably more than 100, and most preferably more than 1000 oligonucleotide probes specific to the each target gene (Where the array refers to the DNA array to be fixed the oligonucleitide probes using a certain method of probe production, such as GeneChip (Affymetrix) technology or the like). In a preferred embodiment, the array comprises at least 10 different oligonucleotide probes for each gene.
In another preferred embodiment, the array 20 or fewer oligonucleotides complementary each gene.

Widely used industrial yeast such as bottom fermenting yeast (S. pastorianus) has been regarded as a natural hybrid of S. cerevisiae and its closely related species (such as S. bayanus) as described above. So the bottom fermenting yeast has at least two different genes whose DNA

sequences are similar to each other. Thereby, it is desirable to remove probes that hybridize to transcription products of more than one gene. One can then remove any probes that are similar to any other genes, and make a probe set for that genes using a certain method of probe production, such as GeneChip (Affymetrix) technology or the like) The array may further comprise mismatch control probes. Where such mismatch control probes are present, the quantifying step may comprise calculating the difference in hybridization signal intensity between each of the oligonucleotide probes and its corresponding mismatch control probe. The quantifying may further comprise calculating the average difference in hybridization signal intensity between each of the oligonucleotide probes and its corresponding mismatch control probe. The term mismatch probe refer to the probe whose sequence is deliberately selected not to be perfectly complementary to a particular target sequences. For each mismatch (MM) control in a high-density array, there typically exists a corresponding perfect match (PM) probe that is perfectly complementary to the same particular target sequence. The mismatch may comprise one or more bases, preferably one base.

While the mismatch(es) may be located anywhere in the mismatch probe, terminal mismatche is less desirable as a terminal mismatch is less likely to prevent hybridization of the target sequences. In a particularly preferred embodiment, the mismatch is located at or near the center of the probe so that the mismatch is most likely to destabilize the duplex with the target sequence under the optimal hybridization conditions. Preferably, the mismatch is adenine (A) to thymine (T) and vice versa, or guanine (G) to cytosine (c) and vice versa.

Numbers of nucleotides of these oligonucleotides are not limited, but 10 to 30 nucleotides are preferable. 8-51 probes for each locus can be designed focusing on 3' prime side of each locus as the use of probes sets for each locus provided redundancy in the detection and analysis of the data, can reduce the potentially confounding effects of occasional cross-hybridization, and can make it so all probes do not have to hybridize identity in order to obtain quantitative information. To further increase the sensitivity and specificity of detection, each PM probe can be designed with a closely related mismatch probe (MM
probe) that is identical to PM probe with the exception of a mismatched base, i.e. base 13. The preferable length of oligonucleotide which is used in this invention is 25 base, but no particular limitation for the length of oligonucleotide. Preferably, the mismatch is adenine (A) to thymine (T) and vice versa, or guanine (G) to cytosine (c) and vice versa.

(l)-3 Adhering oligonucleotides to solid support There is no particular limitation for the methods used for adhering oligonucleotides to solid support, and the method may be conducted according to the known means, while preferred method is mentioned below. For example, all of designed PM and MM probes as above ((l)-2) can be adhered to the surface of solid support to produce a DNA array using a certain method,. such as GeneChip technology or the like.

There is no particular limitation for the methods used for DNA maicroarray analysis, while preferred methods for each of them is mentioned below, i.e., the example of gene expression analysis to identify genes, which show a characteristic expression profile under some conditions, classification of industrial yeast, detection of nucleotide polymorphism and selection of genes for functional analysis are mentioned below.

III. Analyzing methods using the DNA array The arrays of the invention can be used for various methods to analyze genomic DNA, cDNA or cRNA of an industrial yeast. The analyzing methods include, for example, 1) a method for determining expression of each gene of non-Sc type, 2) a method for classifying an industrial yeast, 3) a method for detecting nucleotide polymorphism in genome of an industrial yeast, 4) a method for screening a useful strain of industrial yeasts, and 5) a method for screening a gene of an industrial yeast.
(m) Gene expression analysis Gene expression analysis of an industrial yeast can be carried out using the DNA array of the present invention produced according to the method described in (1). It is possible to identify the highly inducible or reducible gene(s) according to changes of not only medium but also environment using the DNA array. It is also possible to identify the specific gene(s) for lager brewing yeast in brewing using the DNA array. But it is not limited for these examples.

Gene expression analysis includes culturing of a industrial yeast, preparation of mRNA, synthesis of labeled cRNA(or cDNA), hybridization, and data analysis. There is no particular limitation for the methods of Gene expression, while preferred methods for each of them is mentioned below.

(m)-1 Culturing a industrial yeast in a various condition Industrial yeast can be cultivated under various conditions for any purpose. For example, the cultivation for identification of genes which respond to the change of composition of culture medium can be carried out as mentioned below. Industrial yeast can be grown overnight in a Zinc replete medium, such as LZMM medium + 40 pM zinc sulfate at 30 C with shaking. LZMM medium contains 0.17 %
yeast nitrogen base w/o amino acids (manufactured by DIFCO), 0.5 % ammonium sulfate, 20 mM sodium citrate (pH

4.2), 125 E,tM MnC12, 10 p,M FeC12, 2 % maltose, 10 mM EDTA
(pH 8.0), or the like. Cells are harvested and washed three times with sterile distilled water. An adequate amount of cells, an optical density (OD600) of 0.25, or the like, are inoculated to 1) zinc depleted medium (LZMM medium) or the like, 2) zinc replete medium (LZMM+ 40 VM zinc sulfate) or the like, 3) oxidative stress medium (LZMM+ 40 VM zinc sulfate + 2mM H202) or the like, 4) carbon starvation medium (deleting maltose from above LZMM+ 40 pM zinc sulfate) or the like. Cells are grown at 30 C for 6 hours and harvested for RNA preparation.Cells withdrawn from fermentation tube under beer fermenting condition can be used for the following experiments.

(m)-2 Preparation of mRNA

Preparations of total RNA from each cell can be carried out using an RNeasy Mini Kit (manufactured by QIAGEN) or the like according to a manual. Preparations of Poly (A)+ mRNA from each total RNA are carried out using an Oligotex Direct mRNA kit (manufactured by QIAGEN) or the like according to a manual. There is no particular limitation for the methods used for preparation of mRNA and the method may be conducted according to the known means.
(m)-3 Synthesis of Labeled cRNA

Synthesis of Labeled cRNA can be carried out using a BioArray HighYield RNA Transcript Labeling Kit (manufactured by Affymetrix) or the like according to a manual. Biotin can be used for labeling. There is no particular limitation for the methods to synthesize Labeled cRNA and the method may be conducted according to the known means.

(m)-4 Hybridization 5[tg of Biotin-Labeled cRNA, 1.7 1 of 3 nM Control Oligonucleotide B2 (manufactured by Affymetrix), 5jul of 20X Eukaryotic Hybridization Controls (manufactured by Affymetrix), 1Rl of 10 mg/ml Herring Sperm DNA
(manufactured by Affymetrix), 1[tl of 50 mg/ml Acetylated BSA (manufactured by Affymetrix), 50 lul of 2X Hybridization buffer (manufactured by Affymetrix), and water (manufactured by Affymetrix) to give final volume of 100 l are mixed and hybridized to the DNA array according to a Technical Manual of Affymetrix. After 16 hours of hybridization, hybridization cocktail are removed and the DNA array is washed using the a GeneChip Fludics Station (manufactured by Affymetrix) or the like, and stained with a Streptavidin Phycoerythrin (300 Rl of 2X MES Stain Buffer (manufactured by Affymetrix), 24 [tl of 50 mg/ml acetylated BSA (manufactured by Affymetrix), 6 l of lmg/ml StreptAvidin-Phycoerythrin (manufactured by Affymetrix), 270 l of DI Water (manufactured by Affymetrix)) according to a Technical Manual of Affymetrix. There is no particular limitation for the methods to hybridize, and the method may be conducted according to the known means.

(m)-5 Data analysis Data analysis of the DNA array can be carried out using a commercially available software (for example, GCOS
(GeneChip Operating Software manufactured by Affymetrix;
GeneSpring manufactured by Silicon Genetics; ImaGene manufactured by Takara Shuzo; Array Gauge manufactured by Fuji Photo Film; ImageQuant manufactured by Amersham Pharmacia Biotech, or the like) according to a Technical Manual. Genes which show characteristic expression profiles can be identified and selected for functional analysis.

Furthermore, the identified gene can be used as a gene marker to figure out a condition of the yeast cells. A
fluctuation in the expression level of a specific gene can be monitored using a nucleic acid molecule obtained in the time course of culture as the nucleic acid molecule derived from brewing yeast. The culture conditions can be optimized by analyzing the fluctuation. The expression profile of the brewing yeast at the total gene level (namely, which genes among a great number of genes encoded by the genome have been expressed and the expression ratio thereof) can be determined using a nucleic acid molecule having the sequences of many genes determined from the genome sequence of the yeast. Thus, the expression level of the genes determined by the genome sequence can be analyzed and, in its turn, the biological conditions of the yeast can be recognized as the expression pattern at the full gene level.

As a result of gene expression analysis, a group of genes which shows distinctive expression under a certain condition can be identified as target genes for further functional analysis. "A certain condition" may include, without any limitation, changes in environment, such as, temperature, pH, or osmotic pressure, as well as changes in components of medium. As a screening method for identifying genes showing distinctive expression under the certain condition, for example, a gene wherein significant changes in expression of the gene are recognized according to changes in environment, can be selected. "Significant changes" mean preferably, 1.5 times higher, or 2/3 or less, more preferably, 2 times higher, or 1/2 or less, even more preferably 3 times higher, or 1/3 or less, but not limited thereto.

There is no particular limitation for the methods used for analysis of data and the method may be conducted according to the known means.

Comparative hybridization analysis The DNA array of the present invention can also be used for comparative hybridization analysis using genomic DNA, cDNA or cRNA as a sample for hybridization.

(n) Classification of industrial yeast An embodiments of the present invention includes a method for classifying an industrial yeast comprising (a) hybridizing genomic DNA prepared from the industrial yeast to the DNA array of the present invention; and (b) calculating hybridization ratio to any of (1) to (4), and hybridization ratio to (5) and/or (6).

For the purpose of this embodiment, the DNA array comprises, in addition to the DNAs of any of (1) to (4), DNAs of the (5) and/or (6) is preferably used (Embodiment or 16).

Preferably, hybridization intensity to the DNAs of (1) 10 and to the DNAs of (5) is compared. Alternatively, hybridization intensity to the DNAs of (2) and to the DNAs of (6) is compared.

The present DNA array may optionally comprise DNAs of the (5') and/or (6') and/or (7) and/or (8)having one or 15 more mismatch(es) to the DNA of (5) and/or (6) and/or (1) and/or (2),respectively. DNAs of (5') and/or (6') and/or (7) and/or (8) may be optionally used as DNA probes of the present DNA array for determining and confirming hybridization specificity of a sample to the DNAs of (5) and/or (6) and/or (1) and/or (2),respectively.
Specifically, in one of preferred embodiments of the present invention, the DNA array comprises at least one group of DNAs selected from (1) to (4) (preferably (1) and/or (2)), at least one group of DNAs selected from (7) to (10) (preferably (7) and/or (8)), DNAs of (5) and/or (6) and DNAs of (5') and/or (6'). In the method using the above DNA array, percentage of genes which hybridize to DNAs of (1) and/or (2), but not to DNAs of (7) and/or (8) is determined as hybridization ratio to any of (1) to (4), and percentage of genes which hybridize to DNAs of (5) and/or (6), but not to DNAs of (5') and/or (6') is determined as hybridization ratio to any of (5) and/or (6).

It is possible to classify industrial yeast using a DNA array mentioned above. Preparation of yeast genomic DNA
and hybridization to a DNA array may be carried out as described before. Detection of the signal intensity of array is carried out using a Gene Chip Analysis Basic System and analysis soft ware (GCOS; GeneChip Operating Software 1.0) manufactured by Affymetrix. The percentage of probes, to which the DNA of an industrial yeast hybridizes, is calculated. The identity between the strain from which the DNA probes of the DNA array are derived (e.g.34/70) and the tested strain is estimated from the calculation result.

Industrial yeast strains can be classified on the basis of the identity. A strain of industrial yeasts which shows hybridization percentage to the non-Sc genes and the Sc-genes on the DNA array similar to that of another strain can be classified as a close strain of the another strain.
(o) Detection of nucleotide polymorphism An embodiment of the present invention includes a method for detecting nucleotide polymorphism in genome of an industrial yeast comprising (a) hybridizing genomic DNA prepared from the industrial yeast to the DNA array of the present invention; and (b) selecting a gene wherein hybridization intensity to the DNAs of any of (7) to (10) is higher than hybridization intensity to the DNAs of any of (1) to (4).

For the purpose of this embodiment, the DNA array comprises, in addition to the DNAs of any of (1) to (4), DNAs of any of (7) to (10) is preferably used (Embodiments 17-19).

It is possible to detect nucleotide polymorphism of a industrial yeast by comparative genomic hybridization with the DNA array mentioned above. For this embodiment, the probes on the array are preferably oligonuclotide probes.
As an illustrative example, the sets of oligonucleotides for each probe consist of Perfect Match oligonucleotide (PM) which is identical to the sequence of strain 34/70 and MisMatch oligonucleotide (MM) which contains a single base mismatch, e.g., in the central position of the oligonucleotide. It is possible to detect nucleotide polymorphism from the gene whose signal intensity in MM is higher (for example, more than 5-fold) than that in PM.

Genes comprising one or more mismatche(es) can be preferable candidates of target genes for further functional analysis.

(p) Selection of useful yeast strains and genes An embodiment of the present invention includes a method for screening a useful strain of industrial yeast, comprising (a) hybridizing genomic DNA prepared from the industrial yeast strain to the DNA array of the present invention; and (b) determining the industrial yeast strain as useful when the strain contain 1 or more genes, preferably, 2 or more genes, wherein hybridization intensity thereof is 1.5 times higher or less than 2/3 compared to an average hybridization intensity to the DNA of any of (1) to (4).
A gene of genomic DNA which shows hybridization intensity significantly different from other genes may be selected as a candidate of useful gene for further functional analysis. Therefore, strains of industrial yeasts comprising 1 or more such genes, preferably 2 or more such genes can be selected as candidate of useful strains. Preferably, hybridization intensity of such gene is significantly different from that of other genes, more preferably, thereof is 1.5 times higher or less than 2/3 compared to an average hybridization intensity to the DNA
of (1) and/or (2). More preferably, the difference in hibridization intensity is 2 times higher, or 1/2 or less, even more preferably 3 times higher, or 1/3 or less, but not limited thereto.

Further embodiment of the present invention is a method for screening a gene of an industrial yeast, comprising (a) hybridizing genomic DNA prepared from the industrial yeast strain to the DNA array of the present invention; and (b) selecting a gene wherein hybridization intensity thereof is 1.5 times higher or less than 2/3 compared to an average hybridization intensity to the DNA of any of (1) to (4).

Another embodiment of the present invention is a method for screening a gene of an industrial yeast, comprising (a-1) hybridizing genomic DNA, cDNA or cRNA prepared from the industrial yeast to the DNA array of the present invention;

(a-2) independently from the step (a-1), hybridizing genomic DNA, cDNA or cRNA prepared from the industrial yeast of the strain used for preparing the DNA array to the DNA array of the present invention; and (b) selecting a gene wherein hybridization intensity thereof to the DNA any of (1) to (4) in the step (a-1) is significantly different from hybridization intensity thereof in the step (a-2).

The above screening method enable to select genes of which hybridization intensity to the DNA array are different between strains. From the results of comparative genomic hybridization analysis, a gene which has probe sets showing low signal intensities may be lost or have different sequence from that of the strain used for probes of the array (e.g., 34/70). In contrast, a gene which has probe sets showing high signal intensities may be high in copy number. For example, as for a gene, which show hybridization intensity of 2 times higher in the step (a-i) than that of the strain used for preparing the DNA array in the step (a-2), the strain of (a-1) is likely to have two or more copies of the gene.

Another embodiment of the present invention is a method for screening a gene of an industrial yeast, comprising (a-1) hybridizing cDNA or cRNA prepared from the industrial yeast to the DNA array of the present invention;
(a-2) independently from the step (a-i), hybridizing cDNA

or cRNA prepared from another industrial yeast to the DNA
array of any one of Embodiments 10-19, wherein the industrial yeast of (a-2) has been cultured in a different condition from the culture condition for the industrial yeast of (a-i); and (b) selecting a gene wherein hybridization intensity thereof to the DNA of any of (1) to (4) in the step (a-1) is significantly different from hybridization intensity thereof in the step (a-2).

The above screening method enable to select genes wherein expression of the genes may be changed due to difference in culture condition. The "industrial yeast cultured in a different condition" includes yeasts cultured in different medium or temperature, or sequential samples during the process of producing an alcohol or an alcoholic beverage, for example.

Genes obtained by the various screening methods of the present invention may be subjected for further functional analysis, because differences in hybridization intensity may contribute to the difference of fermentation character between strains. The genes which have nucleotide polymorphism detected by the method mentioned above can be also selected for functional analysis.

As another alternative, the DNA array of the present invention may be used to analyze the chromosomal structure of an industrial yeast by DNA array-based comparative genomic hybridization. Following description is an example of the chromosome structure analysis using the DNA array.

Yeast genomic DNA is prepared using a Quiagen Genomic Tip 100/G (#10243) and Qiagen Genomic DNA Buffer Set (#19060) according to the manual attached to the kit. The DNA (10 Rg) is digested with DNase I (manufactured by Invitrogen) according to a method of Winzeler, et al.
(Science, volume 281, pages 1194-1197 (1998)), biotinylated using a terminal transferase (manufactured by Roche) and hybridized to a DNA array (Affymetrix Gene Chip Yeast Genome S98 Array). The DNA array of the present invention may include DNAs of any one of (1) to (4) and (7) to (10) from Non-Sc type genes as well as (5)-and/or (6) and/or (5') and/or (6')of the Sc type. Hybridization and detection of the signal intensity of DNA array are carried out using a Gene Chip Analysis Basic System and analysis soft ware (GCOS; GeneChip Operating Software 1.0) manufactured by Affymetrix.

The signals of probes hybridized with the DNA of brewing yeast were lined following genes order in each chromosome using a spreadsheet program (Microsoft Excel 2000) and the signals are shown in bar graphs. The Sc type genes do not hybridize to the non-Sc type DNA probes (i.e., DNAs of (1) to (4)). Contrary, the non-Sc type genes do not hybridize to the Sc type DNA probes (i.e., DNAs of (5) and/or (6)). Therefore, the gene dosage of Sc type DNA
and/or non-Sc type DNA affect the signal and the points where the signals show vigorous changes and which are considered to be translocation sites between Sc type and non-Sc type chromosome. In a preferred embodiment, hybridization to DNAs of any of (1) to (4) can be determined by hybridization to DNAs of (1) and/or (2), but not to DNAs of (7) and/or (8), and hybridization to DNAs of any of (5) and/or (6) can be determined by hybridization to DNAs of (5) and/or (6), but not to DNAs of (5') and/or (6').

IV. Genes and Polypeptides The present invention further provides a non-Sc gene obtained by the analyzing method and the screening method of the present invention. Preferably, genes of the present invention involved in increase in productivity and/or improvement in flavor in the production of an alcohol or an alcoholic beverage. For example, genes of the present invention is, preferably, characterized in that concentration of sulfite in a culture medium of an industrial yeast increases when the gene is expressed in the yeast.

The present invention also provides polypeptides or proteins encoded by the genes. The polypeptides of the present invention may be obtained by any known conventional methods including expression of the gene by genetic engineering, or via polypeptide synthesizing technique.

The genes of the present invention may include both ORF and non-coding regions (non-ORF regions). "Gene"
includes DNA, cDNA, mRNA, cRNA, without any limitation.
The gene of the present invention can be prepared by any known conventional methods, for example, by screening a cDNA library, or via polynucleotide synthesizing techniques. In the present specification, the term "nucleic acid" is used interchangeably with "gene". In the following explanation, "DNA" will be explained as an example of gene.

With regard to the DNA which can be obtained by the method of the present invention, a DNA containing the DNA
sequence of the non-Sc type gene obtained in the above and a DNA which hybridizes to the said DNA under stringent condition and a protein having the substantially the same biological activity may be listed.

The DNA obtained by the method of the present invention includes single-stranded and double-stranded DNAs although they are non-limitative. A DNA which hybridizes to the DNA containing a DNA sequence of the non-Sc type gene obtained in the above under stringent condition includes a degenerated mutant of codon for the protein encoded by the said gene, for example. A degenerated mutant means a polynucleotide fragment encoding the same amino acid sequence by degeneration of codon, although in terms of a DNA sequence, it is different from a DNA
sequence of the non-Sc type selected by the present invention.

As an example, the gene of the present invention includes a nucleic acid encoding a polypeptide of any one of the following i) and ii):

i) a polypeptide having the amino acid sequence represented by SEQ ID NO:3; and ii) a polypeptide having an amino acid sequence wherein one or more amino acid residue(s) is deleted from, substituted for and/or added to the amino acid sequence represented by SEQ ID NO:3, and having an activity to increase concentration of sulfite in a culture medium of an industrial yeast when the gene is expressed in the yeast.

More preferably, the nucleic-acid according to the present invention is selected from the following a) and b):

(a) a nucleic acid having the nucleotide sequence represented by SEQ ID NO:1; and (b) a nucleic acid having a nucleotide sequence which hybridizes to the nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:1 under a stringent condition, and encodes a polypeptide having an activity to increase concentration of sulfite in a culture medium of an industrial yeast when the gene is expressed in the yeast.

Specific example thereof is a DNA with a sequence as shown by SEQ ID NO:1, a DNA which hybridizes to the said DNA under stringent condition, etc. The DNA which hybridizes under stringent condition means a DNA which is prepared by a colony hybridization method, a plaque hybridization method, a southern blot hybridization method or the like using a DNA fragment with the sequence of the non-Sc type identified hereinabove as a probe. An appropriate stringent condition can be selected as described above.

Hybridization may be carried out according to a method mentioned in "Molecular Cloning, Third Edition", "Current Protocols in Molecular Biology", "DNA Cloning 1: Core Techniques, A Practical Approach, Second Edition, Oxford University (1995)", etc.

Specific examples of the hybridizable DNA is a DNA

which shows at least not less than 60% identity, preferably a DNA which shows not less than 80% identity and, more preferably, a DNA which shows not less than 95% identity to a DNA sequence as shown in SEQ ID NO:1 when calculation is conducted using a parameter of the default setting (initial setting) by a software for homology searching such as FASTA, BLAST, Smith-Waterman "Meth. Enzym., volume 164, page 765 (1988)", etc.

An example of the DNA obtained by the screening method of the present invention is a DNA encoding a polypeptide comprising an amino acid sequence shown by SEQ ID NO:3 , or a DNA which hybridizes to the said DNA under stringent condition.

An example of the polypeptide which is encoded by the DNA obtained by the screening method of the present invention is a polypeptide encoded by the DNA containing the DNA sequence of ORF obtained in the above and a polypeptide encoded by the DNA which is hybridized to the said DNA under stringent condition or a polypeptide comprising an amino acid sequence shown by SEQ ID NO:3 Further, a polypeptide having an amino acid sequence wherein one or more amino acid residue(s) is deleted from, substituted for and/or added to the amino acid sequence of the said polypeptide, and has substantially same biological activity as the activity of the said polypeptide is also included in the present invention. The expression reading "substantially same activity as the activity of the said polypeptide" means the same activity as the activity which is represented by enzymatic activity or the function inherent to the polypeptide before the deletion, .
substitution or addition. The said polypeptide can be prepared by a site-specific mutation introduction which is mentioned in "Molecular Cloning, Third Edition", "Current Protocols in Molecular Biology", "Nuc. Acids. Res., volume 10, page 6487 (1982)", "Proc. Natl. Acad. Sic. USA, volume 79, page 6409 (1982)", "Gene, volume 34, page 315 (1985)", "Nuc. Acids. Res., volume 13, page 4431 (1985)", "Proc.

Natl. Acad. Sci. USA, volume 82, page 488 (1985)", etc.
For example, it is able to be prepared by introducing a site-specific mutation into a DNA encoding a polypeptide comprising an amino acid sequence shown in SEQ ID NO:3 or 4. Although there is no particular limitation for the number of the amino acid residue(s) which is/are deleted and/or substituted and/or added, the number is within such an extent that is able to be deleted and/or substituted and/or added by known methods such as the above-mentioned site-specific mutation method and is one to several tens, preferably 1 to 20, more preferably 1 to 10 and, still more preferably, 1 to 5.

A polypeptide having an amino acid sequence wherein one or more amino acid residue(s) is deleted from, substituted for and/or added to the amino acid of the polypeptide of the present invention means that there is/are one or more deletion(s) and/or substitution(s) and/or addition(s) of one or more amino acid residue(s) at any one or more site(s) of the amino acid sequence in the same sequence. Those deletion(s) and/or substitution(s) and/or addition(s) may take place at the same time and the substituted or added amino acid residue may be either naturally occurring type or a non-naturally occurring type.

Examples of the amino acid residue of a natural type are L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine and L-cysteine, etc.

Examples of the amino acid residue which is able to be substituted each other will be shown below. Amino acid residues in the same group may be substituted each other (conservative substitution).

Group A: leucine, isoleucine, norleucine, valine, norvaline, alanine, 2-aminobutanoic acid, methionine, 0-methylserine, tert-butylglycine, tert-butylalanine and cyclohexylalanine.

Group B: aspartic acid, glutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid and 2-aminosuberic acid.

Group C: asparagine and glutamine.

Group D: lysine, arginine, ornithine, 2,4-diaminobutanoic acid and 2,3-diaminopropionic acid.
Group E: proline, 3-hydroxyproline and 4-hydroxyproline.

Group F: serine, threonine and homoserine.
Group G: phenyl alanine and tyrosine.

For the purpose that the resulting mutated polypeptide has the substantially same activity as the activity of the polypeptide before the mutation, it is preferred that the amino acid sequence of mutated one is at least 60% or more, usually 80% or more or, particularly, 95% or more of identity to the amino acid sequence of the polypeptide before the mutation when calculation is carried out using a parameter of the default setting (initial setting) by a software for the analysis such as BLAST and FASTA.
Identity between two amino acid sequence can be determined as discussed above.

it is also possible to produce the polypeptide of the present invention by a chemical synthetic method such as Fmoc method (fluorenylmethyloxycarbonyl method), tBoc method (tert-butyloxycarbonyl method), etc. It is further possible to synthesize chemically by using a peptide synthesizers manufactured by Advanced ChemTech, Perkin-Elmer, Pharmacia, Protein Technology Instrument, Synthecell-Vega, PerSeptive, Shimadzu, etc.

When the method of the present invention is used, it is possible to determine the genome sequence of industrial yeast, to identify the useful genes of industrial yeast and to assign the functions of the said genes. There are many cases where the genes in industrial yeast are industrially useful and, when the genes are classified on the basis of the assigned functions, character of the yeast is clarified and precious information for breeding of industrial yeast is able to be obtained. For example, when the industrial yeast is a brewing yeast, then a gene involved in increase in productivity and improvement in flavor in the production of alcoholic beverage is identified and, in case the gene is disadvantageous for the increase of productivity or for the improvement of flavor, the gene expression is suppressed by a gene disruption or an antisense method or an RNAi method (c.f., for example, Non-Patent Document 10), whereupon yeast which shows an excellent brewing character can be bred. In case the gene is advantageous for the increase'of productivity, improvement of flavor, etc., then for example the gene is overexpressed in the yeast, whereupon brewing yeast which shows an excellent brewing character, which is industrially useful, can be bred.

An example where the gene obtained by the method of the present invention is used to breed useful yeast is shown as follows.

As already mentioned above, when the sulfite concentration in a product is increased, it is possible to make a product with excellent flavor stability. Therefore, if the gene obtained by the screening method of the present invention contributes to production and efflux of sulfite, it is now possible that a transformant is cultivated and expressed the said gene to make a product with excellent flavor stability as a result of the increase in the concentration of sulfite in the product.

It has been known that a bottom fermenting yeast reduces sulfate ion ( S042- ) taken from outside of the cell to sulfite ion ( S032- ). However, sulfite inhibits the activity of glyceroaldehyde-3-phosphate dehydrogenase and reduces the concentration of intracellular ATP, therefore, yeast has a function of discharging sulfite so that excessive sulfite should not be accumulated in the cell.
SSU1 is a gene, which has been isolated and shown complement the sulfite-sensitive mutation (c.f., for example, Non-Patent Document 11). SSU1 gene product comprises 485 amino acid residues, and the structural analysis suggests that it is a transporter with 9 to 10 membrane-spanning domains (c.f., for example, Non-Patent Document 12). Further, as a result of experiment using a SSU1 overexpressed strain, it has been already proved that the SSU1 gene product effects the discharge of sulfite (c.f., for example, Non-Patent Document 13).

Bottom fermenting yeast usually has a high production ability of sulfite, while top fermenting yeast rarely produces it. By using a screening method of the present invention, it is possible to select non-ScSSU1 gene which is specific to bottom fermenting yeast in addition to ScSSUl gene which exists in both top and bottom fermenting yeast.

Breeding method of yeast, wherein the non-ScSSUl gene 4 is intensified, is specifically mentioned in the Examples.

V. Recombinant vectors, transformants and other embodiments The present invention further includes the following embodiments:

A recombinant vector containing the gene of the present invention.

A transformant comprising the recombinant vector.
The transformant is preferably, a yeast of genus Saccharomyces.

A method for producing an alcohol or an alcoholic beverage, using the transformant of the present invention.
Preferably, the present method may comprise culturing the transformant of the present invention in a sugar-containing medium. Preferably, the sugar containing medium is selected from a group consisting of wort, grape juice, rice juice and glucose and/or maltose syrup.

A breeding method of yeast which is suitable for the production of an alcohol or an alcoholic beverage, characterized in that, expression of the gene or the nucleic acid of the present invention is controlled.
Preferably, the yeast belongs to the genus Saccharomyces.

Yeast obtained by the breeding method of the present invention.

A method for producing an alcohol or an alcoholic beverage using the yeast of the present invention.

An alcohol or an alcoholic beverage which is produced by the producing method of the present invention.
With regard to yeast used as a host in the introduction of the gene selected by the screening method of the present invention, there is no particular limitation so far as it is yeast which is usable for brewing, and any yeast which is widely used as a brewing yeast at present such as beer yeast including NCYC456, NBRC 1951, NBRC 1952, NBRC 1953 and NBRC 1954. Further, whisky yeasts (such as S. cerevisiae NCYC 90), wine yeasts (such as wine yeast Kyokai No. 1, No. 3, No. 4, etc.) and sake yeasts (such as sake yeast Kyokai No. 7, No. 9, etc.) may be also used.

With regard to a vector used for the introduction of gene into the above-mentioned host, there is no particular limitation so far as it is a vector which can express gene in the yeast, and a multicopy plasmid (YEp type), a single-copy plasmid (YCp type) and a chromosomal DNA-integrating plasmid (YIp type) may be utilized. An example of a YEp vector is YEp 51 (J. R. Broach, et al., Experimental Manipulation of Gene Expression, Academic Press, New York, 83, 1983), etc.; an example of a YCp vector is YCp 50 (M.

D. Rose, et al., Gene, volume 60, page 237, 1987), etc.;
and an example of a YIp vector is YIp 5 (K. Struhl, et al., Proc. Natl. Acad. Sci. USA, volume 76, page 1035, 1979), etc. Those plasmids are put into the market and are easily available.

The above-mentioned vector may have other sequence for controlling expression of a gene in yeast such as, promoter, operator, enhancer, silencer, ribosome binding sequence, termiriator, etc. With regard to a promoter and a terminator for a constitutive expression of a gene, but any combination may be used as long as it functions in a brewing yeast and is independent from sulfite concentration in the product. As to a promoter for example, it is possible to use a promoter for glyceraldehyde-3-phosphate dehydrogenase (TDH3) gene, a promoter for phosphoglycerate kinase (PGK1) gene, etc. Those promoters have been known, and PGK1 gene, for example, is mentioned in detail in publicly known documents such as M. F. Tuite, et al., EMBO
J., volume 1, page 603 (1982) and easily available.

It is not necessary that the above-mentioned other sequences which regulate the expression of the introduced gene are particularly provided from vector so far as the DNA obtained by the screening method of the present invention includes them. When such other sequences are not contained in the said DNA, it is preferred that other sequences are prepared separately and ligated to the said DNA. Alternatively, even in the case of higher expression level or specific regulation of expression is required, other sequences appropriate for such a purpose are ligated to the said DNA.

A method for the transformation of the above vector to a host may follow known procedures. For example, the following methods may be used; an electroporation method "Meth. Enzym., volume 194, page 182 (1991)", a spheroplast method "Proc. Natl. Acad. Sci. USA, volume 75, page 1929 (1978)", a lithium acetate method "J. Bacteriology, volume 153, page 163 (1983)", a method mentioned in "Proc. Natl.
Acad. Sci. USA, volume 75, page 1929 (1978)", etc.

To be more specific, a host is cultivated in a standard yeast nutrient medium (such as YEPD medium "Genetic Engineering, vol. 1, Plenum Press, New York, 117 (1979)", etc.) so that the absorbance at 600 nm becomes 1 to 6. Cells are collected by centrifugation, washed and subjected to a pre-treatment with an alkali metal ion or, preferably, lithium ion in a concentration of about 1M to 2M. After the cells are incubated at about 30 C for about 60 minutes, they are incubated together with DNA to be introduced (about 1 to 20 Rg) at about 30 C for about 60 minutes. Polyethyleneglycol or, preferably, polyethyleneglycol of about 4,000 daltons is added as the final concentration will be about 20% to 50%. After the incubation is carried out at about 30 C for about 30 minutes, the cells are subjected to a heating treatment at about 42 C for about 5 minutes. Preferably, the cell suspension is washed with a standard yeast nutrient medium and placed in a predetermined amount of a fresh standard yeast nutrient medium, then incubated at about 30 C for about 1 hour. After the incubation, it is spread on an appropriate selective medium plate.

Besides the above, as for a general cloning technique, "Molecular Cloning, Third Edition", "Methods in Yeast Genetics, A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY)", etc. were.
referred to.

With regard to a selective marker used for the transformation, it is not possible to utilize an auxotrophic marker in the case of brewing yeast and, therefore, G 418-resistance gene (G 418r), copper-resistance gene (CUP 1) "M. Karin, et al., Proc. Natl.
Acad. Sci. USA, volume 81, page 337, (1984)", serulenin-resistance gene (fas2m, PDR 4) "Atsushi Inogoshi, et al., Seikagaku, volume 64, page 660, (1992)", "M. Hussain, et al., Gene, volume 101, page 149, (1991)", etc. are applicable.

The brewing yeast bred according to the present invention is not different from a parental strain in terms of growth and fermentation ability. Accordingly, materials, facilities for the production, production control, etc. may be entirely the same as those in the conventional methods, which is an important aspect of the present invention. However, it goes without saying that, conditions such as fermentation period may be changed on a case-by-case, if desired. For example, when a brewing yeast in which discharging ability of sulfite is intensified and an alcoholic beverage is produced using such yeast, only the content of sulfite in the product changes, and there is no difference from the case where a parental strain is used, in terms of growth and fermentation ability of the yeast. Accordingly, materials, facilities for the production, production control, etc. may be entirely the same as those in the conventional methods, and there is no increase in the cost of production of an alcoholic beverage in which sulfite content increases and of which flavor is improved.

Examples Details of the present invention are mentioned with the following Examples although the present invention is not limited to the following Examples.

(Example 1) Preparation of chromosomal DNA of Saccharomyces pastorianus Weihenstephan 34/70 (hereinafter, abbreviated as strain 34/70) Preparation of chromosomal DNA was carried out by a method mentioned in "Yeast, a practical approach (IRL

Press) 6.2.1 (pages 228-229)", which was partially modified. Cells were inoculated and grown in 200 mL of YPD
medium (2% glucose, 1% yeast extract and 2% polypeptone) at C until absorbance of the culture at 660 nm became 4.

Cells were collected by centrifugation, washed with buffer A (50 mM sodium phosphate, 25 mM EDTA and 1% (v/v) (3-mercaptoethanol; pH 7.5) and resuspended in 25 mL of buffer A. 7 mg of Zymolyase 100T (Seikagaku Kogyo) was added thereto and the mixture was mildly shaken at 37 C for 60 minutes. To this was added 25 mL of buffer B (0.2M Tris-HC1, 80 mM EDTA and 1% SDS; pH 9.5), then the mixture was allowed to stand at 65 C for 30 minutes, cooled on ice, mixed with 12 mL of 5M potassium acetate and allowed to stand on ice for further 60 minutes. The resulting solution was centrifuged at 5,000 g for 10 minutes at 15 C.
To the recovered supernatant was added the same volume of ethanol to precipitate DNA, and the mixture was immediately centrifuged at 5,000 g for 10 minutes at 15 C to collect the precipitate. The resulting precipitate was washed with 70% (v/v) ethanol, subjected to natural drying and dissolved in 5 mL of TE buffer (10 mM Tris-HC1 and 1 mM of EDTA; pH 8.0) to give a crude DNA solution. Cesium chloride (4.06 g) and 840 g of bisbenzimide (Hoechst 33258) were added and dissolved in 3.5 mL of the crude DNA
solution, the mixture was subjected to centrifugal separation at 100,000 g for 17 hours at 25 C and exposed to UV light to make DNA bands visible, whereupon the band of the lower layer was recovered. The recovered DNA solution was extracted with isopropanol which was saturated with a cesium chloride solution to remove bisbenzimide (Hoechst 33258). To the recovered aqueous layer was added 4-fold by volume of 0.3 M sodium acetate followed by mixing. Then, 3-fold by volume of ethanol was added thereto to precipitate the DNA, which was recovered by centrifugation.
The recovered DNA was dissolved in TE buffer containing 75 [tg/mL of RNase, kept at 37 C for 5 minutes, and extracted with phenol/chloroform for three times and the aqueous layer was further subjected to precipitation with ethanol.
The precipitate recovered by centrifugation was washed with 70% (v/v) ethanol, subjected to natural drying and dissolved in TE buffer to prepare a chromosomal DNA

solution.

(Example 2) Preparation of a shotgun library The concentration of a genome solution of strain 34/70 prepared in Example 1 was adjusted to 1 mg/mL using a TE

buffer. 0.1 mL thereof was treated with a Hydroshear (manufactured by GeneMachines; speed: 6; cycle: 20) to fragmentize the genomic DNA. End of the genomic fragment was blunted using a DNA Blunting Kit (manufactured by Takara Shuzo), fractionated by 0.8% agarose gel electrophoresis. Genomic fragments of 1.5 to 2.5 kb were excised from the gel, and DNA was eluted. The DNA eluate was treated with phenol/chloroform and precipitated with ethanol to give a genome library insert. All the above insert and 0.5 Rg of pUC 18 SmaI/BAP (manufactured by Amersham Biosciences) were subjected to ligation at 15 C
for 15 hours using T4 ligase (manufactured by Takara Shuzo).

The product of ligation reaction was precipitated with ethanol and dissolved in 10 RL of a TE buffer. A ligation solution (1 RL) was inserted into 40 L of Escherichia coli Electro Cell DH5a (manufactured by Takara Shuzo) by means of electroporation under the condition mentioned in-the attached experimental manual. The resulting product is spread on an LB plate medium containing 1.6% of agar (the LB medium (1% bactotryptone, 0.5% yeast extract and 1%
sodium chloride; pH 7.0)) containing 0.1 mg/mL of ampicillin, 0.1 mg/mL of X-gal and 1 mmol/L of isopropyl-(3-D-thiogalactopyranoside (IPTG), and incubated through the night at 37 C.

The transformant obtained from colonies formed on the said plate medium was subjected to cultivation without shaking through the night at 37 C in a 384-well titer plate to which 50 RL of an LB medium containing 0.1 mg/mL of ampicillin was added. Then 50 RL of a 50% aqueous solution of glycerol was added thereto followed by stirring, and the mixture was used as a glycerol stock.

(Example 3) Preparation of a cosmid library About 0.1 mg of the genomic DNA obtained in Example 1 was partially digested with Sau3AI (manufactured by Takara Shuzo). Insertion of the fragment into a BamHI site of Super Cos I vector (manufactured by Stratagene) was carried out according to a manual. A ligated product prepared by this method was subjected to packaging using Gigapack III
Gold (manufactured by Stratagene) and introduced into Escherichia coli XL1-Blue MR strain (manufactured by Stratagene) according to a manual. It was spread on an LB
plate medium containing 0.1 mg/mL of ampicillin and incubated through the night at 37 C. The resulting transformants were cultured through the night at 37 C in an LB medium (each well: 50 RL) containing 0.1 mg/mL of ampicillin using a 96-well titer plate, and then 50 RL of 50% glycerol solution was added thereto followed by stirring and the mixture was used as a glycerol stock.

(Example 4) Determination of DNA sequence (4-1) Preparation of DNA fragment The genome sequence of strain 34/70 was determined mainly using the genome shotgun method. A DNA fragment of which DNA sequence is to be determined by that method was prepared by a PCR method from the shotgun library prepared in the above Example 2. To be specific, clone derived from the genome shotgun library was inoculated using a replicator (manufactured by Gene Solution) to a 384-well titer plate where 50 RL of an LB medium containing 0.1 mg/mL of ampicillin was placed to each well and cultivated without shaking through the night at 37 C. The culture liquid was transferred to a 384-well reaction plate (manufactured by AB Gene) containing 10 L of reaction mixture for PCR (TaKaRa Ex Taq manufactured by Takara Shuzo) using a replicator (manufactured by Gene Solution) and PCR was carried out according to a protocol by Makino, et al. "DNA Research, volume 5, pages 1 to 9 (1998)" using a GeneAmp PCR System 9700 (manufactured by Applied Biosystems) to amplify the inserted fragment. After that, excessive primers and nucleotides were removed by a PCR
product purification kit (manufactured by Amersham Bioscience) and a sequence reaction was carried out using that sample as a template.

A DNA fragment from the cosmid library of the above Example 3 was prepared according to the following method.
That is, clone derived from the cosmid library was inoculated to each well of a 96-well plate to which 1.0 mL
each of a 2 x YT medium (1.6% bactotryptone, 0.1% yeast extract and 0.5% sodium chloride; pH 7.0) containing 50 g/mL of ampicillin was placed and subjected to shake culture at 30 C through the night. A cosmid DNA was prepared from the said culture using KURABO PI-1100 AUTOMATIC DNA ISOLATION SYSTEM (manufactured by KURABO) according to a manual of KURABO, and was used as a template for a sequence reaction.

(4-2) Sequence reaction A sequence reaction mixture-was prepared as follows.
The PCR product or cosmid DNA prepared in the above (4-1) is mixed with about 2Rl of DYEnamic ET Terminator Sequencing Kit (manufactured by Amersham Bioscience) and appropriate primers to give about SRl of reaction mixture.

An M13 forward (M13-21) primer and an M13 reverse (M13RV) primer (manufactured by Takara Bio), are used for the sequence reaction of a PCR product derived from shotgun DNA, while a forward primer SS-cos F.1 (SEQ ID NO: 7) and a reverse primer SS-cos R.1 (SEQ ID NO: 8) are used for cosmid DNA. Amounts of the primers and the DNA fragment were 3.2 pmol and 50 to 200 ng, respectively. The said reaction solution was subjected to dye terminator sequence reaction of 60 cycles using a GeneAmp PCR System 9700.
Cycle parameter followed a manual attached to the DYEnamic ET Terminator Sequencing Kit. Purification of the sample was carried out using a Multi Screen HV Plate (manufactured by Millipore) according to a manual of Millipore. The purified reactant was stored in a dark place of 4 C. The purified reactant was analyzed using a Mega BACE 1000 Sequencing System (manufactured by Amersham Bioscience) and ABI PRISM 3700 DNA Analyser (manufactured by Applied Biosystems) according to manuals attached thereto. The data on 332,592 sequences obtained by the Mega BACE 1000 Sequencing System and on 13,461 sequences obtained by the 3700 DNA Analyser were transferred to a server Enterprise 6500 (manufactured by Sun Microsystems) and preserved. The data on 346,053 sequences corresponded to about 7-fold of the genome size.

A list of the primers for the PCR used in the Example is shown in Table 3.

(Example 5) Assembly (A process whereby the order of multiple sequenced DNA fragments is determined) All works for reconstruction of genomic DNA sequence from the sequence information for DNA fragment of the 346,053 sequences obtained in the above Example 4 were carried out on a UNIX platform. Base call was carried out by phred (The University of Washington), masking of vector sequence was carried out using Cross Match (The University of Washington) and assembly was carried out using Phrap (The University of Washington). Contig obtained as a result of the assembly was analyzed using a graphical editor consed (The University of Washington). A series of works from base call to assembly was carried out all together utilizing a script phredPhrap attached to the consed.

(Example 6) Preparation of a comparative database with the genome sequence of S. cerevisiae S. pastorianus is believed to be a natural hybrid of S. cerevisiae with its closely-related species "Int. J.
Syst. Bacteriol., volume 35, pages 508 to 511 (1985)".
Therefore, a DNA sequence (comprising 10,044 bases) of both ends of the cosmid DNA clone obtained in (4-2) was subjected to a homology searching by a homology searching algorithm to S. cerevisiae genome sequence, whereupon for each DNA sequence alignment of homologous region on S.
cerevisiae genome sequence and the identity thereof were determined to prepare a database. An identity distribution chart for cosmid DNA sequence with the corresponding genomic DNA sequence of S. cerevisiae is shown in Fig. 2.
The DNA sequence of cosmid was roughly classified into a DNA sequence group showing not less than 94% identity to the genomic DNA sequence of S. cerevisiae and a DNA

sequence group showing around 84% identity thereto. The DNA sequence group showing not less than 94% identity is named a DNA sequence of an Sc type derived from S.

cerevisiae and the DNA sequence group showing around 84%
identity is named a DNA sequence of a non-Sc type derived from genome of closely related species. Similarly, a comparative database (Table 1) was prepared for the DNA
sequence of both ends of shotgun clone obtained in (4-1) with the genomic DNA sequence of S. cerevisiae. Table 1 shows an example of the comparative database of DNA
sequence of both ends of 3,648-cosmid clone with the genomic DNA sequence of S. cerevisiae. There are shown the homologous region and the identity of forward sequence and reverse sequence of cosmid subjected to the DNA sequence determination on each genomic DNA sequence of S.
cerevisiae.

(Table 1) r- l0 6', CQ a Cq Lq r- o0 cV
0o o r oo co co m 0o ai ai .r' o;
07 0) a~ o~ rn Cr, rn rn rn rn a~ oo rn ~~ o ~m C~7C7~~CJ~CYJ Q'rCfl~Od :4~-:
oe Ir t~ 0~ 0o ,- pQ 0o ~ Q Q) 0~7 N

r I'~,. n~y 0~7 . 070SOLL~~Cl N00 N LC~cU
~ CV [O 00 O OQ Or ~m ON'> ~ N
m'~ Id7 CO 00 0 ~
P4 0 o ro ai z l~. ~~ 7C W ~ 7C 0 -no*) d- r.-rroor~coo ~ ~ ~ ~ ~
~ 7 6 o,.r N t9 ~0 L~ ~ Op CO r ~~ C N
aoi Fp a~i Cp co [O tD (o t!7 cD Cp cL? cD r Lt7 CO
r4~1[?C~t'~ d: N=- dcuLf)N W
00 r 00 CO O? 00 m O7 00 4> O) ~,oo~ Q) v,rno,rnaao~o>a~rnrn '.

c~LD N L LO LC? ONo s C~ g LC~ ~,rp LCJ - Cfl O> QY cD O~ Ct c v CO I-~ 07 t~ f'~ CV cV LC] d L.C~
C oe ~=- co 4 Q~~3 LC~ lO L{? IfJ So Ct3 ~ a ~
d- o co oa cU M co rn r m cn 0.1 o f~~ ~ 09 CO C'~ O O Q N C5 N N
~.~ ~ ,~ ai LC) CO ~ Lc7 1'+ tc~ CV N LI7 LC7 a a~ P; ~ = ~- CrJ ~~1 LC~ LCl l1~ LC~ CD SO
o ~
oO~~~?5~~7G~XX~~~
m~~ r~n N d N CQD L[] ~CV CS? ~7 d N
~~ [L2 M co Co SO co So Co CD GO d CD [O

~~g 8 ~ N~ ~
N
~~q ai co co f0 [O co co Cp CO Cc d CO [D

co o> o0 0 in o 0o r- o r ~ ~CD
U
~oo~
~ J J J J J J J J J J J J
z cncncncncncncncncncn cntncn cncncncncncncncncncncncncn On the basis of the information obtained by the prepared comparative database, mapping of cosmid clone and shotgun clone on S. cerevisiae genome sequence was carried out (Fig. 3). In addition, a comparative database (Table 1) of contig DNA sequence obtained in Example 5 with S.
cerevisiae genome sequence was prepared, then mapping was carried out. Although the means for the mapping was almost the same as the above-mentioned method, if forward and reverse sequences of cosmid and shotgun clones were present in different contigs, these contigs were connected by forward-reverse link (Fig. 4).

(Example 7) Identification and assignment of function of ORF

Identification of ORF (open reading frame) in the DNA
sequence assembled in Example 5 was carried out. The examples are specifically shown below. Identification of ORF existing in the DNA sequence assembled in Example 5 was carried out using a available program using ORF finder (http://www.ncbi.nih.gov/gorf/gorf.html). The identification of ORF was done for six kinds of reading frames in the sequence with the length of not less than 150 bases from initiation codon to termination codon including its complementary sequence. Assignment of function of the extracted ORF was carried out by homology searching of amino acid sequence of ORF of S. cerevisiae that has been registered at the SGD and published. Table 2 is a table showing examples of the name of ORF in S. cerevisiae corresponding to the result to assignment of function of ORF existing in the non-Sc genome. From the left side of the table, there are shown name of the ORF existing in the brewing yeast, ORF length in polynucleotide, ORF length in polypeptide, name of the ORF in S. cerevisiae determined by homology searching, identity, coincided length and functions of the gene.

(Table 2) (D r-.

-o ~ ~

~ co o ~ CL
o to 0 a >~~~
>
to -u ~
Q ~
~_, -a -~ ~
lo ~.
- ~'~ e co o ~ ~ -C ~
s . V -R T 8 ~ - Q ~ s ~;
V CL 0 Q 3 O O o M E
~ T2 ~ ~ ~ ~ ~ ~ CV N {V n CO
U~4 T LJ r- m r- r- t V tiL/ 11 1 \.JrP
-~' ('= t~ 7 07 ~}7 C57 00 ~7 4~ ~7 7 G7 t~f} ~7 f=~

' c'} -1J 1\J 0 (5../ S=) Ld T r' D
0 0 ~ F=- D Y~ry W Li1 W L iJ ~~ Lj 1 Q
~C IL ~5tr) zxd LO LO l C,o LO CV T VJ LO CV K+
FI ~ c~-~Ji- t'J W~~ ~.V cV~'V/- IiJ ~ t"J
oa c3 LO l.i) 00 .- DO M r~ s. l~ ~ ~ C,4o r- r- LS J CY) Oa ~ r- r r r CY) rCO r r \,y Q2 ti'J CD 1 +SJ r '=! LJ
U) T T r J -~
n L , <

0 Q 0 ccnco cn o z o 0 c o co - ~ o ~ ~

(Example 8) Analysis of chromosome structure by DNA
array-based comparative genomic hybridization and PCR

Preparation of genomic DNA from yeast was carried out using Qiagen Genomic Tip 100/G (#10243: manufactured by Qiagen) and Qiagen Genomic DNA Buffer Set (#19060:
manufactured by Qiagen) according to the manuals attached to the kits. The DNA (10 g) was digested with DNase I
(manufactured by Invitrogen) according to a method of Winzeler, et al. "Science, volume 281, pages 1194 to 1197 (1998)", biotinylated by a terminal transferase (manufactured by Roche) and hybridized to a DNA array (Affymetrix Gene Chip Yeast Genome S98 Array: produced by Affymetrix). Hybridization and detection of signal intensity of array were carried out using a Gene Chip Analysis Basic System manufactured by Affymetrix.

The signal of each probe hybridized with the DNA of strain 34/70 is normalized to that of the haploid laboratory yeast strain S288C using an analysis soft ware (Microarray Suite 5.0: manufactured by Affymetrix) and shown as signal log ratio (2n). Signal log ratios were lined following gene order in each chromosome using a spreadsheet program (Microsoft Excel 2000) and the signal log ratios are shown in bar graphs as shown in Fig. 5. The non-Sc type genes do not hybridize to the S. cerevisiae array, therefore, the Sc type gene dosage affects the signal log ratio and the points where the signal log ratios show vigorous changes and which are considered to be translocation sites between Sc type and non-Sc type chromosome.

On the basis of genome sequence of strain 34/70 determined by a shotgun method, the chimera chromosome structure was confirmed by PCR where two pairs of primers having DNA sequences in which one side is Sc type while the other side is a non-Sc type (XVI-1(L)cer-95894 (SEQ ID NO:
9)/XVI-1(R)nonSc-106302rv (SEQ ID NO: 10) and XVI-2(L)cer-859737 (SEQ ID NO: 11)/XVI-2(R)nonSc-864595rv (SEQ ID NO:

12)) were designed and the genomic DNA derived from strain 34/70 was used as a template. Two examples of translocation of chromosome XVI are shown as follows.

The PCR was carried out using Takara LA TaqTM and a buffer attached thereto in accordance with the attached manual by a Takara PCR Thermal Cycler SP.

As a result of the PCR, it was confirmed by a 0.8%
agarose gel electrophoresis that, a DNA fragment in the predicted length was amplified from strain 34/70, while when genomic DNA of the experimental strain S. cerevisiae X2180-1A was used as a template for the PCR, amplification of the DNA fragment was not detected. Furthermore, when DNA sequence of both ends of the DNA fragment amplified from strain 34/70 was confirmed, it was consistent with the genome sequence determined by a shotgun method and it was confirmed that, within such a region, translocation between Sc type and non-Sc type chromosome took place.

From the above result, it is estimated that at least two kinds of chromosomes were present in the chromosomeXVI

as shown in Fig. 6. According to the same techniques, ligation between Sc chromosome and non-Sc chromosome (or inverse thereof) or, in other words, the region where the existence of chimera chromosome structure was suggested was confirmed. Such chimera chromosome structure of the Sc chromosome and non-Sc chromosome was confirmed at least 13 places in the total chromosomes of strain 34/70 (Fig. 1).

As a result of genome analysis, it was found that chromosome structure of bottom fermenting yeast was very complicated and there were at least 37 kinds of chromosomes in strain 34/70.

(Example 9) Cloning of SSU1 genes of strain 34/70 The shotgun clone containing non-ScSSUl gene'was retrieved using a comparative database obtained in Example 6. There was SSS103_G08 which comprises about 2.4 kb of fragment containing full-length of non-ScSSU1 ORF, where identity of forward and reverse sequence of shotgun clone to those of S. cerevisiae were 62.9% and 82.9%, respectively.

SSS103-G08 was selected from a library of genomic DNA, then full length of non-ScSSUl was prepared by PCR.
Synthetic DNAs of SacI-non-Sc-SSU1_forl (SEQ ID NO: 13) and Bg1II-non-Sc-SSU1_rv1460 (SEQ ID NO: 14) were used as primers. As a result of such a combination, base numbers 1 to 1460 of nonScSSUl was amplified to give a Saci-Bg1II
fragment of about 1.5 kb.

With regard to an ScSSUl gene, full length of gene was obtained by PCR using a primer pair designed on the basis of the information of SGD using a genomic DNA of strain 34/70 as a template. Synthetic DNAs of SacI-ScSSU1_forl (SEQ ID NO: 15) and Bg1II-ScSSU1_rv1406 (SEQ ID NO: 16) were used as primers. As a result of such a combination, base numbers 1 to 1406 of ScSSUl gene was amplified to give a SacI-Bg1II fragment of about 1.4 kb.

ScSSUl and non-ScSSUl genes obtained as above were inserted using TA cloning kit (Invitrogen) into pCR 2.1-TOPO vector attached to the kit, and they were named TOPO/ScSSUl and TOPO/non-ScSSU1, respectively. Sequences of the resulting ScSSUl and non-ScSSU1 genes were confirmed by a method of Sanger "F. Sanger, Science, volume 214, page 1215, 1981" (Fig. 10).

(Example 10) Disruption of each SSU1 gene According to a method mentioned in the document "Goldstein, et al., Yeast, volume 15, page 1541 (1999)", DNA fragment for gene disruption was prepared by PCR using a plasmid containing a drug-resistance marker (pFA6a (G418r), pAG 25 (natl)) as a template. As primers for the PCR, non-Sc-SSU1_for (SEQ ID NO: 17)/non-Sc-SSU1_rv (SEQ ID
NO: 18) were used for disruption of non-ScSSUl gene, while for disruption of ScSSUl gene, ScSSU1_for (SEQ ID NO:
19)/ScSSU1_rv (SEQ ID NO: 20) were used. For disruption of non-ScSSUl gene, a plasmid pPGAPAUR (AUR1-C) and primers non-Sc-SSU1_for + pGAPAUR (SEQ ID NO: 21)/non-Sc-SSU1_rv +

AURI-C (SEQ ID NO: 22) were further used. As such, two and three kinds of DNA fragments were prepared for ScSSUl and non-ScSSUl gene disruption, respectively.

The bottom fermenting yeast BH 96 was transformed using the DNA fragments for gene disruption prepared with above method. The transformation was carried out by a method mentioned in the Japanese Patent Laid-Open Gazette No. H07/303,475 and concentrations of the drugs were 300 mg/L for geneticin, 50 mg/L for nourseothricin and 1 mg/L
for aureobasidin A.

With regard to the transformants prepared, gene disruption was confirmed by Southern analysis. Firstly, the genomic DNA extracted from parental strain and disruptant was subjected to restriction enzyme treatment (at 37 C or 18 hours) using NcoI for the confirmation of ScSSUl gene disruption and HindiII for the confirmation of non-ScSSUl gene disruption, and then fractionated by 1.5%
agarose gel electrophoresis and transferred to a membrane.
After that, hybrid3.zation was carried out (at 55 C for 18 hours) with a probe specific to the ScSSUl or non-ScSSUl following a protocol of the Alkphos Direct Labelling Reagents (Amersham) and signals were detected by CDP-Star.

Each of the strains where gene disruption was confirmed was named as follows.

Sc-i (ScSSUl/Scssul::G418r) Sc-2 (Scssul::G418r/Scssul::nat1) non-Sc=1 (non-ScSSU1/non-ScSSU1/non-Scssul::G418r) non-Sc-2 (non-ScSSUl/non-Scssul::G418r/non-Scssul::nat1) non-Sc-3 (non-Scssul::G418r/non-Scssul::nat1/non-Scssul::AUR1-C) (Example 11) Quantitative analysis of sulfite production in a fermentation test Fermentation test using parental strain and disruptant Sc-1 to non-Sc-3 prepared in Example 10 was carried out under the following condition.

Original extract: 12.75%

Fermentation scale: 2 liters Dissolved oxygen concentration: about 9 ppm Fermentation temperature: 15 C

Pitching rate: 10 g of wet yeast cells/2 L of wort Wort is periodically sampled and monitored the cell growth (OD 600) (Fig. 7-(a)), apparent extract (Fig. 7-(b)) and sulfite concentration (Fig. 7-(c)). Quantitative analysis of sulfite in wort was carried out in such a method that it was captured in a hydrogen peroxide solution by means of distillation in an acidic condition and subjected to titration with an alkali (Revised Method for BCOJ Beer Analysis by the Brewing Society of Japan).

As a result, sulfite production in the wort by ScSSU1 disruptant was nearly same as that by parental strain, while it significantly decreased by non-ScSSU1 disruptant.

It was suggested that non-ScSSU1 gene which is specific to bottom fermenting yeast greatly contributes to sulfite production in wort.

At the same time, growth rate and extract-consuming rate were significantly decreased in the non-ScSSUl disruptant, and it supported that excessive sulfite in cells caused inhibition of cell growth.

(Example 12) Overexpression of each SSU1 gene From the plasmid TOPO/non-ScSSU1 mentioned in Example 9, a fragment of about 1.5 kb including the full length of non-ScSSU1 ORF was excised by a treatment with a restriction enzyme (SacI-Bg1II). Then this fragment was inserted into a plasmid pNI-NUT which was similarly treated with a restriction enzyme (SacI-BglII) to construct a non-ScSSU1 overexpression vector pYI-non-ScSSUl. The vector pNI-NUT contains URA3 as a homologous recombination site and nourseothricin-resistance gene (natl) and ampicillin-resistance gene (Ampr) as selective markers. On the other hand, the ScSSU1 overexpression vector pNI-ScSSU1 has a structure wherein the non-ScSSUl gene of the above-mentioned pYI-non-ScSSUl has been substituted with the, SSU1-R of about 2 kb derived from S. cerevisiae "J.
Ferment. Bioeng., volume 86, page.427 (1998)". For overexpression of each SSU1 gene, promoter and terminator of glyceraldehyde-3-phosphate dehydrogenase gene (TDH3) were used.

Bottom fermenting yeast BH225 was transformed with a overexpression vector prepared in the above-mentioned method. Transformation was carried out by a method mentioned in the Japanese Patent Laid-Open Gazette No.

H07/303,475 and selected on YPD plate medium containing 50 mg/L of nourseothricin.

Confirmation of the overexpression was carried out by RT-PCR. Extraction of total RNA was carried out using an RNeasy Mini Kit (Qiagen), according manual of "for total RNA isolation from yeast" attached the kit. ScSSUl_for331 (SEQ ID NO: 23)/ScSSUl_982rv (SEQ ID NO: 24) were used as ScSSUI-specific primers; non-ScSSUl_for329 (SEQ ID NO:
25)/non-ScSSU1_981rv (SEQ ID NO: 26) were used as non-ScSSUl-specific primers; and PDA1_forl (SEQ ID NO:
27)/PDA1_730rv (SEQ ID NO: 28) were used as specific primers for constitutively expressed gene PDA1 used as an internal standard. PCR product was fractionated by 1.2%
agarose gel electrophoresis, stained with an ethidium bromide solution and signal value of each SSU1 gene of transformant was normalized with a signal value of PDA 1 and compared with that of the parental strain. The overexpressed strains confirmed as such were named as ScSSUl overexpressed strain and non-ScSSUl overexpressed strain.

(Example 13) Quantitative analysis of sulfite production in a fermentation test Fermentation test using parental strain and each of SSU1 overexpressed strain obtained in the Example 12 was carried out under the following condition.

Original extract: 12.83%
Fermentation scale: 2 liters Dissolved oxygen concentration: about 9 ppm Fermentation temperature: 12 C

Pitching rate: 10 g of wet yeast cells/2 L of wort As same as in Example 11, wort is periodically sampled and monitored the cell growth (OD 600) (Fig. 8-(a)), apparent extract (Fig. 8-(b)) and sulfite concentration (Fig. 8-(c)). With regard to the sulfite production, it was only somewhat higher in Sc SSU1 overexpressed strain (19 ppm at the end of the fermentation) as compared with that of the parental strain (12 ppm at the same stage), while non-Sc SSU1 over expressed strain showed a significant increase (45 ppm at the same stage). At the same time, there was no difference in the growth rate and in the extract-consuming rate between the parental strain and the overexpressed strains.

From the above result, by overexpression of the gene encoding the sulfite-discharging pump specific to the bottom fermenting yeast shown in the present invention, it is possible to increase sulfite concentration in beer without changing the fermentation process and the fermentation period. As a result, it is now possible to produce an alcoholic beverage with excellent flavor stability and a longer quality preservation period.

(Example 14) Cloning of MET14 gene of strain 34/70 DNA sequence of non-Sc MET14 gene was retrieved from the comparative database obtained in Example 6. A shotgun clone SSS 134_021 containing about 1.9 kb (full-length) of non-Sc MET14 gene was obtained; its forward and reverse DNA
sequence identity to S. cerevisiae were 79.0% and 56.0%, respectively.

The shotgun clone 134_021 was selected from shotgun library and a full length of non-Sc MET14 gene was obtained by PCR. As a primer pair, synthetic DNAs of SacI-nonSc-MET14_for-21 (SEQ ID NO: 29) and BamHI-nonSc-MET14_rv618 (SEQ ID NO: 30) as shown in Table 3 were used. As a result of using such a pair of primers, a non-Sc MET14 gene (about 0.6 kb) embraced by SacI and BamHI restriction sites was obtained.

(Table 3) SEQ ID No. Sequence Name 5'-Base Sequence-3' M13 for agtcac acg t tta 6 M13 rv ca aaaca ctatgac 7 SS-cosF.1 a c tatca cgaggccctt tc 8 SS-cosR.1 cttatc atg ataagcggtc aaacatgag 9 XVI-1 L cer-95894 cgcaa ctcc gtacgttcaa cattcttatg aac c XVI-1 R nonSc-106302rv gcateatcgt c t atcctt cttt caaa t ca 11 XVI-2 L cer- 5973? c tattt t at taaa tctacaagcc ctcggc 12 XVI-2 R nonSc-864595rv cccagacaca tttcca ta tcatcctc c agaac 13 Sacl-nonScSSUI forl gagcteatgg tcgcta ttg gat ct 14 B III-nonScSSUI rv1460 a atctca c ttca cccaa tccatt SacI-ScSSUI forl a ctca! tt ccaatt ggtact 16 B lII-ScSSUI rv1406 a atctctcc tacatgaaat gcttge atggtcgcta gttggatgct cactgccaca agggatttca 17 nonScSSUI_for accctttcat atcgaatatt ctgtacagct gtttgtcatg gttatggggg tc tatttc cctt aca t cttgac t c tgttaaatat gtactatcga tagccgagtt tgattcctcc 18 nonScSSUI_rv acactttcga acagtcttct ccgtcccttc ctctgataaa tgct ti aa aggagaattg cgcacttaac ttcgcatctg atggttgcca attgggtact tgctcttacg aggcagtttg 19 ScSSUI_for accccttcat gtttatgatg gtcatgggtg tcggcatttc atcgaatatt ctatatagct ccttgaca t cttgacgtgc ttatgctaaa cgcgtaaaat ctagagccga gtttgattct ScSSUI_rv tccacgcttt caatgctgtt atacggagaa actgtcgtct tttccgtacc t actctgaa cgcacttaac ttcgcatctg atggtcgcta gttggatgct cactgccaca agggatttca 21 nonScSSUI_for+pGAPAUR accctttcat gtttgtcatg gttatggggg tcggtatttc atc aatatt ct taca ct cc agctta ccagttctca tgttaaatat gtactatcga tagccgagtt tgattcctcc 22 nonScSSUI_rv+AURI-C acactttcga tgctgttgaa aggagaattg acagtcttct ccgtcccttc ctctgataaa tcgactcta aggatccaga 23 ScSSUI for331 tc aaa c a acacgac aa 24 ScSSUI 982rv c acagaaat cacggt aaa a nonScSSUI 329 tgtcacaaaa atttaccacg ac 26 nonScSSUI 981rv aa aaatt acc taaa a ag 27 PDA1 forl atgtttgteg cacctgtatc t 28 PDA1 730rv gattagaggc accatcac 29 SacI-nonSc-MET14 for-21 ctc a ctct c t aaattc attgaaacaa atg BamHI-nonSc-MET14 rv618 atccttat aa atttata gatgcttccg 31 Sacl-ScMET14 for ctc a ctca gaaaagttgg aattatttct cca 32 BamHI-ScMET14 rv atccaat tacagtaatc ggtcaaatta With regard to Sc MET14 gene, a full length of the structural gene was obtained by PCR using a primer pair 5 designed on the basis of the information of SGD and using genomic DNA of strain 34/70 as a template. Synthetic DNAs of SacI-ScMET14_for (SEQ ID NO: 31) and BamHI-ScMET14_rv (SEQ ID NO: 32) were used as primers. As a result of using such a pair of primers, Sc MET14 gene (about 0.6 kb) embraced by SacI and BamHI restriction sites was obtained.

The Sc MET14 and non-Sc MET14 genes obtained as above were inserted using a TA cloning kit (manufactured by Invitrogen) into pCR 2.1-TOPO vector attached to the kit, and they were named TOPO/ScMET14 and TOPO/nonSc-MET14, respectively.

DNA sequences of the resulting Sc MET14 and non-Sc MET14 genes were checked by a method of Sanger "Science, volume 214, page 1205 (1981)" (Fig. 11).

(Example 15) Overexpression of each MET14 gene in Sc SSU1 overexpressed strain A fragment of about 0.6 kb containing Sc MET14 or non-Sc MET14 mentioned in Example 14 was inserted into a multi-cloning site of a expression vector pUP3GLP (Japanese Patent Laid-Open Gazette No. 2000/316,559) to construct overexpression vectors pUP3Sc MET14 and pUP3nonSc-MET14 in which each MET14 gene was expressed under control of glyceraldehyde-3-phosphate dehydrogenase promoter and terminator. On the other hand, top fermenting yeast, strain KN009F, was transformed with an Sc SSU1 overexpression vector pNI-SSU1 mentioned in Example 12 to prepare strain FOY227 which is an Sc SSU1 overexpressed strain. The strain FOY227 was transformed with the above pUP3ScMET14 and pUP3nonSc-MET14 to prepare strain FOY306 and strain FOY 307 in which Sc MET14 and non-Sc MET14, together with Sc SSU1, are overexpressed, respectively.
(Example 16) Quantitative analysis of sulfite production in a fermentation test Fermentation tests were carried out under the following condition using strains prepared in Example 15;
strain FOY227 which is Sc SSU1 overexpressed strain, strain FOY306 which is Sc MET14 overexpressed strain in strain FOY227, strain FOY307 which is a non-Sc MET14 overexpressed strain in strain FOY227and the parental strain KN009 F.
Original extract: 12.84%

Fermentation scale: 1.5 liters Dissolved oxygen concentration: about 9 ppm Fermentation temperature: 25 C at all times Pitching rate: 7.5 g of wet yeast cells/1.5 L of wort In the same way as Example 11, wort is periodically sampled and monitored the cell growth (OD 600), apparent extract and sulfite concentration. With regard to the yeast growth and the consumed amount of extract, there was no difference among the strains. However, with regard to the sulfite production, it was only somewhat higher in Sc SSU1 overexpressed strain FOY227 (3.4 ppm at the end of the fermentation),and Sc MET14 and Sc SSU1 overexpressed strain FOY306 (6.4 ppm at the same stage) as compared with that of the parental strain KN009F(0.32 ppm at the same stage), while non-Sc MET14 and Sc SSU1 overexpressed strain FOY307 showed a significant increase (16.6 ppm at the same stage) as shown in Fig. 9.

From the above results, it was found that overexpression of the gene encoding the adenylyl sulfate kinase specific to the bottom fermenting yeast shown in the present invention was effective to increase sulfite concentration in beer without changing the fermentation process and the fermentation period. As a result, it is now possible to produce an alcoholic beverage with excellent flavor stability and a longer quality preservation period.
(Example 17) Production of the bottom fermenting yeast DNA array DNA array of bottom fermenting yeast was produced based on the DNA sequence information of the ORFs obtained in the above (h) and intergenic DNA sequences located between ORFs deduced from the whole genome sequence of strain 34/70.

Production of the DNA array Based on the DNA sequence information from following three groups, PM probe (Perfect Match Probe; 25 base long) which is unique against the whole genome sequence of the bottom fermenting yeast was designed using GeneChip (Affymetrix) technology; (1) 15712 regions from the whole genome sequence information of strain 34/70, (2) 403 S.
cerevisiae ORFs represented from SEQ ID NOS: 190811 to 191213 from SGD which are not identified as Sc type ORFs in strain 34/70,=(3) 64 DNA sequences of genes represented from SEQ ID NOS: 195588 to 195651 used as internal standard.

In order to obtain quantitative and reproducible information, 8 to 11 probes for each region of (1)and(2), and 20 to 51 probes for each region of (3) were designed.
To further increase the sensitivity and specificity of the detection, mismatch probe (MM probe) that has sequences identical to PM probe with the exception of one mismatched base, which substitutes the complementary base (adenine (A) to thymine (T) and vice versa, or guanine (G) to cytosine (C) and vice versa) at the central position (i.e. base 13), was also designed.

All of designed PM and MM probes were synthesized and packed (manufactured by Affymetrix) to produce the DNA
array using GeneChip technology.

Group (1) consists of:

A) 6204 DNA sequences of non-Sc type ORFs represented from SEQ ID NOS: 33 to 6236;

B) 7448 DNA sequences of Sc type ORFs represented from SEQ ID NOS: 75337 to 82784;

C) 28 DNA sequences of mitochondrial ORFs from 34/70 strain represented from SEQ ID NOS: 166154 to 166181;

D) 553 DNA sequences represented from SEQ ID NOS:
166490 to 167042, which have not been identified as the above ORFs but have significant similarity (E value <=10e-7) to the proteins of S. cerevisiae using NCBI-BlastX
homology searching, E) 1479 DNA sequences represented from SEQ ID NOS:
173125 to 174603, which have not been identified as the above A) or B) but have significant similarity (E-value <=10e-7) to the proteins of S. cerevisiae using NCBI-BlastP
homology searching.

E-value is an expected value for a possibility that a query sequence is found in a data base by chance. For example, E-value 10 means that 10 sequences can be found accidentally. The smaller the E-value is, the lesser is the chance of finding the sequence by chance, and thus meaning that similarity between the found sequence in data base and the query sequence is significant.

The E-value as the result of homology searching such as NCBI-BLAST can be significant when it is less than 10-7, preferably less than 10-10, more preferably less than 10-20.
The function can be assigned as having the least value with the DNA sequences of the ORFs as the result of the homology searching.

Group (2) consists of:

YBL108C-A, YBR074W, YFL061W, YIL165C, YGR291C, YJR052W, YDR2,23W, YAL025C, YAR073W, YFL057C, YLL015W, YJR105W, YLR299C-A, YNR073C, YDL246C, YHL049C, YAR010C, YKL096W, YBL026W, YMR230W, YAL037C-A, YAL037C-B, YAL037W, YAL063C-A, YAL064C-A, YAL064W, YAL065C, YAL068W-A, YAL069W, YAR009C, YAR020C, YAR042W, YAR047C, YAR053W, YAR060C, YAR061W, YAR062W, YBL027W, YBL040C, YBL068W-A, YBL101W-B, YBL109W, YBL112C, YBR092C, YBR191W-A, YBR219C, YCLO19W, YCL029C, YCL065W, YCL066W, YCL068C, YCL069W, YCL073C, YCL074W, YCL075W, YCL076W, YCR035C, YCR036W, YCR038W-A, YCR101C, YCR104W, YCR105W, YCR106W, YCR107W, YCR108C, YDL003W, YDL037C, YDL064W, YDL073W, YDL094C, YDL095W, YDL096C, YDL136W, YDL143W, YDL152W, YDL191W, YDL200C, YDL201W, YDL247W-A, YDL248W, YDR014W, YDR015C, YDR034C-D, YDR039C, YDR045C, YDR098C-B, YDR160W, YDR21OC-D, YDR21OW-B, YDR215C, YDR225W, YDR261C-D, YDR261W-B, YDR292C, YDR302W, YDR304C, YDR305C, YDR342C, YDR344C, YDR364C, YDR365W-B, YDR427W, YDR433W, YDR471W, YDR51OC-A, YDR543C, YDR544C, YEL012W, YEL075W-A, YER039C-A, YER046W-A, YER056C-A, YER060W-A, YER074W, YER138C, YER187W, YER188C-A, YER190C-A, YFL002W-A, YFLO14W, YFLO19C, YFL020C, YFL030W, YFL031W, YFL051C, YFL052W, YFL053W, YFL054C, YFL055W, YFL056C, YFL063W, YFL065C, YFL066C, YFL067W, YFRO12W-A, YGL028C, YGL041C, YGL052W, YGL21OW-A, YGL259W, YGL262W, YGL263W, YGR034W, YGR038C-B, YGRO89W, YGR107W, YGR109W-A, YIL082W-A, YGR122C-A, YGR146C, YGR148C, YGR161W-B, YGR182C, YGR183C, YGR271C-A, YGR290W, YGR295C, YHL009W-A, YHL009W-B, YHLO15W-A, YHL046W-A, YHL047C, YHL048C-A, YHL048W, YHR032C-A, YHR032W-A, YHR039C-A, YHR043C, YHR070C-A, YHR071C-A, YHR071W, YHR141C, YHR165W-A, YHR179W, YHR180C-B, YHR18OW-A, YHR182W, YHR193C, YHR193C-A, YHR207C, YHR211W, YHR213W-A, YHR216W, YHR217C, YHR218W-A, YIL029C, YIL052C, YIL069C, YIL148W, YIL171W, YIL174W, YIL176C, YIR018C-A, YIR041W, YIR042C, YIR043C, YIR044C, YJL012C-A, YJL014W, YJL062W-A, YJL136C, YJL175W, YJL222W-B, YJR024C, YJR027W, YJR032W, YJR053W, YJR054W, YJR094W-A, YJR107W, YJR11OW, YJR111C, YJR140W-A, YJR151C, YJR152W, YJR153W, YJR154W, YJR155W, YJR162C, YKLO18W, YKL020C, YKL044W, YKL224C, YKL225W, YKRO12C, YKRO13W, YKRO17C, YKRO18C, YKRO19C, YKR020W, YKR035C, YKR036C, YKR040C, YKR041W, YKR042W, YKR052C, YKR053C, YKR057W, YKR062W, YKR094C, YKR102W, YKR103W, YKR104W, YLL014W, YLL030C, YLL037W, YLL038C, YLL043W, YLL065W, YLR029C, YLR030W, YLR062C, YLR098C, YLR099W-A, YLR107W, YLR139C, YLR140W, YLR142W, YLR144C, YLR145W, YLR154C-G, YLR154W-A, YLR154W-B, YLR154W-C, YLR154W-E, YLR154W-F, YLR155C, YLR156W, YLR157C-B, YLR157W-C, YLR162W, YLR205C, YLR207W, YLR209C, YLR227W-B, YLR236C, YLR237W, YLR238W, YLR245C, YLR251W, YLR271W, YLR278C, YLR287C-A, YLR305C, YLR306W, YLR311C, YLR317W, YLR338W, YLR344W, YLR345W, YLR354C, YLR364W, YLR380W, YLR401C, YLR402W, YLR41OW-B, YLR411W, YLR412C-A,.YLR412W, YLR413W, YLR448W, YLR460C, YLR461W, YLR463C, YLR465C, YML003W, YML039W, YML073C, YMR087W, YMR143W, YMR175W-A, YMR247W-A, YMR268W-A, YMR324C, YMR325W, YNL020C, YNL035C, YNL054W-B, YNL243W, YNR034W-A, YNR075C-A, YNR077C, YOL038C-A, YOL053W, YOL101C, YOL103W-B, YOL162W, YOL163W, YOL164W, YOL164W-A, YOL165C, YOL166C, YOL166W-A, YOR050C, YOR096W, YOR101W, YOR192C-B, YOR192C-C, YOR225W, YOR235W, YOR343W-B, YOR366W, YOR381W-A, YOR382W, YOR383C, YOR384W, YOR385W, YOR386W, YOR387C, YOR389W, YPL003W, YPLO19C, YPL023C, YPL036W, YPL048W, YPL055C, YPL060C-A, YPL175W, YPL194W, YPL197C, YPL257W-B, YPR002C-A, YPR008W, YPRO14C, YPR028W, YPR043W, YPR048W, YPR087W, YPR094W, YPR108W, YPR137C-B, YPR161C, YPR162C, YPR163C, YPR164W, YPR165W, YPR166C, YPR167C, YPR168W, YPR169W, YPR169W-A, YPR170C, YPR170W-A, YPR171W, YPR172W, YPR173C, YPR174C, YPR175W, YPR176C, YPR177C, YPR178W, YPR179C, YPR180W, YPR181C, YPR182W, YPR183W, YPR184W, YPR185W, YPR186C, YPR187W, YPR188C, YPR189W, and YPR190C
Group (3) consists of (GenBank Accession No.):
AFFX-BioB-5_at (J04423.1), AFFX-BioB-M at (J04423.1), AFFX-BioB-3_at (J04423.1), AFFX-BioC-5_at (J04423.1), AFFX-BioC-3_at (J04423.1), AFFX-BioDn-5_at (J04423.1), AFFX-BioDn-3_at (J04423.1), AFFX-CreX-5_at (X03453.1), AFFX-CreX-3_at (X03453.1), AFFX-DapX-5_at (L38424.1), AFFX-DapX-M_at (L38424.1), AFFX-DapX-3_at (L38424.1), AFFX-LysX-5_at (X17013.1), AFFX-LysX-M_at (X17013.1), AFFX-LysX-3_at (X17013.1), AFFX-PheX-5_at (M24537.1), AFFX-PheX-M_at (M24537.1), AFFX-PheX-3_at (M24537.1), AFFX-ThrX-5_at (X04603.1), AFFX-ThrX-M_at (X04603.1), AFFX-ThrX-3_at (X04603.1), AFFX-TrpnX-5_at (K01391.1), AFFX-TrpnX-M at (K01391.1), AFFX-TrpnX-3_at (K01391.1), AFFX-r2-Ec-bioB-5_at (J04423.1), AFFX-r2-Ec-bioB-M_at (J04423.1),AFFX-r2-Ec-bioB-3_at (J04423.1), AFFX-r2-Ec-bioC-5_at (J04423.1), AFFX-r2-Ec-bioC-3_at (J04423.1),AFFX-r2-Ec-bioD-5_at (J04423.1), AFFX-r2-Ec-bioD-3_at (J04423.1), AFFX-r2-P1-cre-5_at (X03453.1), AFFX-r2-Pl-cre-3_at (X03453.1), AFFX-r2-Bs-dap-5_at (L38424.1), AFFX-r2-Bs-dap-M_at (L38424.1), AFFX-r2-Bs-dap-3_at (L38424.1), AFFX-r2-Bs-dap-3_at (X17013.1), AFFX-r2-Bs-lys-5_at (X17013.1), AFFX-r2-Bs-lys-M_at (X17013.1), AFFX-r2-Bs-phe-5_at (M24537.1), AFFX-r2-Bs-phe-M_at (M24537.1), AFFX-r2-Bs-phe-3_at (M24537.1), AFFX-r2-Bs-thr-5_s_at (X04603.1), AFFX-r2-Bs-thr-M_s_at (X04603.1), AFFX-r2-Bs-thr-3_s_at (X04603.1), AFFX-YFL039C5_at (V01288.1), AFFX-YFL039CM_at (V01288.1), AFFX-YFL039C3_at (V01288.1), AFFX-YER148w5_at (X16860.1), AFFX-YER148wNi at (X16860.1),AFFX-YER148w3_at (X16860.1), AFFX-YER022w5_at (L12026.1), AFFX-YER022wM_at (L12026.1), AFFX-YER022w3_at (L12026.1), AFFX-18srRnaa_at (Z75578.1), AFFX-18srRnab_at (Z75578.1), AFFX-18srRnac_at (Z75578.1), AFFX-18srRnad_at (Z75578.1), AFFX-18srRnae_at (Z75578.1), AFFX-25srRnaa_at (J01355.1), AFFX-25srRnab_at (J01355.1), AFFX-25srRnac_at (J01355.1), AFFX-25srRnad_at (J01355.1) and AFFX-25srRnae_at (J01355.1).

The probes from 6204 DNA sequences of non-Sc type ORFs described as above(1-A) were as follows:

The probes having the nucleotide sequence represented by SEQ ID NOS: 6237, 6238, 6239, 6240, 6241, 6242, 6243, 6244, 6245, 6246, 6247 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 33.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6248, 6249, 6250, 6251, 6252, 6253, 6254, 6255, 6256, 6257, 6258 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 34.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6259, 6260, 6261, 6262, 6263, 6264, 6265, 6266, 6267, 6268, 6269 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 35.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6270, 6271, 6272, 6273, 6274, 6275, 6276, 6277, 6278, 6279, 6280 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 36.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6281, 6282, 6283, 6284, 6285, 6286, 6287, 6288, 6289, 6290, 6291 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 37.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6292, 6293, 6294, 6295, 6296, 6297, 6298, 6299, 6300, 6301, 6302 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 38.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6303, 6304, 6305, 6306, 6307, 6308, 6309, 6310, 6311, 6312, 6313 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 39.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6314, 6315, 6316, 6317, 6318, 6319, 6320, 6321, 6322, 6323, 6324 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 40.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6325, 6326, 6327, 6328, 6329, 6330, 6331, 6332, 6333, 6334, 6335 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 41.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6336, 6337, 6338, 6339, 6340, 6341, 6342, 6343, 6344, 6345, 6346 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 42.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6347, 6348, 6349, 6350, 6351, 6352, 6353, 6354, 6355, 6356, 6357 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 43.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6358, 6359, 6360, 6361, 6362, 6363, 6364, 6365, 6366, 6367, 6368 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 44.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6369, 6370, 6371, 6372, 6373, 6374, 6375, 6376, 6377, 6378, 6379 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 45.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6380, 6381, 6382, 6383, 6384, 6385, 6386, 6387, 6388, 6389, 6390 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 46.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6391, 6392, 6393, 6394, 6395, 6396, 6397, 6398, 6399, 6400, 6401 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 47.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6402, 6403, 6404, 6405, 6406, 6407, 6408, 6409, 6410, 6411, 6412 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 48.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6413, 6414, 6415, 6416, 6417, 6418, 6419, 6420, 6421, 6422, 6423 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 49.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6424, 6425, 6426, 6427, 6428, 6429, 6430, 6431, 6432, 6433, 6434 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 50.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6435, 6436, 6437, 6438, 6439, 6440, 6441, 6442, 6443, 6444, 6445 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 51.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6446, 6447, 6448, 6449, 6450, 6451, 6452, 6453, 6454, 6455, 6456 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 52.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6457, 6458, 6459, 6460, 6461, 6462, 6463, 6464, 6465, 6466, 6467 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 53.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6468, 6469, 6470, 6471, 6472, 6473, 6474, 6475, 6476, 6477, 6478 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 54.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6479, 6480, 6481, 6482, 6483, 6484, 6485, 6486, 6487, 6488, 6489 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 55.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6490, 6491, 6492, 6493, 6494, 6495, 6496, 6497, 6498, 6499, 6500 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 56.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6501, 6502, 6503, 6504, 6505, 6506, 6507, 6508, 6509, 6510, 6511 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 57.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6512, 6513, 6514, 6515, 6516, 6517, 6518, 6519, 6520, 6521, 6522 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 58.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6523, 6524, 6525, 6526, 6527, 6528, 6529, 6530, 6531, 6532, 6533 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 59.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6534, 6535, 6536, 6537, 6538, 6539, 6540, 6541, 6542, 6543, 6544 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 60.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6545, 6546, 6547, 6548, 6549, 6550, 6551, 6552, 6553, 6554, 6555 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 61.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6556, 6557, 6558, 6559, 6560, 6561, 6562, 6563, 6564, 6565, 6566 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 62.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6567, 6568, 6569, 6570, 6571, 6572, 6573, 6574, 6575, 6576, 6577 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 63.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6578, 6579, 6580, 6581, 6582, 6583, 6584, 6585, 6586, 6587, 6588 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 64.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6589, 6590, 6591, 6592; 6593, 6594, 6595, 6596, 6597, 6598, 6599 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 65.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6600, 6601, 6602, 6603, 6604, 6605, 6606, 6607, 6608, 6609, 6610 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 66.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6611, 6612, 6613, 6614, 6615, 6616, 6617, 6618, 6619, 6620, 6621 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 67.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6622, 6623, 6624, 6625, 6626, 6627, 6628, 6629, 6630, 6631, 6632 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 68.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6633, 6634, 6635, 6636, 6637, 6638, 6639, 6640,' 6641, 6642, 6643 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 69.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6644, 6645, 6646, 6647, 6648, 6649, 6650, 6651, 6652, 6653, 6654 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 70.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6655, 6656, 6657, 6658, 6659, 6660, 6661, 6662, 6663, 6664, 6665 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 71.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6666, 6667, 6668, 6669, 6670, 6671, 6672, 6673, 6674, 6675, 6676 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 72.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6677, 6678, 6679, 6680, 6681, 6682, 6683, 6684, 6685, 6686, 6687 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 73.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6688, 6689, 6690, 6691, 6692, 6693, 6694, 6695, 6696, 6697, 6698 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 74.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6699, 6700, 6701, 6702, 6703, 6704, 6705, 6706, 6707, 6708, 6709 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 75.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6710, 6711, 6712, 6713, 6714, 6715, 6716, 6717, 6718, 6719, 6720 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 76.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6721, 6722, 6723, 6724, 6725, 6726, 6727, 6728, 6729, 6730, 6731 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 77.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6732, 6733, 6734, 6735, 6736, 6737, 6738, 6739, 6740, 6741, 6742 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 78.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6743, 6744, 6745, 6746, 6747, 6748, 6749, 6750, 6751, 6752, 6753 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 79.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6754, 6755, 6756, 6757, 6758, 6759, 6760, 6761, 6762, 6763, 6764 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 80.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6765, 6766, 6767, 6768, 6769, 6770, 6771, 6772, 6773, 6774, 6775 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 81.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6776, 6777, 6778, 6779, 6780, 6781, 6782, 6783, 6784, 6785, 6786 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 82.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6787, 6788, 6789, 6790, 6791, 6792, 6793, 6794, 6795, 6796, 6797 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 83.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6798, 6799, 6800, 6801, 6802, 6803, 6804, 6805, 6806, 6807, 6808 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 84.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6809, 6810, 6811, 6812, 6813, 6814, 6815, 6816, 6817, 6818, 6819 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 85.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6820, 6821, 6822, 6823, 6824, 6825, 6826, 6827, 6828, 6829, 6830 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 86.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6831, 6832, 6833, 6834, 6835, 6836, 6837, 6838, 6839, 6840, 6841 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 87.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6842, 6843, 6844, 6845, 6846, 6847, 6848, 6849, 6850, 6851, 6852 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 88.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6853, 6854, 6855, 6856, 6857, 6858, 6859, 6860, 6861, 6862, 6863 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 89.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6864, 6865, 6866, 6867, 6868, 6869, 6870, 6871, 6872, 6873, 6874 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 90.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6875, 6876, 6877, 6878, 6879, 6880, 6881, 6882, 6883, 6884, 6885 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 91.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6886, 6887, 6888, 6889, 6890, 6891, 6892, 6893, 6894, 6895, 6896 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 92.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6897, 6898, 6899, 6900, 6901, 6902, 6903, 6904, 6905, 6906, 6907 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 93.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6908, 6909, 6910, 6911, 6912, 6913, 6914, 6915, 6916, 6917, 6918 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 94.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6919, 6920, 6921, 6922, 6923, 6924, 6925, 6926, 6927, 6928, 6929 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 95.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6930, 6931, 6932, 6933, 6934, 6935, 6936, 6937, 6938, 6939, 6940 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 96.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6941, 6942, 6943, 6944, 6945, 6946, 6947, 6948, 6949, 6950, 6951 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 97.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6952, 6953, 6954, 6955, 6956, 6957, 6958, 6959, 6960, 6961, 6962 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 98.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6963, 6964, 6965, 6966, 6967,'6968, 6969, 6970, 6971, 6972, 6973 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 99.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6974, 6975, 6976, 6977, 6978, 6979, 6980, 6981, 6982, 6983, 6984 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 100.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6985, 6986, 6987, 6988, 6989, 6990, 6991, 6992, 6993, 6994, 6995 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 101.

The probes having the nucleotide sequence represented by SEQ ID NOS: 6996, 6997, 6998, 6999, 7000, 7001, 7002, 7003, 7004, 7005, 7006 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 102.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7007, 7008, 7009, 7010, 7011, 7012, 7013, 7014, 7015, 7016, 7017 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 103.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7018, 7019, 7020, 7021, 7022, 7023, 7024, 7025, 7026, 7027, 7028 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 104.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7029, 7030, 7031, 7032, 7033, 7034, 7035, 7036, 7037, 7038, 7039 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 105.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7040, 7041, 7042, 7043, 7044, 7045, 7046, 7047, 7048, 7049, 7050 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 106.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7051, 7052, 7053, 7054, 7055, 7056, 7057, 7058, 7059, 7060, 7061 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 107.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7062, 7063, 7064, 7065, 7066, 7067, 7068, 7069, 7070, 7071, 7072 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 108.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7073, 7074, 7075, 7076, 7077, 7078, 7079, 7080, 7081, 7082, 7083 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 109.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7084, 7085, 7086, 7087, 7088, 7089, 7090, 7091, 7092, 7093, 7094 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 110.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7095, 7096,,7097, 7098, 7099, 7100, 7101, 7102, 7103, 7104, 7105 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 111.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7106, 7107, 7108, 7109, 7110, 7111, 7112, 7113, 7114, 7115, 7116 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 112.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7117, 7118, 7119, 7120, 7121, 7122, 7123, 7124, 7125 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 113.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7126, 7127, 7128, 7129, 7130, 7131, 7132, 7133, 7134, 7135, 7136 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 114.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7137, 7138, 7139, 7140, 7141, 7142, 7143, 7144, 7145, 7146, 7147 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 115.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7148, 7149, 7150, 7151, 7152, 7153, 7154, 7155, 7156, 7157, 7158 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 116.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7159, 7160, 7161, 7162, 7163, 7164, 7165, 7166, 7167, 7168, 7169 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 117.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7170, 7171, 7172, 7173, 7174, 7175, 7176, 7177, 7178, 7179, 7180 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 118.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7181, 7182, 7183, 7184, 7185, 7186, 7187, 7188, 7189, 7190, 7191 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 119.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7192, 7193, 7194, 7195, 7196, 7197, 7198, 7199, 7200, 7201, 7202 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 120.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7203, 7204, 7205, 7206, 7207, 7208, 7209, 7210, 7211, 7212, 7213 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 121.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7214, 7215, 7216, 7217, 7218, 7219, 7220, 7221, 7222, 7223, 7224 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 122.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7225, 7226, 7227, 7228, 7229, 7230, 7231, 7232, 7233, 7234, 7235 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 123.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7236, 7237, 7238, 7239, 7240, 7241, 7242, 7243, 7244, 7245, 7246 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 124.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7247, 7248, 7249, 7250, 7251, 7252, 7253, 7254, 7255, 7256, 7257 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 125.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7258, 7259, 7260, 7261, 7262, 7263, 7264, 7265, 7266, 7267, 7268 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 126.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7269, 7270, 7271, 7272, 7273, 7274, 7275, 7276, 7277, 7278, 7279 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 127.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7280, 7281, 7282, 7283, 7284, 7285, 7286, 7287, 7288, 7289, 7290 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 128.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7291, 7292, 7293, 7294, 7295, 7296, 7297, 7298, 7299, 7300, 7301 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 129.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7302, 7303, 7304, 7305, 7306, 7307, 7308, 7309, 7310, 7311, 7312 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 130.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7313, 7314, 7315, 7316, 7317, 7318, 7319, 7320, 7321, 7322, 7323 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 131.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7324, 7325, 7326, 7327, 7328, 7329, 7330, 7331, 7332, 7333, 7334 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 132.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7335, 7336, 7337, 7338, 7339, 7340, 7341, 7342, 7343, 7344, 7345 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 133.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7346, 7347, 7348, 7349, 7350, 7351, 7352, 7353, 7354, 7355, 7356 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 134.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7357, 7358, 7359, 7360, 7361, 7362, 7363, 7364, 7365, 7366, 7367 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 135.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7368, 7369, 7370, 7371, 7372, 7373, 7374, 7375, 7376, 7377, 7378 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 136.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7379, 7380, 7381, 7382, 7383, 7384, 7385, 7386, 7387, 7388, 7389 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 137.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7390, 7391, 7392, 7393, 7394, 7395, 7396, 7397, 7398, 7399, 7400 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 138.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7401, 7402, 7403, 7404, 7405, 7406, 7407, 7408, 7409, 7410, 7411 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 139.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7412, 7413, 7414, 7415, 7416, 7417, 7418, 7419, 7420, 7421, 7422 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 140.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7423, 7424, 7425, 7426, 7427, 7428, 7429, 7430, 7431, 7432, 7433 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 141.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7434, 7435, 7436, 7437, 7438, 7439, 7440, 7441, 7442, 7443, 7444 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 142.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7445, 7446, 7447, 7448, 7449, 7450, 7451, 7452, 7453, 7454, 7455 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 143.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7456, 7457, 7458, 7459, 7460, 7461, 7462, 7463, 7464, 7465, 7466 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 144.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7467, 7468, 7469, 7470, 7471, 7472, 7473, 7474, 7475, 7476, 7477 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 145.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7478, 7479, 7480, 7481, 7482, 7483, 7484, 7485, 7486, 7487, 7488 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 146.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7489, 7490, 7491, 7492, 7493, 7494, 7495, 7496, 7497, 7498, 7499 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 147.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7500, 7501, 7502, 7503, 7504, 7505, 7506, 7507, 7508, 7509, 7510 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 148.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7511, 7512, 7513, 7514, 7515, 7516, 7517, 7518, 7519, 7520, 7521 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 149.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7522, 7523, 7524, 7525, 7526, 7527, 7528, 7529, 7530, 7531, 7532 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 150.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7533, 7534, 7535, 7536, 7537, 7538, 7539, 7540, 7541, 7542, 7543 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 151.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7544, 7545, 7546, 7547, 7548, 7549, 7550, 7551, 7552, 7553, 7554 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 152.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7555, 7556, 7557, 7558, 7559, 7560, 7561, 7562, 7563, 7564, 7565 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 153.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7566, 7567, 7568, 7569, 7570, 7571, 7572, 7573, 7574, 7575, 7576 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 154.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7577, 7578, 7579, 7580, 7581, 7582, 7583, 7584, 7585, 7586, 7587 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 155.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7588, 7589, 7590, 7591, 7592, 7593, 7594, 7595, 7596, 7597, 7598 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 156.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7599, 7600, 7601, 7602, 7603, 7604, 7605, 7606, 7607, 7608, 7609 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 157.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7610, 7611, 7612, 7613, 7614, 7615, 7616, 7617, 7618, 7619, 7620 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 158.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7621, 7622, 7623, 7624, 7625, 7626, 7627, 7628, 7629, 7630, 7631 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 159.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7632, 7633, 7634, 7635, 7636, 7637, 7638, 7639, 7640, 7641, 7642 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 160.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7643, 7644, 7645, 7646, 7647, 7648, 7649, 7650, 7651, 7652, 7653 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 161.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7654, 7655, 7656, 7657, 7658, 7659, 7660, 7661, 7662, 7663, 7664 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 162.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7665, 7666, 7667, 7668, 7669, 7670, 7671, 7672, 7673, 7674, 7675 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 163.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7676, 7677, 7678, 7679, 7680, 7681, 7682, 7683, 7684, 7685, 7686 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 164.

The probes.having the nucleotide sequence represented by SEQ ID NOS: 7687, 7688, 7689, 7690, 7691, 7692, 7693, 7694, 7695, 7696, 7697 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 165.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7698, 7699, 7700, 7701, 7702, 7703, 7704, 7705, 7706, 7707, 7708 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 166.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7709, 7710, 7711, 7712, 7713, 7714, 7715, 7716, 7717, 7718, 7719 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 167.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7720, 7721, 7722, 7723, 7724, 7725, 7726, 7727, 7728, 7729, 7730 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 168.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7731, 7732, 7733, 7734, 7735, 7736, 7737, 7738, 7739, 7740, 7741 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 169.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7742, 7743, 7744, 7745, 7746, 7747, 7748, 7749, 7750, 7751, 7752 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 170.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7753, 7754, 7755, 7756, 7757, 7758, 7759, 7760, 7761, 7762, 7763 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 171.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7764, 7765, 7766, 7767, 7768, 7769, 7770, 7771, 7772, 7773, 7774 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 172.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7775, 7776, 7777, 7778, 7779, 7780, 7781, 7782, 7783, 7784, 7785 were selected from the ORFs having the .20 nucleotide sequence represented by SEQ ID NO: 173.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7786, 7787, 7788, 7789, 7790, 7791, 7792, 7793, 7794, 7795, 7796 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 174.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7797, 7798, 7799, 7800, 7801, 7802, 7803, 7804, 7805, 7806, 7807 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 175.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7808, 7809, 7810, 7811, 7812, 7813, 7814, 7815, 7816, 7817, 7818 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 176.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7819, 7820, 7821, 7822, 7823, 7824, 7825, 7826, 7827, 7828, 7829 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 177.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7830, 7831, 7832, 7833, 7834, 7835, 7836, 7837, 7838, 7839, 7840 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 178.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7841, 7842, 7843, 7844, 7845, 7846, 7847, 7848, 7849, 7850, 7851 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 179.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7852, 7853, 7854, 7855, 7856, 7857, 7858, 7859, 7860, 7861, 7862 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 180.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7863, 7864, 7865, 7866, 7867, 7868, 7869, 7870, 7871, 7872, 7873 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 181.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7874, 7875, 7876, 7877, 7878, 7879, 7880, 7881, 7882, 7883, 7884 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 182.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7885, 7886, 7887, 7888, 7889, 7890, 7891, 7892, 7893, 7894, 7895 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 183.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7896, 7897, 7898, 7899, 7900, 7901, 7902, 7903, 7904, 7905, 7906 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 184.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7907, 7908, 7909, 7910, 7911, 7912, 7913, 7914, 7915, 7916, 7917 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 185.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7918, 7919, 7920, 7921, 7922, 7923, 7924, 7925, 7926, 7927, 7928 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 186.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7929, 7930, 7931, 7932, 7933, 7934, 7935, 7936, 7937, 7938, 7939 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 187.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7940, 7941, 7942, 7943, 7944, 7945, 7946, 7947, 7948, 7949, 7950 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 188.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7951, 7952, 7953, 7954, 7955, 7956, 7957, 7958, 7959, 7960, 7961 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 189.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7962, 7963, 7964, 7965, 7966, 7967, 7968, 7969, 7970, 7971, 7972 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 190.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7973, 7974, 7975, 7976, 7977, 7978, 7979, 7980, 7981, 7982, 7983 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 191.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7984, 7985, 7986, 7987, 7988, 7989, 7990, 7991, 7992, 7993, 7994 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 192.

The probes having the nucleotide sequence represented by SEQ ID NOS: 7995, 7996, 7997, 7998, 7999, 8000, 8001, 8002, 8003, 8004, 8005 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 193.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8006, 8007, 8008, 8009, 8010, 8011, 8012, 8013, 8014, 8015, 8016 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 194.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8017, 8018, 8019, 8020, 8021, 8022, 8023, 8024, 8025, 8026, 8027 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 195.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8028, 8029, 8030, 8031, 8032, 8033, 8034, 8035, 8036, 8037, 8038 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 196.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8039, 8040, 8041, 8042, 8043, 8044, 8045, 8046, 8047, 8048, 8049 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 197.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8050, 8051, 8052, 8053, 8054, 8055, 8056, 8057, 8058, 8059, 8060 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 198.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8061, 8062, 8063, 8064, 8065, 8066, 8067, 8068, 8069, 8070, 8071 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 199.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8072, 8073, 8074, 8075, 8076, 8077, 8078, 8079, 8080, 8081, 8082 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 200.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8083, 8084, 8085, 8086, 8087, 8088, 8089, 8090, 8091, 8092, 8093 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 201.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8094, 8095, 8096, 8097, 8098, 8099, 8100, 8101, 8102, 8103, 8104 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 202.

The probes having the nucleotide sequence repre,sented by SEQ ID NOS: 8105, 8106, 8107, 8108, 8109, 8110, 8111, 8112, 8113, 8114, 8115 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 203.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8116, 8117, 8118, 8119, 8120, 8121, 8122, 8123, 8124, 8125, 8126 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 204.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8127, 8128, 8129, 8130, 8131, 8132, 8133, 8134, 8135, 8136, 8137 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 205.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8138, 8139, 8140, 8141, 8142, 8143, 8144, 8145, 8146, 8147, 8148 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 206.
The,probes having the nucleotide sequence represented by SEQ ID NOS: 8149, 8150, 8151, 8152, 8153, 8154, 8155, 8156, 8157, 8158, 8159 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 207.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8160, 8161, 8162, 8163, 8164, 8165, 8166, 8167, 8168, 8169, 8170 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 208.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8171, 8172, 8173, 8174, 8175, 8176, 8177, 8178, 8179, 8180, 8181 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 209.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8182, 8183, 8184, 8185, 8186, 8187, 8188, 8189, 8190, 8191, 8192 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 210.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8193, 8194, 8195, 8196, 8197, 8198, 8199, 8200, 8201, 8202, 8203 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 211.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8204, 8205, 8206, 8207, 8208, 8209, 8210, 8211, 8212; 8213, 8214 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 212.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8215, 8216, 8217., 8218, 8219, 8220, 8221, 8222, 8223, 8224, 8225 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 213.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8226, 8227, 8228, 8229, 8230, 8231, 8232, 8233, 8234, 8235, 8236 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 214.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8237, 8238, 8239, 8240, 8241, 8242, 8243, 8244, 8245, 8246, 8247 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 215.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8248, 8249, 8250, 8251, 8252, 8253, 8254, 8255, 8256, 8257, 8258 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 216.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8259, 8260, 8261, 8262, 8263, 8264, 8265, 8266, 8267, 8268, 8269 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 217.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8270, 8271, 8272, 8273, 8274, 8275, 8276, 8277, 8278, 8279, 8280 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 218.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8281, 8282, 8283, 8284, 8285, 8286, 8287, 8288, 8289, 8290, 8291 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 219.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8292, 8293, 8294, 8295, 8296, 8297, 8298, 8299, 8300, 8301, 8302 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 220.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8303, 8304, 8305, 8306, 8307, 8308, 8309, 8310, 8311, 8312, 8313 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 221.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8314, 8315, 8316, 8317, 8318, 8319, 8320, 8321, 8322, 8323, 8324 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 222.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8325, 8326, 8327, 8328, 8329, 8330, 8331, 8332, 8333, 8334, 8335 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 223.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8336, 8337, 8338, 8339, 8340, 8341, 8342, 8343, 8344, 8345, 8346 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 224.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8347, 8348, 8349, 8350, 8351, 8352, 8353, 8354, 8355, 8356, 8357 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 225.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8358, 8359, 8360, 8361, 8362, 8363, 8364, 8365, 8366, 8367, 8368 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 226.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8369, 8370, 8371, 8372, 8373, 8374, 8375, 8376, 8377, 8378, 8379 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 227.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8380, 8381, 8382, 8383, 8384, 8385, 8386, 8387, 8388, 8389, 8390 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 228.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8391, 8392, 8393, 8394, 8395, 8396, 8397, 8398, 8399, 8400, 8401 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 229.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8402, 8403, 8404, 8405, 8406, 8407, 8408, 8409, 8410, 8411, 8412 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 230.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8413, 8414, 8415, 8416, 8417, 8418, 8419, 8420, 8421, 8422, 8423 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 231.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8424, 8425, 8426, 8427, 8428, 8429, 8430, 8431, 8432, 8433, 8434 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 232.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8435, 8436, 8437, 8438, 8439, 8440, 8441, 8442, 8443, 8444, 8445 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 233.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8446, 8447, 8448, 8449, 8450, 8451, 8452, 8453, 8454, 8455, 8456 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 234.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8457, 8458, 8459, 8460, 8461, 8462, 8463, 8464, 8465, 8466, 8467 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 235.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8468, 8469, 8470, 8471, 8472, 8473, 8474, 8475, 8476, 8477, 8478 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 236.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8479, 8480, 8481, 8482, 8483, 8484, 8485, 8486, 8487, 8488, 8489 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 237.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8490, 8491, 8492, 8493, 8494, 8495, 8496, 8497, 8498, 8499, 8500 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 238.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8501, 8502, 8503, 8504, 8505, 8506, 8507, 8508, 8509, 8510, 8511 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 239.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8512, 8513, 8514, 8515, 8516, 8517, 8518, 8519, 8520, 8521, 8522 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 240.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8523, 8524, 8525, 8526, 8527, 8528, 8529, 8530, 8531, 8532, 8533 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 241.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8534, 8535, 8536, 8537, 8538, 8539, 8540, 8541, 8542, 8543, 8544 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 242.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8545, 8546, 8547, 8548, 8549, 8550, 8551, 8552, 8553, 8554, 8555 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 243.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8556, 8557, 8558, 8559, 8560, 8561, 8562, 8563, 8564, 8565, 8566 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 244.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8567, 8568, 8569, 8570, 8571, 8572, 8573, 8574, 8575, 8576, 8577 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 245.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8578, 8579, 8580, 8581, 8582, 8583, 8584, 8585, 8586, 8587, 8588 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 246.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8589, 8590, 8591, 8592, 8593, 8594, 8595, 8596, 8597, 8598, 8599 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 247.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8600, 8601, 8602, 8603, 8604, 8605, 8606, 8607, 8608, 8609, 8610 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 248.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8611, 8612, 8613, 8614, 8615, 8616, 8617, 8618, 8619, 8620, 8621 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 249.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8622, 8623, 8624, 8625, 8626, 8627, 8628, 8629, 8630, 8631, 8632 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 250.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8633, 8634, 8635, 8636, 8637, 8638, 8639, 8640, 8641, 8642, 8643 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 251.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8644, 8645, 8646, 8647, 8648, 8649, 8650, 8651, 8652, 8653, 8654 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 252.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8655, 8656, 8657, 8658, 8659, 8660, 8661, 8662, 8663, 8664, 8665 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 253.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8666, 8667, 8668, 8669, 8670, 8671, 8672, 8673, 8674, 8675, 8676 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 254.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8677, 8678, 8679, 8680, 8681, 8682, 8683, 8684, 8685, 8686, 8687 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 255.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8688, 8689, 8690, 8691, 8692, 8693, 8694, 8695, 8696, 8697, 8698 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 256.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8699, 8700, 8701, 8702, 8703, 8704, 8705, 8706, 8707, 8708, 8709 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 257.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8710, 8711, 8712, 8713, 8714, 8715, 8716, 8717, 8718, 8719, 8720 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 258.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8721, 8722, 8723, 8724, 8725, 8726, 8727, 8728, 8729, 8730, 8731 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 259.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8732, 8733, 8734, 8735, 8736, 8737, 8738, 8739, 8740, 8741, 8742 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 260.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8743, 8744, 8745, 8746, 8747, 8748, 8749, 8750, 8751, 8752, 8753 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 261.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8754, 8755, 8756, 8757, 8758, 8759, 8760, 8761, 8762, 8763, 8764 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 262.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8765, 8766, 8767, 8768, 8769, 8770, 8771, 8772, 8773, 8774, 8775 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 263.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8776, 8777, 8778, 8779, 8780, 8781, 8782, 8783, 8784, 8785, 8786 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 264.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8787, 8788, 8789, 8790, 8791, 8792, 8793, 8794, 8795, 8796, 8797 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 265.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8798, 8799, 8800, 8801, 8802, 8803, 8804, 8805, 8806, 8807, 8808 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 266.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8809, 8810, 8811, 8812, 8813, 8814, 8815, 8816, 8817, 8818, 8819 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 267.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8820, 8821, 8822, 8823, 8824, 8825, 8826, 8827, 8828, 8829, 8830 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 268.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8831, 8832, 8833, 8834, 8835, 8836, 8837, 8838, 8839, 8840, 8841 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 269.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8842, 8843, 8844, 8845, 8846, 8847, 8848, 8849, 8850, 8851, 8852 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 270.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8853, 8854, 8855, 8856, 8857, 8858, 8859, 8860, 8861, 8862, 8863 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 271.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8864, 8865, 8866, 8867, 8868, 8869, 8870, 8871, 8872, 8873, 8874 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 272.

The probes having the nucleotide sequence represented by SEQ ID'NOS: 8875, 8876, 8877, 8878, 8879, 8880, 8881, 8882, 8883, 8884, 8885 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 273.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8886, 8887, 8888, 8889, 8890, 8891, 8892, 8893, 8894, 8895, 8896 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 274.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8897, 8898, 8899, 8900, 8901, 8902, 8903, 8904, 8905, 8906, 8907 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 275.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8908, 8909, 8910, 8911, 8912, 8913, 8914, 8915, 8916, 8917, 8918 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 276.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8919, 8920, 8921, 8922, 8923, 8924, 8925, 8926, 8927, 8928, 8929 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 277.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8930, 8931, 8932, 8933, 8934, 8935, 8936, 8937, 8938, 8939, 8940 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 278.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8941, 8942, 8943, 8944, 8945, 8946, 8947, 8948, 8949, 8950, 8951 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 279.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8952, 8953, 8954, 8955, 8956, 8957, 8958, 8959, 8960, 8961, 8962 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 280.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8963, 8964, 8965, 8966, 8967, 8968, 8969, 8970, 8971, 8972, 8973 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 281.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8974, 8975, 8976, 8977, 8978, 8979, 8980, 8981, 8982, 8983, 8984 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 282.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8985, 8986, 8987, 8988, 8989, 8990, 8991, 8992, 8993, 8994, 8995 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 283.

The probes having the nucleotide sequence represented by SEQ ID NOS: 8996, 8997, 8998, 8999, 9000, 9001, 9002, 9003, 9004, 9005, 9006 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 284.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9007, 9008, 9009, 9010, 9011, 9012, 9013, 9014, 9015, 9016, 9017 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 285.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9018, 9019, 9020, 9021, 9022, 9023, 9024, 9025, 9026, 9027, 9028 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 286.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9029, 9030, 9031, 9032, 9033, 9034, 9035, 9036, 9037, 9038, 9039 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 287.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9040, 9041, 9042, 9043, 9044, 9045, 9046, 9047, 9048, 9049, 9050 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 288.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9051, 9052, 9053, 9054, 9055, 9056, 9057, 9058, 9059, 9060, 9061 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 289.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9062, 9063, 9064, 9065, 9066, 9067, 9068, 9069, 9070, 9071, 9072 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 290.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9073, 9074, 9075; 9076, 9077, 9078, 9079, 9080, 9081, 9082, 9083 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 291.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9084, 9085, 9086, 9087, 9088, 9089, 9090, 9091, 9092, 9093, 9094 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 292.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9095, 9096, 9097, 9098, 9099, 9100, 9101, 9102, 9103, 9104, 9105 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 293.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9106, 9107, 9108, 9109, 9110, 9111, 9112, 9113, 9114, 9115, 9116 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 294.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9117, 9118, 9119, 9120, 9121, 9122, 9123, 9124, 9125, 9126, 9127 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 295.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9128, 9129, 9130, 9131, 9132, 9133, 9134, 9135, 9136, 9137, 9138 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 296.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9139, 9140, 9141, 9142, 9143, 9144, 9145, 9146, 9147, 9148, 9149 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 297.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9150, 9151,'9152, 9153, 9154, 9155, 9156, 9157, 9158, 9159, 9160 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 298.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9161, 9162, 9163, 9164, 9165, 9166, 9167, 9168, 9169, 9170, 9171 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 299.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9172, 9173, 9174, 9175, 9176, 9177, 9178, 9179, 9180, 9181, 9182 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 300.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9183, 9184, 9185, 9186, 9187, 9188, 9189, 9190, 9191, 9192, 9193 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 301.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9194, 9195, 9196, 9197, 9198, 9199, 9200, 9201, 9202, 9203, 9204 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 302.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9205, 9206, 9207, 9208, 9209, 9210, 9211, 9212, 9213, 9214, 9215 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 303.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9216, 9217, 9218, 9219, 9220, 9221, 9222, 9223, 9224, 9225, 9226 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 304.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9227, 9228, 9229, 9230, 9231, 9232, 9233, 9234, 9235, 9236, 9237 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 305.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9238, 9239, 9240, 9241, 9242, 9243, 9244, 9245, 9246, 9247, 9248 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 306.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9249, 9250, 9251, 9252, 9253, 9254, 9255, 9256, 9257, 9258, 9259 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 307.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9260, 9261, 9262, 9263, 9264, 9265, 9266, 9267, 9268, 9269, 9270 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 308.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9271, 9272, 9273, 9274, 9275, 9276, 9277, 9278, 9279, 9280, 9281 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 309.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9282, 9283, 9284, 9285, 9286, 9287, 9288, 9289, 9290, 9291, 9292 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 310.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9293, 9294, 9295, 9296, 9297, 9298, 9299, 9300, 9301, 9302, 9303 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 311.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9304, 9305, 9306, 9307, 9308, 9309, 9310, 9311, 9312, 9313, 9314 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 312.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9315, 9316, 9317, 9318, 9319, 9320, 9321, 9322, 9323, 9324, 9325 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 313.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9326, 9327, 9328, 9329, 9330, 9331, 9332, 9333, 9334, 9335, 9336 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 314.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9337, 9338, 9339, 9340, 9341, 9342, 9343, 9344, 9345, 9346, 9347, 9348, 9349, 9350, 9351, 9352, 9353, 9354, 9355, 9356, 9357, 9358 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 315.
The probes having the nucleotide sequence represented by SEQ ID NOS: 9359, 9360, 9361, 9362, 9363, 9364, 9365, 9366, 9367, 9368, 9369 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 316.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9370, 9371, 9372, 9373, 9374, 9375, 9376, 9377, 9378, 9379, 9380 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 317.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9381, 9382, 9383, 9384, 9385, 9386, 9387, 9388, 9389, 9390, 9391 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 318.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9392, 9393, 9394, 9395, 9396, 9397, 9398, 9399, 9400, 9401, 9402 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 319.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9403, 9404, 9405, 9406, 9407, 9408, 9409, 9410, 9411, 9412, 9413 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 320.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9414, 9415, 9416, 9417, 9418, 9419, 9420, 9421, 9422, 9423, 9424 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 321.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9425, 9426, 9427, 9428, 9429, 9430, 9431, 9432, 9433, 9434, 9435 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 322.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9436, 9437, 9438, 9439, 9440, 9441, 9442, 9443, 9444, 9445, 9446 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 323.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9447, 9448, 9449, 9450, 9451, 9452, 9453, 9454, 9455, 9456, 9457 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 324.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9458, 9459, 9460, 9461, 9462, 9463, 9464, 9465, 9466, 9467, 9468 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 325.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9469, 9470, 9471, 9472, 9473, 9474, 9475, 9476, 9477, 9478, 9479 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 326.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9480, 9481, 9482, 9483, 9484, 9485, 9486, 9487, 9488, 9489, 9490 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 327.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9491, 9492, 9493, 9494, 9495, 9496, 9497, 9498, 9499, 9500, 9501 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 328.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9502, 9503, 9504, 9505, 9506, 9507, 9508, 9509, 9510, 9511, 9512 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 329.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9513, 9514, 9515, 9516, 9517, 9518, 9519, 9520, 9521, 9522, 9523 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 330.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9524, 9525, 9526, 9527, 9528, 9529, 9530, 9531, 9532, 9533, 9534 were selected from the ORFs having the nucleotide sequence represented by SEQ ID.NO: 331.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9535, 9536, 9537, 9538, 9539, 9540, 9541, 9542, 9543, 9544, 9545, 9546, 9547, 9548, 9549, 9550, 9551, 9552, 9553, 9554, 9555, 9556 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 332.
The probes having the nucleotide sequence represented by SEQ ID NOS: 9557, 9558, 9559, 9560, 9561, 9562, 9563, 9564, 9565, 9566, 9567, 9568, 9569, 9570, 9571, 9572, 9573, 9574, 9575, 9576, 9577, 9578 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 333.
The probes having the nucleotide sequence represented by SEQ ID NOS: 9579, 9580, 9581, 9582, 9583, 9584, 9585, 9586, 9587, 9588, 9589 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 334.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9590, 9591, 9592, 9593, 9594, 9595, 9596, 9597, 9598, 9599, 9600 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 335.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9601, 9602, 9603, 9604, 9605, 9606, 9607, 9608, 9609, 9610, 9611 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 336..

The probes having the nucleotide sequence represented by SEQ ID NOS: 9612, 9613, 9614, 9615, 9616, 9617, 9618, 9619, 9620, 9621, 9622 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 337.

The probes having the nucleotide sequence represented.by SEQ ID NOS: 9623, 9624, 9625, 9626, 9627, 9628, 9629, 9630, 9631, 9632, 9633 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 338.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9634, 9635, 9636, 9637, 9638, 9639, 9640, 9641, 9642, 9643, 9644 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 339.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9645, 9646, 9647, 9648, 9649, 9650, 9651, 9652, 9653, 9654, 9655 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 340.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9656, 9657, 9658, 9659, 9660, 9661, 9662, 9663, 9664, 9665, 9666 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 341.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9667, 9668, 9669, 9670, 9671, 9672, 9673, 9674, 9675, 9676, 9677 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 342.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9678, 9679, 9680, 9681, 9682, 9683, 9684, 9685, 9686, 9687, 9688 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 343.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9689, 9690, 9691, 9692, 9693, 9694, 9695, 9696, 9697, 9698, 9699 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 344.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9700, 9701, 9702, 9703, 9704, 9705, 9706, 9707, 9708, 9709, 9710 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 345.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9711, 9712, 9713, 9714, 9715, 9716, 9717, 9718, 9719, 9720, 9721 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 346.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9722, 9723, 9724, 9725, 9726, 9727, 9728, 9729, 9730, 9731, 9732 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 347.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9733, 9734, 9735, 9736, 9737, 9738, 9739, 9740, 9741, 9742, 9743 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 348.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9744, 9745, 9746, 9747, 9748, 9749, 9750, 9751, 9752, 9753, 9754 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 349.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9755, 9756, 9757, 9758, 9759, 9760, 9761, 9762, 9763, 9764, 9765 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 350.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9766, 9767, 9768, 9769, 9770, 9771, 9772, 9773, 9774, 9775, 9776 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 351.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9777, 9778, 9779, 9780, 9781, 9782, 9783, 9784, 9785, 9786, 9787 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 352.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9788, 9789, 9790, 9791, 9792, 9793, 9794, 9795, 9796, 9797, 9798 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 353.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9799, 9800, 9801, 9802, 9803, 9804, 9805, 9806, 9807, 9808, 9809 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 354.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9810, 9811, 9812, 9813, 9814, 9815, 9816, 9817, 9818, 9819, 9820 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 355.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9821, 9822, 9823, 9824, 9825, 9826, 9827, 9828, 9829, 9830, 9831 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 356.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9832, 9833, 9834, 9835, 9836, 9837, 9838, 9839, 9840, 9841, 9842 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 357.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9843, 9844, 9845, 9846, 9847, 9848, 9849, 9850, 9851, 9852, 9853 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 358.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9854, 9855, 9856, 9857, 9858, 9859, 9860, 9861, 9862, 9863, 9864 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 359.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9865, 9866, 9867, 9868, 9869, 9870, 9871, 9872, 9873, 9874, 9875 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 360.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9876, 9877, 9878, 9879, 9880, 9881, 9882, 9883, 9884, 9885, 9886 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 361.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9887, 9888, 9889, 9890, 9891, 9892, 9893, 9894, 9895, 9896, 9897 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 362.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9898, 9899, 9900, 9901, 9902, 9903, 9904, 9905, 9906, 9907, 9908 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 363.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9909, 9910, 9911, 9912, 9913, 9914, 9915, 9916, 9917, 9918, 9919 were selected from the ORFs having the nucleotide sequence represented by'SEQ ID NO: 364.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9920, 9921, 9922, 9923, 9924, 9925, 9926, 9927, 9928, 9929, 9930 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 365.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9931, 9932, 9933, 9934, 9935, 9936, 9937, 9938, 9939, 9940, 9941 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 366.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9942, 9943, 9944, 9945, 9946, 9947, 9948, 9949, 9950, 9951, 9952 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 367.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9953, 9954, 9955, 9956, 9957, 9958, 9959, 9960, 9961, 9962, 9963 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 368.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9964, 9965, 9966, 9967, 9968, 9969, 9970, 9971, 9972, 9973, 9974 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 369.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9975, 9976, 9977, 9978, 9979, 9980, 9981, 9982, 9983, 9984, 9985 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 370.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9986, 9987, 9988, 9989, 9990, 9991, 9992, 9993, 9994, 9995, 9996 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 371.

The probes having the nucleotide sequence represented by SEQ ID NOS: 9997, 9998, 9999, 10000, 10001, 10002, 10003, 10004, 10005, 10006, 10007 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO:
372.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10008, 10009, 10010, 10011, 10012, 10013, 10014, 10015, 10016, 10017, 10018 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 373.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10019, 10020, 10021, 10022, 10023, 10024, 10025, 10026, 10027, 10028, 10029 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 374.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10030, 10031, 10032, 10033, 10034, 10035, 10036, 10037, 10038, 10039, 10040 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 375.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10041, 10042, 10043, 10044, 10045, 10046, 10047, 10048, 10049, 10050, 10051 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 376.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10052, 10053, 10054, 10055, 10056, 10057, 10058, 10059, 10060, 10061, 10062 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 377.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10063, 10064, 10065, 10066, 10067, 10068, 10069, 10070, 10071, 10072, 10073 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 378.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10074, 10075, 10076, 10077, 10078, 10079, 10080, 10081, 10082, 10083, 10084 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 379.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10085, 10086, 10087, 10088, 10089, 10090, 10091, 10092, 10093, 10094, 10095 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 380.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10096, 10097, 10098, 10099, 10100, 10101, 10102, 10103, 10104, 10105, 10106 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 381.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10107, 10108, 10109, 10110, 10111, 10112, 10113, 10114, 10115, 10116, 10117 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 382.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10118, 10119, 10120, 10121, 10122, 10123, 10124, 10125, 10126, 10127, 10128 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 383.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10129, 10130, 10131, 10132, 10133, 10134, 10135, 10136, 10137, 10138, 10139 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 384.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10140, 10141, 10142, 10143, 10144, 10145, 10146, 10147, 10148, 10149, 10150 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 385.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10151, 10152, 10153, 10154, 10155, 10156, 10157, 10158, 10159, 10160, 10161 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 386.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10162, 10163, 10164, 10165, 10166, 10167, 10168, 10169, 10170, 10171, 10172 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 387.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10173, 10174, 10175, 10176, 10177, 10178, 10179, 10180, 10181, 10182, 10183 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 388.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10184, 10185, 10186, 10187, 10188, 10189, 10190, 10191, 10192, 10193, 10194 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 389.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10195, 10196, 10197, 10198, 10199, 10200, 10201, 10202, 10203, 10204, 10205 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 390.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10206, 10207, 10208, 10209, 10210, 10211, 10212, 10213, 10214, 10215, 10216 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 391.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10217, 10218, 10219, 10220, 10221, 10222, 10223, 10224, 10225, 10226, 10227 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 392.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10228, 10229, 10230, 10231, 10232, 10233, 10234, 10235, 10236, 10237, 10238 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 393.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10239, 10240, 10241, 10242, 10243, 10244, 10245, 10246, 10247, 10248, 10249 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 394.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10250, 10251, 10252, 10253, 10254, 10255, 10256, 10257, 10258, 10259, 10260 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 395.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10261, 10262, 10263, 10264, 10265, 10266, 10267, 10268, 10269, 10270, 10271 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 396.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10272, 10273, 10274, 10275, 10276, 10277, 10278, 10279, 10280, 10281, 10282 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 397.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10283, 10284, 10285, 10286, 10287, 10288, 10289, 10290, 10291, 10292, 10293 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 398.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10294, 10295, 10296, 10297, 10298, 10299, 10300, 10301, 10302, 10303, 10304 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 399.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10305, 10306, 10307, 10308, 10309, 10310, 10311, 10312, 10313, 10314, 10315 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 400.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10316, 10317, 10318, 10319, 10320, 10321, 10322, 10323, 10324, 10325, 10326 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 401.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10327, 10328, 10329, 10330, 10331, 10332, 10333, 10334, 10335, 10336, 10337 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 402.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10338, 10339, 10340, 10341, 10342, 10343, 10344, 10345, 10346, 10347, 10348 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 403.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10349, 10350, 10351, 10352, 10353, 10354, 10355, 10356, 10357, 10358, 10359 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 404.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10360, 10361, 10362, 10363, 10364, 10365, 10366, 10367, 10368, 10369, 10370 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 405.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10371, 10372, 10373, 10374, 10375, 10376, 10377, 10378, 10379, 10380, 10381 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 406.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10382, 10383, 10384, 10385, 10386, 10387, 10388, 10389, '10390, 10391, 10392 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 407.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10393, 10394, 10395, 10396, 10397, 10398, 10399, 10400, 10401, 10402, 10403 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 408.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10404, 10405, 10406, 10407, 10408, 10409, 10410, 10411, 10412, 10413, 10414 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 409.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10415, 10416, 10417, 10418, 10419, 10420, 10421, 10422, 10423, 10424, 10425 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 410.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10426, 10427, 10428, 10429, 10430, 10431, 10432, 10433, 10434, 10435, 10436 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 411.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10437, 10438, 10439, 10440, 10441, 10442, 10443, 10444, 10445, 10446, 10447 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 412.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10448, 10449, 10450, 10451, 10452, 10453, 10454, 10455, 10456, 10457, 10458 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 413.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10459, 10460, 10461, 10462, 10463, 10464, 10465, 10466, 10467, 10468, 10469 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 414.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10470, 10471, 10472, 10473, 10474, 10475, 10476, 10477, 10478, 10479, 10480 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 415.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10481, 10482, 10483, 10484, 10485, 10486, 10487, 10488, 10489, 10490, 10491 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 416.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10492, 10493, 10494, 10495, 10496, 10497, 10498, 10499, 10500, 10501, 10502 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 417.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10503, 10504, 10505, 10506, 10507, 10508, 10509, 10510, 10511, 10512, 10513 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 418.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10514, 10515, 10516, 10517, 10518, 10519, 10520, 10521, 10522, 10523, 10524 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 419.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10525, 10526, 10527, 10528, 10529, 10530, 10531, 10532, 10533, 10534, 10535 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 420.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10536, 10537, 10538, 10539, 10540, 10541, 10542, 10543, 10544, 10545, 10546 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 421.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10547, 10548, 10549, 10550, 10551, 10552, 10553, 10554, 10555, 10556, 10557 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 422.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10558, 10559, 10560, 10561, 10562, 10563, 10564, 10565, 10566, 10567, 10568 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 423.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10569, 10570, 10571, 10572, 10573, 10574, 10575, 10576, 10577, 10578, 10579 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 424.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10580, 10581, 10582, 10583, 10584, 10585, 10586, 10587, 10588, 10589, 10590 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 425.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10591, 10592, 10593, 10594, 10595, 10596, 10597, 10598, 10599, 10600, 10601 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 426.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10602, 10603, 10604, 10605, 10606, 10607, 10608, 10609, 10610, 10611, 10612 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 427.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10613, 10614, 10615, 10616, 10617, 10618, 10619, 10620, 10621, 10622, 10623 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 428.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10624, 10625, 10626, 10627, 10628, 10629, 10630, 10631, 10632, 10633, 10634 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 429.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10635, 10636, 10637, 10638, 10639, 10640, 10641, 10642, 10643, 10644, 10645 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 430.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10646, 10647, 10648, 10649, 10650, 10651, 10652, 10653, 10654, 10655, 10656 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 431.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10657, 10658, 10659, 10660, 10661, 10662, 10663, 10664, 10665, 10666, 10667 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 432.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10668, 10669, 10670, 10671, 10672, 10673, 10674, 10675, 10676, 10677, 10678 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 433.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10679, 10680, 10681, 10682, 10683, 10684, 10685, 10686, 10687, 10688, 10689 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 434.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10690, 10691, 10692, 10693, 10694, 10695, 10696, 10697, 10698, 10699, 10700 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 435.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10701, 10702, 10703, 10704, 10705, 10706, 10707, 10708, 10709, 10710, 10711 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 436.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10712, 10713, 10714, 10715, 10716, 10717, 10718, 10719, 10720, 10721, 10722 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 437.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10723, 10724, 10725, 10726, 10727, 10728, 10729, 10730, 10731, 10732, 10733 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 438.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10734, 10735, 10736, 10737, 10738, 10739, 10740, 10741, 10742, 10743, 10744 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 439.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10745, 10746, 10747, 10748, 10749, 10750, 10751, 10752, 10753, 10754, 10755 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 440.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10756, 10757, 10758, 10759, 10760, 10761, 10762, 10763, 10764, 10765, 10766 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 441.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10767, 10768, 10769, 10770, 10771, 10772, 10773, 10774, 10775, 10776, 10777 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 442.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10778, 10779, 10780, 10781, 10782, 10783, 10784, 10785, 10786, 10787, 10788 were selected from the ORFs having the nucleotide sequence represented by.SEQ ID
NO: 443.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10789, 10790, 10791, 10792, 10793, 10794, 10795, 10796, 10797, 10798, 10799 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 444.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10800, 10801, 10802, 10803, 10804, 10805, 10806, 10807, 10808, 10809, 10810 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 445.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10811, 10812, 10813, 10814, 10815, 10816, 10817, 10818, 10819, 10820, 10821 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 446.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10822, 10823, 10824, 10825, 10826, 10827, 10828, 10829, 10830, 10831, 10832 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 447.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10833, 10834, 10835, 10836, 10837, 10838, 10839, 10840, 10841, 10842, 10843 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 448.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10844, 10845, 10846, 10847, 10848, 10849, 10850, 10851, 10852, 10853, 10854 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 449.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10855, 10856, 10857, 10858, 10859, 10860, 10861, 10862, 10863, 10864, 10865 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 450.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10866, 10867, 10868, 10869, 10870, 10871, 10872, 10873, 10874, 10875, 10876 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 451.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10877, 10878, 10879, 10880, 10881, 10882, 10883, 10884, 10885, 10886, 10887 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 452.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10888, 10889, 10890, 10891, 10892, 10893, 10894, 10895, 10896, 10897, 10898 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 453.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10899, 10900, 10901, 10902, 10903, 10904, 10905, 10906, 10907, 10908, 10909 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 454.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10910, 10911, 10912, 10913, 10914, 10915, 10916, 10917, 10918, 10919, 10920 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 455.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10921, 10922, 10923, 10924, 10925, 10926, 10927, 10928, 10929, 10930, 10931 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 456.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10932, 10933, 10934, 10935, 10936, 10937, 10938, 10939, 10940, 10941, 10942 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 457.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10943, 10944, 10945, 10946, 10947, 10948, 10949, 10950, 10951, 10952, 10953 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 458.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10954, 10955, 10956, 10957, 10958, 10959, 10960, 10961, 10962, 10963, 10964 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 459.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10965, 10966, 10967, 10968, 10969, 10970, 10971, 10972, 10973, 10974, 10975 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 460.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10976, 10977, 10978, 10979, 10980, 10981, 10982, 10983, 10984, 10985, 10986 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 461.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10987, 10988, 10989, 10990, 10991, 10992, 10993, 10994, 10995, 10996, 10997 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 462.

The probes having the nucleotide sequence represented by SEQ ID NOS: 10998, 10999, 11000, 11001, 11002, 11003, 11004, 11005, 11006, 11007, 11008 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 463.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11009, 11010, 11011, 11012, 11013, 11014, 11015, 11016, 11017, 11018, 11019 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 464.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11020, 11021,'11022, 11023, 11024, 11025, 11026, 11027, 11028, 11029, 11030 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 465.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11031, 11032, 11033, 11034, 11035, 11036, 11037, 11038, 11039, 11040, 11041 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 466.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11042, 11043, 11044, 11045, 11046, 11047, 11048, 11049, 11050, 11051, 11052 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 467.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11053, 11054, 11055, 11056, 11057, 11058, 11059, 11060, 11061, 11062, 11063 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 468.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11064, 11065, 11066, 11067, 11068, 11069, 11070, 11071, 11072, 11073, 11074 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 469.

P
The probes having the nucleotide sequence represented by SEQ ID NOS: 11075, 11076, 11077, 11078, 11079, 11080, 11081, 11082, 11083, 11084, 11085 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 470.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11086, 11087, 11088, 11089, 11090, 11091, 11092, 11093, 11094, 11095, 11096 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 471.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11097, 11098, 11099, 11100, 11101, 11102, 11103, 11104, 11105, 11106, 11107 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 472.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11108, 11109, 11110, 11111, 11112, 11113, 11114, 11115, 11116, 11117, 11118 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 473.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11119, 11120, 11121, 11122, 11123, 11124, 11125, 11126, 11127, 11128, 11129 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 474.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11130, 11131, 11132, 11133, 11134, 11135, 11136, 11137, 11138, 11139, 11140 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 475.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11141, 11142, 11143, 11144, 11145, 11146, 11147, 11148, 11149, 11150, 11151 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 476.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11152, 11153, 11154, 11155, 11156, 11157, 11158, 11159, 11160, 11161, 11162 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 477.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11163, 11164, 11165, 11166, 11167, 11168, 11169, 11170, 11171, 11172, 11173 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 478.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11174, 11175, 11176, 11177, 11178, 11179, 11180, 11181, 11182, 11183,.11184 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 479.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11185, 11186, 11187, 11188, 11189, 11190, 11191, 11192, 11193, 11194, 11195 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 480.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11196, 11197, 11198, 11199, 11200, 11201, 11202, 11203, 11204, 11205, 11206 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 481.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11207, 11208, 11209, 11210, 11211, 11212, 11213, 11214, 11215, 11216, 11217 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 482.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11218, 11219, 11220, 11221, 11222, 11223, 11224, 11225, 11226, 11227, 11228 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 483.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11229, 11230, 11231, 11232, 11233, 11234, 11235, 11236, 11237, 11238, 11239 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 484.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11240, 11241, 11242, 11243, 11244, 11245, 11246, 11247, 11248, 11249, 11250 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 485.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11251, 11252, 11253, 11254, 11255, 11256, 11257, 11258, 11259, 11260, 11261 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 486.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11262, 11263, 11264, 11265, 11266, 11267, 11268, 11269, 11270, 11271, 11272 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 487.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11273, 11274, 11275, 11276, 11277, 11278, 11279, 11280, 11281, 11282, 11283 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 488.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11284, 11285, 11286, 11287, 11288, 11289, 11290, 11291, 11292, 11293, 11294 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 489.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11295, 11296, 11297, 11298, 11299, 11300, 11301, 11302, 11303, 11304, 11305 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 490.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11306, 11307, 11308, 11309, 11310, 11311, 11312, 11313, 11314, 11315, 11316 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 491.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11317, 11318, 11319, 11320, 11321, 11322, 11323, 11324, 11325, 11326, 11327 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 492.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11328, 11329, 11330, 11331, 11332, 11333, 11334, 11335, 11336, 11337, 11338 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 493.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11339, 11340, 11341, 11342, 11343, 11344, 11345, 11346, 11347, 11348, 11349 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 494.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11350, 11351, 11352, 11353, 11354, 11355, 11356, 11357, 11358, 11359, 11360 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 495.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11361, 11362, 11363, 11364, 11365, 11366, 11367, 11368, 11369, 11370, 11371 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 496.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11372, 11373, 11374, 11375, 11376, 11377, 11378, 11379, 11380, 11381, 11382 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 497.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11383, 11384, 11385, 11386, 11387, 11388, 11389, 11390, 11391, 11392, 11393 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 498.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11394, 11395, 11396, 11397, 11398, 11399, 11400, 11401, 11402, 11403, 11404 were selected from the ORFs having the.nucleotide sequence represented by SEQ ID
NO: 499.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11405, 11406, 11407, 11408, 11409, 11410, 11411, 11412, 11413, 11414, 11415 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 500.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11416, 11417, 11418, 11419, 11420, 11421, 11422, 11423, 11424, 11425, 11426 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 501.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11427, 11428, 11429, 11430, 11431, 11432, 11433, 11434, 11435, 11436, 11437 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 502.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11438, 11439, 11440, 11441, 11442, 11443, 11444, 11445, 11446, 11447, 11448 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 503.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11449, 11450, 11451, 11452, 11453, 11454, 11455, 11456, 11457, 11458, 11459 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 504.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11460, 11461, 11462, 11463, 11464, 11465, 11466, 11467, 11468, 11469, 11470 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 505.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11471, 11472, 11473, 11474, 11475, 11476, 11477, 11478, 11479, 11480, 11481 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 506.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11482, 11483, 11484, 11485, 11486, 11487, 11488, 11489, 11490, 11491, 11492 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 507.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11493, 11494, 11495, 11496, 11497, 11498, 11499, 11500, 11501, 11502, 11503 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 508.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11504, 11505, 11506, 11507, 11508, 11509, 11510, 11511, 11512, 11513, 11514 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 509.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11515, 11516, 11517, 11518, 11519, 11520, 11521, 11522, 11523, 11524, 11525 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 510.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11526, 11527, 11528, 11529, 11530, 11531, 11532, 11533, 11534, 11535, 11536 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 511.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11537, 11538, 11539, 11540, 11541, 11542, 11543, 11544, 11545, 11546, 11547 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 512.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11548, 11549, 11550, 11551, 11552, 11553, 11554, 11555, 11556, 11557, 11558 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 513.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11559, 11560, 11561, 11562, 11563, 11564, 11565, 11566, 11567, 11568, 11569 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 514.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11570, 11571, 11572, 11573, 11574, 11575, 11576, 11577, 11578, 11579, 11580 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 515.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11581, 11582, 11583, 11584, 11585, 11586, 11587, 11588, 11589, 11590, 11591 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 516.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11592, 11593, 11594, 11595, 11596, 11597, 11598, 11599, 11600, 11601, 11602 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 517.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11603, 11604, 11605, 11606, 11607, 11608, 11609, 11610, 11611, 11612, 11613 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 518.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11614, 11615, 11616, 11617, 11618, 11619, 11620, 11621, 11622, 11623, 11624 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 519.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11625, 11626, 11627, 11628, 11629, 11630, 11631, 11632, 11633, 11634, 11635 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 520.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11636, 11637, 11638, 11639, 11640, 11641, 11642, 11643, 11644, 11645, 11646 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 521.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11647, 11648, 11649, 11650, 11651, 11652, 11653, 11654, 11655, 11656, 11657 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 522.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11658, 11659, 11660, 11661, 11662, 11663, 11664, 11665, 11666, 11667, 11668 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 523.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11669, 11670, 11671, 11672, 11673, 11674, 11675, 11676, 11677, 11678, 11679 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 524.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11680, 11681, 11682, 11683, 11684, 11685, 11686, 11687, 11688, 11689, 11690 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 525.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11691, 11692, 11693, 11694, 11695, 11696, 11697, 11698, 11699, 11700, 11701 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 526.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11702, 11703, 11704, 11705, 11706, 11707, 11708, 11709, 11710, 11711, 11712 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 527.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11713, 11714, 11715, 11716, 11717, 11718, 11719, 11720, 11721, 11722, 11723 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 528.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11724, 11725, 11726, 11727, 11728, 11729, 11730, 11731, 11732, 11733, 11734 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 529.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11735, 11736, 11737, 11738, 11739, 11740, 11741, 11742, 11743, 11744, 11745 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 530.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11746, 11747, 11748, 11749, 11750, 11751, 11752, 11753, 11754, 11755, 11756 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 531.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11757, 11758, 11759, 11760, 11761, 11762, 11763, 11764, 11765, 11766, 11767 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 532.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11768, 11769, 11770, 11771, 11772, 11773, 11774, 11775, 11776, 11777, 11778 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 533.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11779, 11780, 11781, 11782, 11783, 11784, 11785, 11786, 11787, 11788, 11789 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 534.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11790, 11791, 11792, 11793, 11794, 11795, 11796, 11797, 11798, 11799, 11800 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 535.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11801, 11802, 11803, 11804, 11805, 11806, 11807, 11808, 11809, 11810, 11811 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 536.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11812, 11813, 11814, 11815, 11816, 11817, 11818, 11819, 11820, 11821, 11822 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 537.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11823, 11824, 11825, 11826, 11827, 11828, 11829, 11830, 11831, 11832, 11833 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 538.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11834, 11835, 11836, 11837, 11838, 11839, 11840, 11841, 11842, 11843, 11844 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 539.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11845, 11846, 11847, 11848, 11849, 11850, 11851, 11852, 11853, 11,854, 11855 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 540.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11856, 11857, 11858, 11859, 11860, 11861, 11862, 11863, 11864, 11865, 11866 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 541.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11867, 11868, 11869, 11870, 11871, 11872, 11873, 11874, 11875, 11876, 11877 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 542.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11878, 11879, 11880, 11881, 11882, 11883, 11884, 11885, 11886, 11887, 11888 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 543.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11889, 11890, 11891, 11892, 11893, 11894, 11895, 11896, 11897, 11898, 11899 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 544.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11900, 11901, 11902, 11903, 11904, 11905, 11906, 11907, 11908, 11909, 11910 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 545.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11911, 11912, 11913, 11914, 11915, 11916, 11917, 11918, 11919, 11920, 11921 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 546.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11922, 11923, 11924, 11925, 11926, 11927, 11928, 11929, 11930, 11931, 11932 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 547.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11933, 11934, 11935, 11936, 11937, 11938, 11939, 11940, 11941, 11942, 11943 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 548.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11944, 11945, 11946, 11947, 11948, 11949, 11950, 11951, 11952, 11953, 11954 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 549.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11955, 11956, 11957, 11958, 11959, 11960, 11961, 11962, 11963, 11964, 11965 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 550.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11966, 11967, 11968, 11969, 11970, 11971, 11972, 11973, 11974, 11975, 11976 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 551.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11977, 11978, 11979, 11980, 11981, 11982, 11983, 11984, 11985, 11986, 11987 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 552.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11988, 11989, 11990, 11991, 11992, 11993, 11994, 11995, 11996, 11997, 11998 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 553.

The probes having the nucleotide sequence represented by SEQ ID NOS: 11999, 12000, 12001, 12002, 12003, 12004, 12005, 12006, 12007, 12008, 12009 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 554.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12010, 12011, 12012, 12013, 12014, 12015, 12016, 12017, 12018, 12019, 12020 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 555.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12021, 12022, 12023, 12024, 12025, 12026, 12027, 12028, 12029, 12030, 12031 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 556.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12032, 12033, 12034, 12035, 12036, 12037, 12038, 12039, 12040, 12041, 12042 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 557.

The probes having.the nucleotide sequence represented by SEQ ID NOS: 12043, 12044, 12045, 12046, 12047, 12048, 12049, 12050, 12051, 12052, 12053 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 558.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12054, 12055, 12056, 12057, 12058, 12059, 12060, 12061, 12062, 12063, 12064 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 559.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12065, 12066, 12067, 12068, 12069, 12070, 12071, 12072, 12073, 12074, 12075 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 560.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12076, 12077, 12078, 12079, 12080, 12081, 12082, 12083, 12084, 12085, 12086 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 561.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12087, 12088, 12089, 12090, 12091, 12092, 12093, 12094, 12095, 12096, 12097 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 562.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12098, 12099, 12100, 12101, 12102, 12103, 12104, 12105, 12106, 12107, 12108 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 563.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12109, 12110, 12111, 12112, 12113, 12114, 12115, 12116, 12117, 12118, 12119 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 564.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12120, 12121, 12122, 12123, 12124, 12125, 12126, 12127, 12128, 12129, 12130 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 565.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12131, 12132, 12133, 12134, 12135, 12136, 12137, 12138, 12139, 12140, 12141 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 566.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12142, 12143, 12144, 12145, 12146, 12147, 12148, 12149, 12150, 12151, 12152 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 567.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12153, 12154, 12155, 12156, 12157, 12158, 12159, 12160, 12161, 12162, 12163 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 568.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12164, 12165, 12166, 12167, 12168, 12169, 12170, 12171, 12172, 12173, 12174 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 569.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12175, 12176, 12177, 12178, 12179, 12180, 12181, 12182, 12183, 12184, 12185 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 570.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12186, 12187, 12188, 12189, 12190, 12191, 12192, 12193, 12194, 12195, 12196 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 571.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12197, 12198, 12199, 12200, 12201, 12202, 12203, 12204, 12205, 12206, 12207 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 572.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12208, 12209, 12210, 12211, 12212, 12213, 12214, 12215, 12216, 12217, 12218 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 573.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12219, 12220, 12221, 12222, 12223, 12224, 12225, 12226, 12227, 12228, 12229 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 574.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12230, 12231, 12232, 12233, 12234, 12235, 12236, 12237, 12238, 12239, 12240 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 575.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12241, 12242, 12243, 12244, 12245, 12246, 12247, 12248, 12249, 12250, 12251 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 576.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12252, 12253, 12254, 12255, 12256, 12257, 12258, 12259, 12260, 12261, 12262 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 577.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12263, 12264, 12265, 12266, 12267, 12268, 12269, 12270, 12271, 12272, 12273 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 578.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12274, 12275, 12276, 12277, 12278, 12279, 12280, 12281, 12282, 12283, 12284 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 579.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12285, 12286, 12287, 12288, 12289, 12290, 12291, 12292, 12293, 12294, 12295 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 580.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12296, 12297, 12298, 12299, 12300, 12301, 12302, 12303, 12304, 12305, 12306 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 581.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12307, 12308, 12309, 12310, 12311, 12312, 12313, 12314, 12315, 12316, 12317 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 582.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12318, 12319, 12320, 12321, 12322, 12323, 12324, 12325, 12326, 12327, 12328 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 583.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12329, 12330, 12331, 12332, 12333, 12334, 12335, 12336, 12337, 12338, 12339 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 584.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12340, 12341, 12342, 12343, 12344, 12345, 12346, 12347, 12348, 12349, 12350 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 585.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12351, 12352, 12353, 12354, 12355, 12356, 12357, 12358, 12359, 12360, 12361 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 586.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12362, 12363, 12364, 12365, 12366, 12367, 12368, 12369, 12370, 12371, 12372 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 587.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12373, 12374, 12375, 12376, 12377, 12378, 12379, 12380, 12381, 12382, 12383 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 588.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12384, 12385, 12386, 12387, 12388, 12389, 12390, 12391, 12392, 12393, 12394 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 589.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12395, 12396, 12397, 12398, 12399, 12400, 12401, 12402, 12403, 12404, 12405 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 590.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12406, 12407, 12408, 12409, 12410, 12411, 12412, 12413, 12414, 12415, 12416 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 591.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12417, 12418, 12419, 12420, 12421, 12422, 12423, 12424, 12425, 12426, 12427 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 592.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12428, 12429, 12430, 12431, 12432, 12433, 12434, 12435, 12436, 12437, 12438 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 593.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12439, 12440, 12441, 12442, 12443, 12444, 12445, 12446, 12447, 12448, 12449 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 594.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12450, 12451, 12452, 12453, 12454, 12455, 12456, 12457, 12458, 12459, 12460 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 595.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12461, 12462, 12463, 12464, 12465, 12466, 12467, 12468, 12469, 12470, 12471 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 596.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12472, 12473, 12474, 12475, 12476, 12477, 12478, 12479, 12480, 12481, 12482 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 597.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12483, 12484, 12485, 12486, 12487, 12488, 12489, 12490, 12491, 12492, 12493 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 598.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12494, 12495, 12496, 12497, 12498, 12499, 12500, 12501, 12502, 12503, 12504 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 599.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12505, 12506, 12507, 12508, 12509, 12510, 12511, 12512, 12513, 12514, 12515 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 600.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12516, 12517, 12518, 12519, 12520, 12521, 12522, 12523, 12524, 12525, 12526 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 601.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12527, 12528, 12529, 12530, 12531, 12532, 12533, 12534, 12535, 12536, 12537 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 602.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12538, 12539, 12540, 12541, 12542, 12543, 12544, 12545, 12546, 12547, 12548 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 603.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12549, 12550, 12551, 12552, 12553, 12554, 12555, 12556, 12557, 12558, 12559 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 604.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12560, 12561, 12562, 12563, 12564, 12565, 12566, 12567, 12568, 12569, 12570 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 605.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12571, 12572, 12573, 12574, 12575, 12576, 12577, 12578, 12579, 12580, 12581 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 606.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12582, 12583, 12584, 12585, 12586, 12587, 12588, 12589, 12590, 12591, 12592 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 607.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12593, 12594, 12595, 12596, 12597, 12598, 12599, 12600, 12601, 12602, 12603 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 608.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12604, 12605, 12606, 12607, 12608, 12609, 12610, 12611, 12612, 12613, 12614 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 609.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12615, 12616, 12617, 12618, 12619, 12620, 12621, 12622, 12623, 12624, 12625 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 610.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12626, 12627, 12628, 12629, 12630, 12631, 12632, 12633, 12634, 12635, 12636 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 611.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12637, 12638, 12639, 12640, 12641, 12642, 12643, 12644, 12645, 12646, 12647 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 612.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12648, 12649, 12650, 12651, 12652, 12653, 12654, 12655, 12656, 12657, 12658 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 613.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12659, 12660, 12661, 12662, 12663, 12664, 12665, 12666, 12667, 12668, 12669 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 614.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12670, 12671, 12672, 12673, 12674, 12675, 12676, 12677, 12678, 12679, 12680 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 615.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12681, 12682, 12683, 12684, 12685, 12686, 12687, 12688, 12689, 12690, 12691 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 616.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12692, 12693, 12694, 12695, 12696, 12697, 12698, 12699, 12700, 12701, 12702 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 617.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12703, 12704, 12705, 12706, 12707, 12708, 12709, 12710, 12711, 12712, 12713 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 618.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12714, 12715, 12716, 12717, 12718, 12719, 12720, 12721, 12722, 12723, 12724 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 619.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12725, 12726, 12727, 12728, 12729, 12730, 12731, 12732, 12733, 12734, 12735 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 620.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12736, 12737, 12738, 12739, 12740, 12741, 12742, 12743, 12744, 12745, 12746 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 621.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12747, 12748, 12749, 12750, 12751, 12752, 12753, 12754, 12755, 12756, 12757 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 622.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12758, 12759, 12760, 12761, 12762, 12763, 12764, 12765, 12766, 12767, 12768 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 623.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12769, 12770, 12771, 12772, 12773, 12774, 12775, 12776, 12777, 12778, 12779 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 624.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12780, 12781, 12782, 12783, 12784, 12785, 12786, 12787, 12788, 12789, 12790 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 625.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12791, 12792, 12793, 12794, 12795, 12796, 12797, 12798, 12799, 12800, 12801 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 626.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12802, 12803, 12804, 12805, 12806, 12807, 12808, 12809, 12810, 12811, 12812 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 627.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12813, 12814, 12815, 12816, 12817, 12818, 12819, 12820, 12821, 12822, 12823 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 628.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12824, 12825, 12826, 12827, 12828, 12829, 12830, 12831, 12832, 12833, 12834 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 629.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12835, 12836, 12837, 12838, 12839, 12840, 12841, 12842, 12843, 12844, 12845 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 630.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12846, 12847, 12848, 12849, 12850, 12851, 12852, 12853, 12854, 12855, 12856 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 631.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12857, 12858, 12859, 12860, 12861, 12862, 12863, 12864, 12865, 12866, 12867 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 632.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12868, 12869, 12870, 12871, 12872, 12873, 12874, 12875, 12876, 12877, 12878 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 633.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12879, 12880, 12881, 12882, 12883, 12884, 12885, 12886, 12887, 12888, 12889 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 634.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12890, 12891, 12892, 12893, 12894, 12895, 12896, 12897, 12898, 12899, 12900 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 635.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12901, 12902, 12903, 12904, 12905, 12906, 12907, 12908, 12909, 12910, 12911 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 636.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12912, 12913, 12914, 12915, 12916, 12917, 12918, 12919, 12920, 12921, 12922 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 637.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12923, 12924, 12925, 12926, 12927, 12928, 12929, 12930, 12931, 12932, 12933 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 638.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12934, 12935, 12936, 12937, 12938, 12939, 12940, 12941, 12942, 12943, 12944 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 639.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12945, 12946, 12947, 12948, 12949, 12950, 12951, 12952, 12953, 12954, 12955 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 640.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12956, 12957, 12958, 12959, 12960, 12961, 12962, 12963, 12964, 12965, 12966 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 641.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12967, 12968, 12969, 12970, 12971, 12972, 12973, 12974, 12975, 12976, 12977 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 642.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12978, 12979, 12980, 12981, 12982, 12983, 12984, 12985, 12986, 12987, 12988 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 643.

The probes having the nucleotide sequence represented by SEQ ID NOS: 12989, 12990, 12991, 12992, 12993, 12994, 12995, 12996, 12997, 12998, 12999 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 644.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13000, 13001, 13002, 13003, 13004, 13005, 13006, 13007, 13008, 13009, 13010 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 645.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13011, 13012, 13013, 13014, 13015, 13016, 13017, 13018, 13019, 13020, 13021 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 646.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13022, 13023, 13024, 13025, 13026, 13027, 13028, 13029, 13030, 13031, 13032 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 647.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13033, 13034, 13035, 13036, 13037, 13038, 13039, 13040, 13041, 13042, 13043 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 648.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13044, 13045, 13046, 13047, 13048, 13049, 13050, 13051, 13052, 13053, 13054 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 649.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13055, 13056, 13057, 13058, 13059, 13060, 13061, 13062, 13063, 13064, 13065 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 650.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13066, 13067, 13068, 13069, 13070, 13071, 13072, 13073, 13074, 13075, 13076 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 651.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13077, 13078, 13079, 13080, 13081, 13082, 13083, 13084, 13085, 13086, 13087 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 652.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13088, 13089, 13090, 13091, 13092, 13093, 13094, 13095, 13096, 13097, 13098 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 653.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13099, 13100, 13101, 13102, 13103, 13104, 13105, 13106, 13107, 13108, 13109 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 654.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13110, 13111, 13112, 13113, 13114, 13115, 13116, 13117, 13118, 13119, 13120 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 655.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13121, 13122, 13123, 13124, 13125, 13126, 13127, 13128, 13129, 13130, 13131 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 656.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13132, 13133, 13134, 13135, 13136, 13137, 13138, 13139, 13140, 13141, 13142 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 657.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13143, 13144, 13145, 13146, 13147, 13148, 13149, 13150, 13151, 13152, 13153 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 658.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13154, 13155, 13156, 13157, 13158, 13159, 13160, 13161, 13162, 13163, 13164 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 659.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13165, 13166, 13167, 13168, 13169, 13170, 13171, 13172, 13173, 13174, 13175 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 660.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13176, 13177, 13178, 13179, 13180, 13181, 13182, 13183, 13184, 13185, 13186 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 661..

The probes having the nucleotide sequence represented by SEQ ID NOS: 13187, 13188, 13189, 13'190, 13191, 13192, 13193, 13194, 13195, 13196, 13197 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 662.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13198, 13199, 13200, 13201, 13202, 13203, 13204, 13205, 13206, 13207, 13208 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 663.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13209, 13210, 13211, 13212, 13213, 13214, 13215, 13216, 13217, 13218, 13219 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 664.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13220, 13221, 13222, 13223, 13224, 13225, 13226, 13227, 13228, 13229, 13230 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 665.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13231, 13232, 13233, 13234, 13235; 13236, 13237, 13238, 13239, 13240, 13241 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 666.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13242, 13243, 13244, 13245, 13246, 13247, 13248, 13249, 13250, 13251, 13252 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 667.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13253, 13254, 13255, 13256, 13257, 13258, 13259, 13260, 13261, 13262, 13263 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 668.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13264, 13265, 13266, 13267, 13268, 13269, 13270, 13271, 13272, 13273, 13274 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 669.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13275, 13276, 13277, 13278, 13279, 13280, 13281, 13282, 13283, 13284, 13285 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 670.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13286, 13287, 13288, 13289, 13290, 13291, 13292, 13293, 13294, 13295, 13296 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 671.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13297, 13298, 13299, 13300, 13301, 13302, 13303, 13304, 13305, 13306, 13307 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 672.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13308, 13309, 13310, 13311, 13312, 13313, 13314, 13315, 13316, 13317, 13318 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 673.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13319, 13320, 13321, 13322, 13323, 13324, 13325, 13326, 13327, 13328, 13329 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 674.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13330, 13331, 13332, 13333, 13334, 13335, 13336, 13337, 13338, 13339, 13340 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 675.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13341, 13342, 13343, 13344, 13345, 13346, 13347, 13348, 13349, 13350, 13351 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 676.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13352, 13353, 13354, 13355, 13356, 13357, 13358, 13359, 13360, 13361, 13362 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 677.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13363, 13364, 13365, 13366, 13367, 13368, 13369, 13370, 13371, 13372, 13373 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 678.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13374, 13375, 13376, 13377, 13378, 13379, 13380, 13381, 13382, 13383, 13384 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 679.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13385, 13386, 13387, 13388, 13389, 13390, 13391, 13392, 13393, 13394, 13395 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 680.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13396, 13397, 13398, 13399, 13400, 13401, 13402, 13403, 13404, 13405, 13406 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 681.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13407, 13408, 13409, 13410, 13411, 13412, 13413, 13414, 13415, 13416, 13417, 13418, 13419, 13420, 13421, 13422, 13423, 13424, 13425, 13426, 13427, 13428 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 682.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13429, 13430, 13431, 13432, 13433, 13434, 13435, 13436, 13437, 13438, 13439 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 683.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13440, 13441, 13442, 13443, 13444, 13445, 13446, 13447, 13448, 13449, 13450 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 684.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13451, 13452, 13453, 13454, 13455, 13456, 13457, 13458, 13459, 13460, 13461 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 685.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13462, 13463, 13464, 13465, 13466, 13467, 13468, 13469, 13470, 13471, 13472 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 686.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13473, 13474, 13475, 13476, 13477, 13478, 13479, 13480, 13481, 13482, 13483 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 687.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13484, 13485, 13486, 13487, 13488, 13489, 13490, 13491, 13492, 13493, 13494 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 688.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13495, 13496, 13497, 13498, 13499, 13500, 13501, 13502, 13503, 13504, 13505 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 689.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13506, 13507, 13508, 13509, 13510, 13511, 13512, 13513, 13514, 13515, 13516 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 690.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13517, 13518, 13519, 13520, 13521, 13522, 13523, 13524, 13525, 13526, 13527 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 691.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13528, 13529, 13530, 13531, 13532, 13533, 13534, 13535, 13536, 13537, 13538 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 692.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13539, 13540, 13541, 13542, 13543, 13544, 13545, 13546, 13547, 13548, 13549 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 693.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13550, 13551, 13552, 13553, 13554, 13555, 13556, 13557, 13558, 13559, 13560 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 694.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13561, 13562, 13563, 13564, 13565, 13566, 13567, 13568, 13569, 13570, 13571 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 695.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13572, 13573, 13574, 13575, 13576, 13577, 13578, 13579, 13580, 13581, 13582 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 696.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13583, 13584, 13585, 13586, 13587, 13588, 13589, 13590, 13591, 13592, 13593 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 697.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13594, 13595, 13596, 13597, 13598, 13599, 13600, 13601, 13602, 13603, 13604 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 698.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13605, 13606, 13607, 13608, 13609, 13610, 13611, 13612, 13613, 13614, 13615 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 699.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13616, 13617, 13618, 13619, 13620, 13621, 13622, 13623, 13624, 13625, 13626 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 700.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13627, 13628, 13629, 13630, 13631, 13632, 13633, 13634, 13635, 13636, 13637 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 701.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13638, 13639, 13640, 13641, 13642, 13643, 13644, 13645, 13646, 13647, 13648 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 702.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13649, 13650, 13651,, 13652, 13653, 13654, 13655, 13656, 13657, 13658, 13659 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 703.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13660, 13661, 13662, 13663, 13664, 13665, 13666, 13667, 13668, 13669, 13670 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 704.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13671, 13672, 13673, 13674, 13675, 13676, 13677, 13678, 13679, 13680, 13681 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 705.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13682, 13683, 13684, 13685, 13686, 13687, 13688, 13689, 13690, 13691, 13692 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 706.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13693, 13694, 13695, 13696, 13697, 13698, 13699, 13700, 13701, 13702, 13703 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 707.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13704, 13705, 13706, 13707, 13708, 13709, 13710, 13711, 13712, 13713, 13714 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 708.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13715, 13716, 13717, 13718, 13719, 13720, 13721, 13722, 13723, 13724, 13725 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 709.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13726, 13727, 13728, 13729, 13730, 13731, 13732, 13733, 13734, 13735, 13736 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 710.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13737, 13738, 13739, 13740, 13741, 13742, 13743, 13744, 13745, 13746, 13747 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 711.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13748, 13749, 13750, 13751, 13752, 13753, 13754, 13755, 13756, 13757, 13758 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 712.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13759, 13760, 13761, 13762, 13763, 13764, 13765, 13766, 13767, 13768, 13769 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 713.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13770, 13771, 13772, 13773, 13774, 13775, 13776, 13777, 13778, 13779, 13780 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 714.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13781, 13782, 13783, 13784, 13785, 13786, 13787, 13788, 13789, 13790, 13791 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 715.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13792, 13793, 13794, 13795, 13796, 13797, 13798, 13799, 13800, 13801, 13802 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 716.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13803, 13804, 13805, 13806, 13807, 13808, 13809, 13810, 13811, 13812, 13813 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 717.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13814, 13815, 13816, 13817, 13818, 13819, 13820, 13821, 13822, 13823, 13824 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 718.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13825, 13826, 13827, 13828, 13829, 13830, 13831, 13832, 13833, 13834, 13835 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 719.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13836, 13837, 13838, 13839, 13840, 13841, 13842, 13843, 13844, 13845, 13846 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 720.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13847, 13848, 13849, 13850, 13851, 13852, 13853, 13854, 13855, 13856, 13857 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 721.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13858, 13859, 13860, 13861, 13862, 13863, 13864, 13865, 13866, 13867, 13868 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 722.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13869, 13870, 13871, 13872, 13873, 13874, 13875, 13876, 13877, 13878, 13879 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 723.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13880, 13881, 13882, 13883, 13884, 13885, ,13886, 13887, 13888, 13889, 13890 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 724.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13891, 13892, 13893, 13894, 13895, 13896, 13897, 13898, 13899, 13900, 13901 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 725.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13902, 13903, 13904, 13905, 13906, 13907, 13908, 13909, 13910, 13911, 13912 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 726.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13913, 13914, 13915, 13916, 13917, 13918, 13919, 13920, 13921, 13922, 13923 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 727.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13924, 13925, 13926, 13927, 13928, 13929, 13930, 13931, 13932, 13933, 13934 were.selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 728.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13935, 13936, 13937, 13938, 13939, 13940, 13941, 13942, 13943, 13944, 13945 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 729.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13946, 13947, 13948, 13949, 13950, 13951, 13952, 13953, 13954, 13955, 13956 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 730.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13957, 13958, 13959, 13960, 13961, 13962, 13963, 13964, 13965, 13966, 13967 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 731.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13968, 13969, 13970, 13971, 13972, 13973, 13974, 13975, 13976, 13977, 13978 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 732.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13979, 13980, 13981, 13982, 13983, 13984, 13985, 13986, 13987, 13988, 13989 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 733.

The probes having the nucleotide sequence represented by SEQ ID NOS: 13990, 13991, 13992, 13993, 13994, 13995, 13996, 13997, 13998, 13999, 14000 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 734.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14001, 14002, 14003, 14004, 14005, 14006, 14007, 14008, 14009, 14010, 14011 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 735.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14012, 14013, 14014, 14015, 14016, 14017, 14018, 14019, 14020, 14021, 14022 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 736.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14023, 14024, 14025, 14026, 14027, 14028, 14029, 14030, 14031, 14032, 14033 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 737.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14034, 14035, 14036, 14037, 14038, 14039, 14040, 14041, 14042, 14043, 14044, 14045, 14046, 14047, 14048, 14049, 14050, 14051, 14052, 14053, 14054, 14055 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 738.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14056, 14057, 14058, 14059, 14060, 14061, 14062, 14063, 14064, 14065, 14066 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 739.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14067, 14068, 14069, 14070, 14071, 14072, 14073, 14074, 14075, 14076, 14077 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 740.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14078, 14079, 14080, 14081, 14082, 14083, 14084, 14085, 14086, 14087, 14088 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 741.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14089, 14090, 14091, 14092, 14093, 14094, 14095, 14096, 14097, 14098, 14099 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 742.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14100, 14101, 14102, 14103, 14104, 14105, 14106, 14107, 14108, 14109, 14110 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 743.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14111, 14112, 14113, 14114, 14115, 14116, 14117, 14118, 14119, 14120, 14121 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 744.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14122, 14123, 14124, 14125, 14126, 14127, 14128, 14129, 14130, 14131, 14132 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 745.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14133, 14134, 14135, 14136, 14137, 14138, 14139, 14140, 14141, 14142, 14143 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 746.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14144, 14145, 14146, 14147, 14148, 14149, 14150, 14151, 14152, 14153, 14154 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 747.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14155, 14156, 14157, 14158, 14159, 14160, 14161, 14162, 14163, 14164, 14165 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 748.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14166, 14167, 14168, 14169, 14170, 14171, 14172, 14173, 14174, 14175, 14176 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 749.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14177, 14178, 14179, 14180, 14181, 14182, 14183, 14184, 14185, 14186, 14187 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 750.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14188, 14189, 14190, 14191, 14192, 14193, 14194, 14195, 14196, 14197, 14198 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 751.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14199, 14200, 14201, 14202, 14203, 14204, 14205, 14206, 14207, 14208, 14209 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 752.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14210, 14211, 14212, 14213, 14214, 14215, 14216, 14217, 14218, 14219, 14220 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 753.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14221, 14222, 14223, 14224, 14225, 14226, 14227, 14228, 14229, 14230, 14231 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 754.

The probes having the.nucleotide sequence represented by SEQ ID NOS: 14232, 14233, 14234, 14235, 14236, 14237, 14238, 14239, 14240, 14241, 14242 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 755.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14243, 14244, 14245, 14246, 14247, 14248, 14249, 14250, 14251, 14252, 14253 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 756.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14254, 14255, 14256, 14257, 14258, 14259, 14260, 14261, 14262, 14263, 14264 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 757.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14265, 14266, 14267, 14268, 14269, 14270, 14271, 14272, 14273, 14274, 14275 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 758.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14276, 14277, 14278, 14279, 14280, 14281, 14282, 14283, 14284, 14285, 14286 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 759.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14287, 14288, 14289, 14290, 14291, 14292, 14293, 14294, 14295, 14296, 14297 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 760.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14298, 14299, 14300, 14301, 14302, 14303, 14304, 14305, 14306, 14307, 14308 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 761.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14309, 14310, 14311, 14312, 14313, 14314, 14315, 14316, 14317, 14318, 14319 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 762.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14320, 14321, 14322, 14323, 14324, 14325, 14326, 14327, 14328, 14329, 14330 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 763.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14331, 14332, 14333, 14334, 14335, 14336, 14337, 14338, 14339, 14340, 14341 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 764.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14342, 14343, 14344, 14345, 14346, 14347, 14348, 14349, 14350,'14351, 14352, 14353, 14354, 14355, 14356, 14357, 14358, 14359, 14360, 14361, 14362, 14363 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 765.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14364, 14365, 14366, 14367, 14368, 14369, 14370, 14371, 14372, 14373, 14374 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 766.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14375, 14376, 14377, 14378, 14379, 14380, 14381, 14382, 14383, 14384, 14385 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 767.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14386, 14387, 14388, 14389, 14390, 14391, 14392, 14393, 14394, 14395, 14396 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 768.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14397, 14398, 14399, 14400, 14401, 14402, 14403, 14404, 14405, 14406, 14407 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 769.

The probes having the nucleotide sequence represented by SEQ,ID NOS: 14408, 14409, 14410, 14411, 14412, 14413, 14414, 14415, 14416, 14417, 14418 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 770.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14419, 14420, 14421, 14422, 14423, 14424, 14425, 14426, 14427, 14428, 14429 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 771.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14430, 14431, 14432, 14433, 14434, 14435, 14436, 14437, 14438, 14439, 14440 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 772.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14441, 14442, 14443, 14444, 14445, 14446, 14447, 14448, 14449, 14450, 14451 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 773.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14452, 14453, 14454, 14455, 14456, 14457, 14458, 14459, 14460, 14461, 14462 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 774.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14463, 14464, 14465, 14466, 14467, 14468, 14469, 14470, 14471, 14472, 14473 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 775.

The probes having the nucleotide sequence represented by -SEQ ID NOS: 14474, 14475, 14476, 14477, 14478, 14479, 14480, 14481, 14482, 14483, 14484 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 776.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14485, 14486, 14487, 14488, 14489, 14490, 14491, 14492, 14493, 14494, 14495 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 777.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14496, 14497, 14498, 14499, 14500, 14501, 14502, 14503, 14504, 14505, 14506 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 778.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14507, 14508, 14509, 14510, 14511, 14512, 14513, 14514, 14515, 14516, 14517 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 779.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14518, 14519, 14520, 14521, 14522, 14523, 14524, 14525, 14526, 14527, 14528 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 780.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14529, 14530, 14531, 14532, 14533, 14534, 14535, 14536, 14537, 14538, 14539 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 781.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14540, 14541, 14542, 14543, 14544, 14545, 14546, 14547, 14548, 14549, 14550 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 782.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14551, 14552, 14553, 14554, 14555, 14556, 14557, 14558, 14559, 14560, 14561 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 783.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14562, 14563, 14564, 14565, 14566, 14567, 14568, 14569, 14570, 14571, 14572 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 784.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14573, 14574, 14575, 14576, 14577, 14578, 14579, 14580, 14581, 14582, 14583 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 785.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14584, 14585, 14586, 14587, 14588, 14589, 14590, 14591, 14592, 14593, 14594 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 786.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14595, 14596, 14597, 14598, 14599, 14600, 14601, 14602, 14603, 14604, 14605 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 787.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14606, 14607, 14608, 14609, 14610, 14611, 14612, 14613, 14614, 14615, 14616 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 788.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14617, 14618, 14619, 14620, 14621, 14622, 14623, 14624, 14625, 14626, 14627 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 789.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14628, 14629, 14630, 14631, 14632, 14633, 14634, 14635, 14636, 14637, 14638 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 790.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14639, 14640, 14641, 14642, 14643, 14644, 14645, 14646, 14647, 14648, 14649 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 791.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14650, 14651, 14652, 14653, 14654, 14655, 14656, 14657, 14658, 14659, 14660 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 792.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14661, 14662, 14663, 14664, 14665, 14666, 14667, 14668, 14669, 14670, 14671 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 793.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14672, 14673, 14674, 14675, 14676, 14677, 14678, 14679, 14680, 14681, 14682 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 794.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14705, 14706, 14707, 14708, 14709, 14710, 14711, 14712, 14713, 14714, 14715 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 795.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14683, 14684, 14685, 14686, 14687, 14688, 14689, 14690, 14691, 14692, 14693 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 796.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14694, 14695, 14696, 14697, 14698, 14699, 14700, 14701, 14702, 14703, 14704 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 797.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14716, 14717, 14718, 14719, 14720, 14721, 14722, 14723, 14724, 14725, 14726 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 798.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14727, 14728, 14729, 14730, 14731, 14732, 14733, 14734, 14735, 14736, 14737 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 799.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14738, 14739, 14740, 14741, 14742, 14743, 14744, 14745, 14746, 14747, 14748 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 800.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14749, 14750, 14751, 14752, 14753, 14754, 14755, 14756, 14757, 14758, 14759 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 801.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14760, 14761, 14762, 14763, 14764, 14765, 14766, 14767, 14768, 14769, 14770 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 802.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14771, 14772, 14773, 14774, 14775, 14776, 14777, 14778, 14779, 14780, 14781 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 803.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14782, 14783, 14784, 14785, 14786, 14787, 14788, 14789, 14790, 14791, 14792 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 804.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14793, 14794, 14795, 14796, 14797, 14798, 14799, 14800, 14801, 14802, 14803 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 805.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14804, 14805, 14806, 14807, 14808, 14809, 14810, 14811, 14812, 14813, 14814 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 806.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14815, 14816, 14817, 14818, 14819, 14820, 14821, 14822, 14823, 14824, 14825 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 807.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14826, 14827, 14828, 14829, 14830, 14831, 14832, 14833, 14834, 14835, 14836 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 808.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14837, 14838, 14839, 14840, 14841, 14842, 14843, 14844, 14845, 14846, 14847 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 809.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14848, 14849, 14850, 14851, 14852, 14853, 14854, 14855, 14856, 14857, 14858 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 810.

The probes having the~nucleotide sequence represented by SEQ ID NOS: 14859, 14860, 14861, 14862, 14863, 14864, 14865, 14866, 14867, 14868, 14869 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 811.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14870, 14871, 14872, 14873, 14874, 14875, 14876, 14877, 14878, 14879, 14880 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 812.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14881, 14882, 14883, 14884, 14885, 14886, 14887, 14888, 14889, 14890, 14891 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 813.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14892, 14893, 14894, 14895, 14896, 14897, 14898, 14899, 14900, 14901, 14902 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 814.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14903, 14904, 14905, 14906, 14907, 14908, 14909, 14910, 14911, 14912, 14913 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 815.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14914, 14915, 14916, 14917, 14918, 14919, 14920, 14921, 14922, 14923, 14924 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 816.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14925, 14926, 14927, 14928,, 14929, 14930, 14931, 14932, 14933, 14934, 14935 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 817.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14936, 14937, 14938, 14939, 14940, 14941, 14942, 14943, 14944, 14945, 14946 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 818.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14947, 14948, 14949, 14950, 14951, 14952, 14953, 14954, 14955, 14956, 14957 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 819.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14958, 14959, 14960, 14961, 14962, 14963, 14964, 14965, 14966, 14967, 14968 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 820.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14969, 14970, 14971, 14972, 14973, 14974, 14975, 14976, 14977, 14978, 14979 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 821.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14980, 14981, 14982, 14983, 14984, 14985, 14986, 14987, 14988, 14989, 14990 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 822.

The probes having the nucleotide sequence represented by SEQ ID NOS: 14991, 14992, 14993, 14994, 14995, 14996, 14997, 14998, 14999, 15000, 15001 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 823.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15002, 15003, 15004, 15005, 15006, 15007, 15008, 15009, 15010, 15011, 15012 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 824.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15013, 15014, 15015, 15016, 15017, 15018, 15019, 15020, 15021, 15022, 15023 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 825.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15024, 15025, 15026, 15027, 15028, 15029, 15030, 15031, 15032, 15033, 15034 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 826.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15035, 15036, 15037, 15038, 15039, 15040, 15041, 15042, 15043, 15044, 15045 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 827.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15046, 15047, 15048, 15049, 15050, 15051, 15052, 15053, 15054, 15055, 15056 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 828.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15057, 15058, 15059, 15060, 15061, 15062, 15063, 15064, 15065, 15066, 15067 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 829.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15068, 15069, 15070, 15071, 15072, 15073, 15074, 15075, 15076, 15077, 15078 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 830.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15079, 15080, 15081, 15082, 15083, 15084, 15085, 15086, 15087, 15088, 15089 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 831.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15090, 15091, 15092, 15093, 15094, 15095, 15096, 15097, 15098, 15099, 15100 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 832.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15101, 15102, 15103, 15104, 15105, 15106, 15107, 15108, 15109, 15110, 15111 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 833.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15112, 15113, 15114, 15115, 15116, 15117, 15118, 15119, 15120, 15121, 15122 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 834.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15123, 15124, 15125, 15126, 15127, 15128, 15129, 15130, 15131, 15132,15133 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 835.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15134, 15135, 15136, 15137, 15138, 15139, 15140, 15141, 15142, 15143, 15144 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 836.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15145, 15146, 15147, 15148, 15149, 15150, 15151, 15152, 15153, 15154, 15155 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 837.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15156, 15157, 15158, 15159, 15160, 15161, 15162, 15163, 15164, 15165, 15166 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 838.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15167, 15168, 15169, 15170, 15171, 15172, 15173, 15174, 15175, 15176, 15177 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 839.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15178, 15179, 15180, 15181, 15182, 15183, 15184, 15185, 15186, 15187, 15188 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 840.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15189, 15190, 15191, 15192, 15193, 15194, 15195, 15196, 15197, 15198, 15199 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 841.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15200, 15201, 15202, 15203, 15204, 15205, 15206, 15207, 15208, 15209, 15210 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 842.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15211, 15212, 15213, 15214, 15215, 15216, 15217, 15218, 15219, 15220, 15221 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 843.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15222, 15223, 15224, 15225, 15226, 15227, 15228, 15229, 15230, 15231, 15232 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 844.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15233, 15234, 15235, 15236, 15237, 15238, 15239, 15240, 15241, 15242, 15243 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 845.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15244, 15245, 15246, 15247, 15248, 15249, 15250, 15251, 15252, 15253, 15254 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 846.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15255, 15256, 15257, 15258, 15259, 15260, 15261, 15262, 15263, 15264, 15265 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 847.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15266, 15267, 15268, 15269, 15270, 15271, 15272, 15273, 15274, 15275, 15276 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 848.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15277, 15278, 15279, 15280, 15281, 15282, 15283, 15284, 15285, 15286, 15287 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 849.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15288, 15289, 15290, 15291, 15292, 15293, 15294, 15295, 15296, 15297, 15298 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 850.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15299, 15300, 15301, 15302, 15303, 15304, 15305, 15306, 15307, 15308, 15309 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 851.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15310, 15311, 15312, 15313, 15314, 15315, 15316, 15317, 15318, 15319, 15320 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 852.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15321, 15322, 15323, 15324, 15325, 15326, 15327, 15328, 15329, 15330, 15331 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 853.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15332, 15333, 15334, 15335, 15336, 15337, 15338, 15339, 15340, 15341, 15342 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 854.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15343, 15344, 15345, 15346, 15347, 15348, 15349, 15350, 15351, 15352, 15353 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 855.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15354, 15355, 15356, 15357, 15358, 15359, 15360, 15361, 15362, 15363, 15364 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 856.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15365, 15366, 15367, 15368, 15369, 15370, 15371, 15372, 15373, 15374, 15375 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 857.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15376, 15377, 15378, 15379, 15380, 15381, 15382, 15383, 15384, 15385, 15386 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 858.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15387, 15388, 15389, 15390, 15391, 15392, 15393, 15394, 15395, 15396, 15397 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 859.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15398, 15399, 15400, 15401, 15402, 15403, 15404, 15405, 15406, 15407, 15408 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 860.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15409, 15410, 15411, 15412, 15413, 15414, 15415, 15416, 15417, 15418, 15419 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 861.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15420, 15421, 15422, 15423, 15424, 15425, 15426, 15427, 15428, 15429, 15430 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 862.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15431, 15432, 15433, 15434, 15435, 15436, 15437, 15438, 15439, 15440, 15441 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 863.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15442, 15443, 15444, 15445, 15446, 15447, 15448, 15449, 15450, 15451, 15452 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 864.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15453, 15454, 15455, 15456, 15457, 15458, 15459, 15460, 15461, 15462, 15463 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 865.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15464, 15465, 15466, 15467, 15468, 15469, 15470, 15471, 15472,.15473, 15474 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 866.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15475, 15476, 15477, 15478, 15479, 15480, 15481, 15482, 15483, 15484, 15485 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 867.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15486, 15487, 15488, 15489, 15490, 15491, 15492, 15493, 15494, 15495, 15496 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 868.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15497, 15498, 15499, 15500, 15501, 15502, 15503, 15504, 15505, 15506, 15507 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 869.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15508, 15509, 15510, 15511, 15512, 15513, 15514, 15515, 15516, 15517, 15518 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 870.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15519, 15520, 15521, 15522, 15523, 15524, 15525, 15526, 15527, 15528, 15529 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 871.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15530, 15531, 15532, 15533, 15534, 15535, 15536, 15537, 15538, 15539, 15540 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 872.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15541, 15542, 15543, 15544, 15545, 15546, 15547, 15548, 15549, 15550, 15551 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 873.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15552, 15553, 15554, 15555, 15556, 15557, 15558, 15559, 15560, 15561, 15562 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 874.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15563, 15564, 15565, 15566, 15567, 15568, 15569, 15570, 15571, 15572, 15573 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 875.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15574, 15575, 15576, 15577, 15578, 15579, 15580, 15581, 15582, 15583, 15584 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 876.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15585, 15586, 15587, 15588, 15589, 15590, 15591, 15592, 15593, 15594, 15595 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 877.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15596, 15597, 15598, 15599, 15600, 15601, 15602, 15603, 15604, 15605, 15606 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 878.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15607, 15608, 15609, 15610, 15611, 15612, 15613, 15614, 15615, 15616, 15617 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 879.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15618, 15619, 15620, 15621, 15622, 15623, 15624, 15625, 15626, 15627, 15628 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 880.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15629, 15630, 15631, 15632, 15633, 15634, 15635, 15636, 15637, 15638, 15639 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 881.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15640, 15641, 15642, 15643, 15644, 15645, 15646, 15647, 15648, 15649, 15650 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 882.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15651, 15652, 15653, 15654, 15655, 15656, 15657, 15658, 15659, 15660, 15661 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 883.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15662, 15663, 15664, 15665, 15666, 15667, 15668, 15669, 15670, 15671, 15672 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 884.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15673, 15674, 15675, 15676, 15677, 15678, 15679, 15680, 15681, 15682, 15683 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 885.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15684, 15685, 15686, 15687, 15688, 15689, 15690, 15691, 15692, 15693, 15694 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 886.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15695, 15696, 15697, 15698, 15699, 15700, 15701, 15702, 15703, 15704, 15705 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 887.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15706, 15707, 15708, 15709, 15710, 15711, 15712, 15713, 15714, 15715, 15716 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 888.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15717, 15718, 15719, 15720, 15721, 15722, 15723, 15724, 15725, 15726, 15727 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 889.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15728, 15729, 15730, 15731, 15732, 15733, 15734, 15735, 15736, 15737, 15738 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 890.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15739, 15740, 15741, 15742, 15743, 15744, 15745, 15746, 15747, 15748, 15749 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 891.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15750, 15751, 15752, 15753, 15754, 15755, 15756, 15757, 15758, 15759, 15760 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 892.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15761, 15762, 15763, 15764, 15765, 15766, 15767, 15768, 15769, 15770, 15771 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 893.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15772, 15773, 15774, 15775, 15776, 15777, 15778, 15779, 15780, 15781, 15782 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 894.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15783, 15784, 15785, 15786, 15787, 15788, 15789, 15790, 15791, 15792, 15793 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 895.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15794, 15795, 15796, 15797, 15798, 15799, 15800, 15801, 15802, 15803, 15804 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 896.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15805, 15806, 15807, 15808, 15809, 15810, 15811, 15812, 15813, 15814, 15815 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 897.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15816, 15817, 15818, 15819, 15820, 15821, 15822, 15823, 15824, 15825, 15826 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 898.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15827, 15828, 15829, 15830, 15831, 15832, 15833, 15834, 15835, 15836, 15837 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 899.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15838, 15839, 15840, 15841, 15842, 15843, 15844, 15845, 15846, 15847, 15848 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 900.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15849, 15850, 15851, 15852, 15853, 15854, 15855, 15856, 15857, 15858, 15859 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 901.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15860, 15861, 15862, 15863, 15864, 15865, 15866, 15867, 15868, 15869, 15870 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 902.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15871, 15872, 15873, 15874, 15875, 15876, 15877, 15878, 15879, 15880, 15881 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 903.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15882, 15883, 15884, 15885, 15886, 15887, 15888, 15889, 15890, 15891, 15892 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 904.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15893, 15894, 15895, 15896, 15897, 15898, 15899, 15900, 15901, 15902, 15903 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 905.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15904, 15905, 15906, 15907, 15908, 15909, 15910, 15911, 15912, 15913, 15914 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 906.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15915, 15916, 15917, 15918, 15919, 15920, 15921, 15922, 15923, 15924, 15925 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 907.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15926, 15927, 15928, 15929, 15930, 15931, 15932, 15933, 15934, 15935, 15936 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 908.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15937, 15938, 15939, 15940, 15941, 15942, 15943, 15944, 15945, 15946, 15947 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 909.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15948, 15949, 15950, 15951, 15952, 15953, 15954, 15955, 15956, 15957, 15958 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 910.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15959, 15960, 15961, 15962, 15963, 15964, 15965, 15966, 15967, 15968, 15969 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 911.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15970, 15971, 15972, 15973, 15974, 15975, 15976, 15977, 15978, 15979, 15980 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 912.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15981, 15982, 15983, 15984, 15985, 15986, 15987, 15988, 15989, 15990, 15991 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 913.

The probes having the nucleotide sequence represented by SEQ ID NOS: 15992, 15993, 15994, 15995, 15996, 15997, 15998, 15999, 16000, 16001, 16002 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 914.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16003, 16004, 16005, 16006, 16007, 16008, 16009, 16010, 16011, 16012, 16013 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 915.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16014, 16015, 16016, 16017, 16018, 16019, 16020, 16021, 16022, 16023, 16024 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 916.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16025, 16026, 16027, 16028, 16029, 16030, 16031, 16032, 16033, 16034, 16035 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 917.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16036, 16037, 16038, 16039, 16040, 16041, 16042, 16043, 16044, 16045, 16046 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 918.

The probes having the nucleotide sequence represented by SEQ ID NOS: 1,6047, 16048, 16049, 16050, 16051, 16052, 16053, 16054, 16055, 16056, 16057 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 919.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16058, 16059, 16060, 16061, 16062, 16063, 16064, 16065, 16066, 16067, 16068 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 920.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16069, 16070, 16071, 16072, 16073, 16074, 16075, 16076, 16077, 16078, 16079 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 921.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16080, 16081, 16082, 16083, 16084, 16085, 16086, 16087, 16088, 16089, 16090 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 922.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16091, 16092, 16093, 16094, 16095, 16096, 16097, 16098, 16099, 16100, 16101 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 923.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16102, 16103, 16104, 16105, 16106, 16107, 16108, 16109, 16110, 16111, 16112 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 924.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16113, 16114, 16115, 16116, 16117, 16118, 16119, 16120, 16121, 16122, 16123 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 925.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16124, 16125, 16126, 16127, 16128, 16129, 16130, 16131, 16132, 16133, 16134 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 926.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16135, 16136, 16137, 16138, 16139, 16140, 16141, 16142, 16143, 16144, 16145 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 927.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16146, 16147, 16148, 16149, 16150, 16151, 16152, 16153, 16154, 16155, 16156 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 928.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16157, 16158, 16159, 16160, 16161, 16162, 16163, 16164, 16165, 16166, 16167 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 929.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16168, 16169, 16170, 16171, 16172, 16173, 16174, 16175, 16176, 16177, 16178 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 930.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16179, 16180, 16181, 16182, 16183, 16184, 16185, 16186, 16187, 16188, 16189 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 931.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16190, 16191, 16192, 16193, 16194, 16195, 16196, 16197, 16198, 16199, 16200 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 932.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16201, 16202, 16203, 16204, 16205, 16206, 16207, 16208, 16209, 16210, 16211 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 933.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16212, 16213, 16214, 16215, 16216, 16217, 16218, 16219, 16220, 16221, 16222 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 934.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16223, 16224, 16225, 16226, 16227, 16228, 16229, 16230, 16231, 16232, 16233 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 935.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16234, 16235, 16236, 16237, 16238, 16239, 16240, 16241, 16242, 16243, 16244 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 936.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16245, 16246, 16247, 16248, 16249, 16250, 16251, 16252, 16253, 16254, 16255 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 937.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16256, 16257, 16258, 16259, 16260, 16261, 16262, 16263, 16264, 16265, 16266 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 938.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16267, 16268, 16269, 16270, 16271, 16272, 16273, 16274, 16275, 16276, 16277 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 939.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16278, 16279, 16280, 16281, 16282, 16283, 16284, 16285, 16286, 16287, 16288 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 940.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16289, 16290, 16291, 16292, 16293, 16294, 16295, 16296, 16297, 16298, 16299 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 941.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16300, 16301, 16302, 16303, 16304, 16305, 16306, 16307, 16308, 16309, 16310 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 942.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16311, 16312, 16313, 16314, 16315, 16316, 16317, 16318, 16319, 16320, 16321 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 943.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16322, 16323, 16324, 16325, 16326, 16327, 16328, 16329, 16330, 16331, 16332 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 944.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16333, 16334, 16335, 16336, 16337, 16338, 16339, 16340, 16341, 16342, 16343 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 945.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16344, 16345, 16346, 16347, 16348, 16349, 16350, 16351, 16352, 16353, 16354 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 946.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16355, 16356, 16357, 16358, 16359, 16360, 16361, 16362, 16363, 16364, 16365 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 947.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16366, 16367, 16368, 16369, 16370, 16371, 16372, 16373, 16374, 16375, 16376 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 948.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16377, 16378, 16379, 16380, 16381, 16382, 16383, 16384, 16385, 16386, 16387 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 949.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16388, 16389, 16390, 16391, 16392, 16393, 16394, 16395, 16396, 16397, 16398 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 950.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16399, 16400, 16401, 16402, 16403, 16404, 16405, 16406, 16407, 16408, 16409 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 951.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16410, 16411, 16412, 16413, 16414, 16415, 16416, 16417, 16418, 16419, 16420 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 952.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16421, 16422, 16423, 16424, 16425, 16426, 16427, 16428, 16429, 16430, 16431 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 953.

The probes having the nucleotide sequencerepresented by SEQ ID NOS: 16432, 16433, 16434, 16435, 16436, 16437, 16438, 16439,- 16440, 16441, 16442 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 954.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16443, 16444, 16445, 16446, 16447, 16448, 16449, 16450, 16451, 16452, 16453 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 955.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16454, 16455, 16456, 16457, 16458, 16459, 16460, 16461, 16462, 16463, 16464 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 956.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16465, 16466, 16467, 16468, 16469, 16470, 16471, 16472, 16473, 16474 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO:
957.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16475, 16476, 16477, 16478, 16479, 16480, 16481, 16482, 16483, 16484, 16485 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 958.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16486, 16487, 16488, 16489, 16490, 16491, 16492, 16493, 16494, 16495, 16496 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 959.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16497, 16498, 16499, 16500, 16501, 16502, 16503, 16504, 16505, 16506, 16507 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 960.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16508, 16509, 16510, 16511, 16512, 16513, 16514, 16515, 16516, 16517, 16518 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 961.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16519, 16520, 16521, 16522, 16523, 16524, 16525, 16526, 16527, 16528, 16529 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 962.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16530, 16531, 16532, 16533, 16534, 16535, 16536, 16537, 16538, 16539, 16540 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 963.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16541, 16542, 16543, 16544, 16545, 16546, 16547, 16548, 16549, 16550, 16551 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 964.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16552, 16553, 16554, 16555, 16556, 16557, 16558, 16559, 16560, 16561, 16562 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 965.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16563, 16564, 16565, 16566, 16567, 16568, 16569, 16570, 16571, 16572, 16573 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 966.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16574, 16575, 16576, 16577, 16578, 16579, 16580, 16581, 16582, 16583, 16584 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 967.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16585, 16586, 16587, 16588, 16589, 16590, 16591, 16592, 16593, 16594, 16595 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 968.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16596, 16597, 16598, 16599, 16600, 16601, 16602, 16603, 16604, 16605, 16606 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 969.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16607, 16608, 16609, 16610, 16611, 16612, 16613, 16614, 16615, 16616, 16617 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 970.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16618, 16619, 16620, 16621, 16622, 16623, 16624, 16625, 16626, 16627, 16628 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 971.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16629, 16630, 16631, 16632, 16633, 16634, 16635, 16636, 16637, 16638, 16639 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 972.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16640, 16641, 16642, 16643, 16644, 16645, 16646, 16647, 16648, 16649, 16650 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 973.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16651, 16652, 16653, 16654, 16655,' 16656, 16657, 16658, 16659, 16660, 16661 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 974.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16662, 16663, 16664, 16665, 16666, 16667, 16668, 16669, 16670, 16671, 16672 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 975.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16673, 16674, 16675, 16676, 16677, 16678, 16679, 16680, 16681, 16682, 16683 were selected from the ORFs having the nucleotide sequence-represented by SEQ ID
NO: 976.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16684, 16685, 16686, 16687, 16688, 16689, 16690, 16691, 16692, 16693, 16694 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 977.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16695, 16696, 16697, 16698, 16699, 16700, 16701, 16702, 16703, 16704, 16705 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 978.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16706, 16707, 16708, 16709, 16710, 16711, 16712, 16713, 16714, 16715, 16716 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 979.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16717, 16718, 16719, 16720, 16721, 16722, 16723, 16724, 16725, 16726, 16727 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 980.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16728, 16729, 16730, 16731, 16732, 16733, 16734, 16735, 16736, 16737, 16738 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 981.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16739, 16740, 16741, 16742, 16743, 16744, 16745, 16746, 16747, 16748, 16749 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 982.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16750, 16751, 16752, 16753, 16754, 16755, 16756, 16757, 16758, 16759, 16760 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 983.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16761, 16762, 16763, 16764, 16765, 16766, 16767, 16768, 16769, 16770, 16771 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 984.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16772, 16773, 16774, 16775, 16776, 16777, 16778, 16779, 16780, 16781, 16782 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 985.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16783, 16784, 16785, 16786, 16787, 16788, 16789, 16790, 16791, 16792, 16793 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 986.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16794, 16795, 16796, 16797, 16798, 16799, 16800, 16801, 16802, 16803, 16804 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 987.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16805, 16806, 16807, 16808, 16809, 16810, 16811, 16812, 16813, 16814, 16815 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 988.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16816, 16817, 16818, 16819, 16820, 16821, 16822, 16823, 16824, 16825, 16826 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 989.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16827, 16828, 16829, 16830, 16831, 16832, 16833, 16834, 16835, 16836, 16837 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 990.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16838, 16839, 16840, 16841, 16842, 16843, 16844, 16845, 16846, 16847, 16848 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 991.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16849, 16850, 16851, 16852, 16853, 16854, 16855, 16856, 16857, 16858, 16859 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 992.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16860, 16861, 16862, 16863, 16864, 16865, 16866, 16867, 16868, 16869, 16870 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 993.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16871, 16872, 16873, 16874, 16875, 16876, 16877, 16878, 16879, 16880, 16881 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 994.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16882, 16883, 16884, 16885, 16886, 16887, 16888, 16889, 16890, 16891, 16892 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 995.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16893, 16894, 16895, 16896, 16897, 16898, 16899, 16900, 16901, 16902, 16903 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 996.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16904, 16905, 16906, 16907, 16908, 16909, 16910, 16911, 16912, 16913, 16914 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 997.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16915, 16916, 16917, 16918, 16919, 16920, 16921, 16922, 16923, 16924, 16925 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 998.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16926, 16927, 16928, 16929, 16930, 16931, 16932, 16933, 16934, 16935, 16936 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 999.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16937, 16938, 16939, 16940, 16941, 16942, 16943, 16944, 16945, 16946, 16947 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1000.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16948, 16949, 16950, 16951, 16952, 16953, 16954, 16955, 16956, 16957, 16958 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1001.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16959, 16960, 16961, 16962, 16963, 16964, 16965, 16966, 16967, 16968, 16969 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1002.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16970, 16971, 16972, 16973, 16974, 16975, 16976, 16977, 16978, 16979, 16980 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1003.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16981, 16982, 16983, 16984, 16985, 16986, 16987, 16988, 16989, 16990, 16991 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1004.

The probes having the nucleotide sequence represented by SEQ ID NOS: 16992, 16993, 16994, 16995, 16996, 16997, 16998, 16999, 17000, 17001, 17002 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1005.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17003, 17004, 17005, 17006, 17007, 17008, 17009, 17010, 17011, 17012, 17013 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1006.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17014, 17015, 17016, 17017, 17018, 17019, 17020, 17021, 17022, 17023, 17024 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1007.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17025, 17026, 17027, 17028, 17029, 17030, 17031, 17032, 17033, 17034, 17035 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1008.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17036, 17037, 17038, 17039, 17040, 17041, 17042, 17043, 17044, 17045, 17046 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1009.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17047, 17048, 17049, 17050, 17051, 17052, 17053, 17054, 17055, 17056, 17057 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1010.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17058, 17059, 17060, 17061, 17062, 17063, 17064, 17065, 17066, 17067, 17068 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1011.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17069, 17070, 17071, 17072, 17073, 17074, 17075, 17076, 17077, 17078, 17079 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1012.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17080, 17081, 17082, 17083, 17084, 17085, 17086, 17087, 17088, 17089, 17090 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1013.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17091, 17092, 17093, 17094, 17095, 17096, 17097, 17098, 17099, 17100, 17101 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1014.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17102, 17103, 17104, 17105, 17106, 17107, 17108, 17109, 17110, 17111, 17112 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1015.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17113, 17114, 17115, 17116, 17117, 17118, 17119, 17120, 17121, 17122, 17123 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1016.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17124, 17125, 17126, 17127, 17128, 17129, 17130, 17131, 17132, 17133, 17134 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1017.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17135, 17136, 17137, 17138, 17139, 17140, 17141, 17142, 17143, 17144, 17145 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1018.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17146, 17147, 17148, 17149, 17150, 17151, 17152, 17153, 17154, 17155, 17156 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1019.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17157, 17158, 17159, 17160, 17161, 17162, 17163, 17164, 17165, 17166, 17167 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1020.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17168, 17169, 17170, 17171, 17172, 17173, 17174, 17175, 17176, 17177, 17178 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1021.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17179, 17180, 17181, 17182, 17183, 17184, 17185, 17186, 17187, 17188, 17189 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1022.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17190, 17191, 17192, 17193, 17194, 17195, 17196, 17197, 17198, 17199, 17200 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1023.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17201, 17202, 17203, 17204, 17205, 17206, 17207, 17208, 17209, 17210, 17211 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1024.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17212, 17213, 17214, 17215, 17216, 17217, 17218, 17219, 17220, 17221, 17222 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1025.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17223, 17224, 17225, 17226, 17227, 17228, 17229, 17230, 17231, 17232, 17233 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1026.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17234, 17235, 17236, 17237, 17238, 17239, 17240, 17241, 17242, 17243, 17244 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1027.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17245, 17246, 17247, 17248, 17249, 17250, 17251, 17252, 17253, 17254, 17255 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1028.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17256, 17257, 17258, 17259, 17260, 17261, 17262, 17263, 17264, 17265, 17266 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1029.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17267, 17268, 17269, 17270, 17271, 17272, 17273, 17274, 17275, 17276, 17277 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1030.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17278, 17279, 17280, 17281, 17282, 17283, 17284, 17285, 17286, 17287, 17288 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1031.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17289, 17290, 17291, 17292, 17293, 17294, 17295, 17296, 17297, 17298, 17299 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1032.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17300, 17301, 17302, 17303, 17304, 17305, 17306, 17307, 17308, 17309, 17310 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1033.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17311, 17312, 17313, 17314, 17315, 17316, 17317, 17318, 17319, 17320, 17321 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1034.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17322, 17323, 17324, 17325, 17326, 17327, 17328, 17329, 17330, 17331, 17332 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1035.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17333, 17334, 17335, 17336, 17337, 17338, 17339, 17340, 17341, 17342, 17343 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1036.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17344, 17345, 17346, 17347, 17348, 17349, 17350, 17351, 17352, 17353, 17354 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1037.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17355, 17356, 17357, 17358, 17359, 17360, 17361, 17362, 17363, 17364, 17365 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1038.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17366, 17367, 17368, 17369, 17370, 17371, 17372, 17373, 17374, 17375, 17376 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1039.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17377, 17378, 17379, 17380, 17381, 17382, 17383, 17384, 17385, 17386, 17387 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1040.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17388, 17389, 17390, 17391, 17392, 17393, 17394, 17395, 17396, 17397, 17398 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1041.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17399, 17400, 17401, 17402, 17403, 17404, 17405, 17406, 17407, 17408, 17409 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1042.

The probes.having the nucleotide sequence represented by SEQ ID NOS: 17410, 17411, 17412, 17413, 17414, 17415, 17416, 17417, 17418, 17419, 17420 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1043.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17421, 17422, 17423, 17424, 17425, 17426, 17427, 17428, 17429, 17430, 17431 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1044.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17432, 17433, 17434, 17435, 17436, 17437, 17438, 17439, 17440, 17441, 17442 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1045.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17443, 17444, 17445, 17446, 17447, 17448, 17449, 17450, 17451, 17452, 17453 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1046.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17454, 17455, 17456, 17457, 17458, 17459, 17460, 17461, 17462, 17463, 17464 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1047.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17465, 17466, 17467, 17468, 17469, 17470, 17471, 17472, 17473, 17474, 17475 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1048.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17476, 17477, 17478, 17479, 17480, 17481, 17482, 17483, 17484, 17485, 17486 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1049.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17487, 17488, 17489, 17490, 17491, 17492, 17493, 17494, 17495, 17496, 17497 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1050.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17498, 17499, 17500, 17501, 17502, 17503, 17504, 17505, 17506, 17507, 17508 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1051.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17509, 17510, 17511, 17512, 17513, 17514, 17515, 17516, 17517, 17518, 17519 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1052.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17520, 17521, 17522, 17523, 17524, 17525, 17526, 17527, 17528, 17529, 17530 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1053.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17531, 17532, 17533, 17534, 17535, 17536, 17537, 17538, 17539, 17540, 17541 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1054.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17542, 17543, 17544, 17545, 17546, 17547, 17548, 17549, 17550, 17551, 17552 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1055.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17553, 17554, 17555, 17556, 17557, 17558, 17559, 17560, 17561, 17562, 17563 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1056.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17564, 17565, 17566, 17567, 17568, 17569, 17570, 17571, 17572, 17573, 17574 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1057.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17575, 17576, 17577, 17578, 17579, 17580, 17581, 17582, 17583, 17584, 17585 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1058.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17586, 17587, 17588, 17589, 17590, 17591, 17592, 17593, 17594, 17595, 17596 were s,elected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1059.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17597, 17598, 17599, 17600, 17601, 17602, 17603, 17604, 17605, 17606, 17607 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1060.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17608, 17609, 17610, 17611, 17612, 17613, 17614, 17615, 17616, 17617, 17618 were selected from the ORFs having the xiucleotide sequence represented by SEQ ID
NO: 1061.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17619, 17620, 17621, 17622, 17623, 17624, 17625, 17626, 17627, 17628, 17629 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1062.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17630, 17631, 17632, 17633, 17634, 17635, 17636, 17637, 17638, 17639, 17640 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1063.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17641, 17642, 17643, 17644, 17645, 17646, 17647, 17648, 17649, 17650, 17651 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1064.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17652, 17653, 17654, 17655, 17656, 17657, 17658, 17659, 17660, 17661, 17662 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1065.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17663, 17664, 17665, 17666, 17667, 17668, 17669, 17670, 17671; 17672, 17673 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1066.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17674, 17675, 17676, 17677, 17678, 17679, 17680, 17681, 17682, 17683, 17684 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1067.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17685, 17686, 17687, 17688, 17689, 17690, 17691, 17692, 17693, 17694, 17695 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1068.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17696, 17697, 17698, 17699, 17700, 17701, 17702, 17703, 17704, 17705, 17706 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1069.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17707, 17708, 17709, 17710, 17711, 17712, 17713, 17714, 17715, 17716, 17717 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1070.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17718, 17719, 17720, 17721, 17722, 17723, 17724, 17725, 17726, 17727, 17728 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1071.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17729, 17730, 17731, 17732, 17733, 17734, 17735, 17736, 17737, 17738, 17739 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1072.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17740, 17741, 17742, 17743, 17744, 17745, 17746, 17747, 17748, 17749, 17750 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1073.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17751, 17752, 17753, 17754, 17755, 17756, 17757, 17758, 17759, 17760, 17761 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1074.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17762, 17763, 17764, 17765, 17766, 17767, 17768, 17769, 17770, 17771, 17772 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1075.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17773, 17774, 17775, 17776, 17777, 17778, 17779, 17780, 17781, 17782, 17783 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1076.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17784, 17785, 17786, 17787, 17788, 17789, 17790, 17791, 17792, 17793, 17794 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1077.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17795, 17796, 17797, 17798, 17799, 17800, 17801, 17802, 17803, 17804, 17805 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1078.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17806, 17807, 17808, 17809, 17810, 17811, 17812, 17813, 17814, 17815, 17816 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1079.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17817, 17818, 17819, 17820, 17821, 17822, 17823, 17824, 17825, 17826, 17827 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1080.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17828, 17829, 17830, 17831, 17832, 17833, 17834, 17835, 17836, 17837, 17838 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1081.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17839, 17840, 17841, 17842, 17843, 17844, 17845, 17846, 17847, 17848, 17849 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1082.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17850, 17851, 17852, 17853, 17854, 17855, 17856, 17857, 17858, 17859, 17860 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1083.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17861, 17862, 17863, 17864, 17865, 17866, 17867, 17868, 17869, 17870, 17871 were selected from the ORFs having the nucleot'ide sequence represented by SEQ ID
NO: 1084.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17872, 17873, 17874, 17875, 17876, 17877, 17878, 17879, 17880, 17881, 17882 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1085.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17883, 17884, 17885, 17886, 17887, 17888, 17889, 17890, 17891, 17892, 17893 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1086.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17894, 17895, 17896, 17897, 17898, 17899, 17900, 17901, 17902, 17903, 17904 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1087.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17905, 17906, 17907, 17908, 17909, 17910, 17911, 17912, 17913, 17914, 17915 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1088.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17916, 17917, 17918, 17919, 17920, 17921, 17922, 17923, 17924, 17925, 17926 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1089.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17927, 17928, 17929, 17930, 17931, 17932, 17933, 17934, 17935, 17936, 17937 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1090.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17938, 17939, 17940, 17941, 17942, 17943, 17944, 17945, 17946, 17947, 17948 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1091.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17949, 17950, 17951, 17952, 17953, 17954, 17955, 17956, 17957, 17958, 17959 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1092.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17960, 17961, 17962, 17963, 17964, 17965, 17966, 17967, 17968, 17969, 17970 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1093.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17971, 17972, 17973, 17974, 17975, 17976, 17977, 17978, 17979, 17980, 17981 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1094.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17982, 17983, 17984, 17985, 17986, 17987, 17988, 17989, 17990, 17991, 17992 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1095.

The probes having the nucleotide sequence represented by SEQ ID NOS: 17993, 17994, 17995, 17996, 17997, 17998, 17999, 18000, 18001, 18002, 18003 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1096.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18004, 18005, 18006, 18007, 18008, 18009, 18010, 18011, 18012, 18013, 18014 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1097.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18015, 18016, 18017, 18018, 18019, 18020, 18021, 18022, 18023, 18024, 18025 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1098.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18026, 18027, 18028, 18029, 18030, 18031, 18032, 18033, 18034, 18035, 18036 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1099.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18037, 18038, 18039, 18040, 18041, 18042, 18043, 18044, 18045, 18046, 18047 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1100.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18048, 18049, 18050, 18051, 18052, 18053, 18054, 18055, 18056, 18057, 18058 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1101.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18059, 18060, 18061, 18062, 18063, 18064, 18065, 18066, 18067, 18068, 18069 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1102.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18070, 18071, 18072, 18073, 18074, 18075, 18076, 18077, 18078, 18079, 18080 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1103.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18081, 18082, 18083, 18084, 18085, 18086, 18087, 18088, 18089, 18090, 18091 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1104.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18092, 18093, 18094, 18095, 18096, 18097, 18098, 18099, 18100, 18101, 18102 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1105.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18103, 18104, 18105, 18106, 18107, 18108, 18109, 18110, 18111, 18112, 18113 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1106.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18114, 18115, 18116, 18117, 18118, 18119, 18120, 18121, 18122, 18123, 18124 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1107.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18125, 18126, 18127, 18128, 18129, 18130, 18131, 18132, 18133, 18134, 18135 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1108.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18136, 18137, 18138, 18139, 18140, 18141, 18142, 18143, 18144, 18145, 18146 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1109.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18147, 18148, 18149, 18150, 18151, 18152, 18153, 18154, 18155, 18156, 18157 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1110.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18158, 18159, 18160, 18161, 18162, 18163, 18164, 18165, 18166, 18167, 18168 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1111.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18169, 18170, 18171, 18172, 18173, 18174, 18175, 18176, 18177, 18178, 18179 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1112.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18180, 18181, 18182, 18183, 18184, 18185, 18186, 18187, 18188, 18189, 18190 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1113.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18191, 18192, 18193, 18194, 18195, 18196, 18197, 18198, 18199, 18200, 18201 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1114.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18202, 18203, 18204, 18205, 18206, 18207, 18208, 18209, 18210, 18211, 18212 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1115.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18213, 18214, 18215, 18216, 18217, 18218, 18219, 18220, 18221, 18222, 18223 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1116.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18224, 18225, 18226, 18227, 18228, 18229, 18230, 18231, 18232, 18233, 18234 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1117.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18235, 18236, 18237, 18238, 18239, 18240, 18241, 18242, 18243, 18244, 18245 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1118.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18246, 18247, 18248, 18249, 18250, 18251, 18252, 18253, 18254, 18255, 18256 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1119.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18257, 18258, 18259, 18260, 18261, 18262, 18263, 18264, 18265, 18266, 18267 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1120.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18268, 18269, 18270, 18271, 18272, 18273, 18274, 18275, 18276, 18277, 18278 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1121.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18279, 18280, 18281, 18282, 18283, 18284, 18285, 18286, 18287, 18288, 18289 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1122.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18290, 18291, 18292, 18293, 18294, 18295, 18296, 18297, 18298, 18299, 18300 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1123.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18301, 18302, 18303, 18304, 18305, 18306, 18307, 18308, 18309, 18310, 18311 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1124.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18312, 18313, 18314, 18315, 18316, 18317, 18318, 18319, 18320, 18321, 18322 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1125.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18323, 18324, 18325, 18326, 18327, 18328, 18329, 18330, 18331, 18332, 18333, 18334, 18335, 18336, 18337, 18338, 18339, 18340, 18341, 18342, 18343, 18344 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 1126.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18345, 18346, 18347, 18348, 18349, 18350, 18351, 18352, 18353, 18354, 18355 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1127.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18356, 18357, 18358, 18359, 18360, 18361, 18362, 18363, 18364, 18365, 18366 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1128.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18367, 18368, 18369, 18370, 18371, 18372, 18373, 18374, 18375, 18376, 18377 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1129.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18378, 18379, 18380, 18381, 18382, 18383, 18384, 18385, 18386, 18387, 18388 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1130.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18389, 18390, 18391, 18392, 18393, 18394, 18395, 18396, 18397, 18398, 18399, 18400, 18401, 18402, 18403, 18404, 18405, 18406, 18407, 18408, 18409, 18410 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 1131.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18411, 18412, 18413, 18414, 18415, 18416, 18417, 18418, 18419, 18420, 18421 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1132.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18422, 18423, 18424, 18425, 18426, 18427, 18428, 18429, 18430, 18431, 18432 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1133.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18433, 18434, 18435, 18436, 18437, 18438, 18439, 18440, 18441, 18442, 18443 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1134.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18444, 18445, 18446, 18447, 18448, 18449, 18450, 18451, 18452, 18453, 18454 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1135.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18455, 18456, 18457, 18458, 18459, 18460, 18461, 18462, 18463, 18464, 18465 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1136.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18466, 18467, 18468, 18469, 18470, 18471, 18472, 18473, 18474, 18475, 18476 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1137.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18477, 18478, 18479, 18480, 18481, 18482, 18483, 18484, 18485, 18486, 18487 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1138.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18488, 18489, 18490, 18491, 18492, 18493, 18494, 18495, 18496, 18497, 18498 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1139.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18499, 18500, 18501, 18502, 18503, 18504, 18505, 18506, 18507, 18508, 18509 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1140.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18510, 18511, 18512, 18513, 18514, 18515, 18516, 18517, 18518, 18519, 18520 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1141.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18521, 18522, 18523, 18524, 18525, 18526, 18527, 18528, 18529, 18530, 18531 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1142.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18532, 18533, 18534, 18535, 18536, 18537, '18538, 18539, 18540, 18541, 18542 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1143.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18543, 18544, 18545, 18546, 18547, 18548, 18549, 18550, 18551, 18552, 18553 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1144.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18554, 18555, 18556, 18557, 18558, 18559, 18560, 18561, 18562, 18563, 18564 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1145.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18565, 18566, 18567, 18568, 18569, 18570, 18571, 18572, 18573, 18574, 18575 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1146.

Theprobes having the nucleotide sequence represented by SEQ ID NOS: 18576, 18577, 18578, 18579, 18580, 18581, 18582, 18583, 18584, 18585, 18586 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1147.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18587, 18588, 18589, 18590, 18591, 18592, 18593, 18594, 18595, 18596, 18597 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1148.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18598, 18599, 18600, 18601, 18602, 18603, 18604, 18605, 18606, 18607, 18608 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1149.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18609, 18610, 18611, 18612, 18613, 18614, 18615, 18616, 18617, 18618, 18619 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1150.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18620, 18621, 18622, 18623, 18624, 18625, 18626, 18627, 18628, 18629, 18630 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1151.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18631, 18632, 18633, 18634, 18635, 18636, 18637, 18638, 18639, 18640, 18641 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1152.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18642, 18643, 18644, 18645, 18646, 18647, 18648, 18649, 18650, 18651, 18652 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1153.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18653, 18654, 18655, 18656, 18657, 18658, 18659, 18660, 18661, 18662, 18663 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1154.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18664, 18665, 18666, 18667, 18668, 18669, 18670, 18671, 18672, 18673, 18674 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1155.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18675, 18676, 18677, 18678, 18679, 18680, 18681, 18682, 18683, 18684, 18685 were selected from the ORFs having the nucleotide sequence represented by SEQ ID

NO: 1156. -The probes having the nucleotide sequence represented by SEQ ID NOS: 18686, 18687, 18688, 18689, 18690, 18691, 18692, 18693, 18694, 18695, 18696 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1157.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18697, 18698, 18699, 18700, 18701, 18702, 18703, 18704, 18705, 18706, 18707 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1158.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18708, 18709, 18710, 18711, 18712, 18713, 18714, 18715, 18716, 18717, 18718 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1159.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18719, 18720, 18721, 18722, 18723, 18724, 18725, 18726, 18727, 18728, 18729 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1160.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18730, 18731, 18732, 18733, 18734, 18735, 18736; 18737, 18738, 18739, 18740 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1161.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18741, 18742, 18743, 18744, 18745, 18746, 18747, 18748, 18749, 18750, 18751 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1162.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18752, 18753, 18754, 18755, 18756, 18757, 18758, 18759, 18760, 18761, 18762 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1163.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18763, 18764, 18765, 18766, 18767, 18768, 18769, 18770, 18771, 18772, 18773 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1164.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18774, 18775, 18776, 18777, 18778, 18779, 18780, 18781, 18782, 18783, 18784 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1165.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18785, 18786, 18787, 18788, 18789, 18790, 18791, 18792, 18793, 18794, 18795 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1166.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18796, 18797, 18798, 18799, 18800, 18801, 18802, 18803, 18804, 18805, 18806 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1167.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18807, 18808, 18809, 18810, 18811, 18812, 18813, 18814, 18815, 18816, 18817 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1168.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18818, 18819, 18820, 18821, 18822, 18823, 18824, 18825, 18826, 18827, 18828 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1169.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18829, 18830, 18831, 18832, 18833, 18834, 18835, 18836, 18837, 18838, 18839 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1170.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18840, 18841, 18842, 18843, 18844, 18845, 18846, 18847, 18848, 18849, 18850 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1171.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18851, 18852, 18853, 18854, 18855, 18856, 18857, 18858, 18859, 18860, 18861 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1172.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18862, 18863, 18864, 18865, 18866, 18867, 18868, 18869, 18870, 18871, 18872 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1173.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18873, 18874, 18875, 18876, 18877, 18878, 18879, 18880, 18881, 18882, 18883 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1174.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18884, 18885, 18886, 18887, 18888, 18889, 18890, 18891, 18892, 18893, 18894 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1175.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18895, 18896, 18897, 18898, 18899, 18900, 18901, 18902, 18903, 18904, 18905 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1176.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18906, 18907, 18908, 18909, 18910, 18911, 18912, 18913, 18914, 18915, 18916 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1177.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18917, 18918, 18919, 18920, 18921, 18922, 18923, 18924, 18925, 18926, 18927 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1178.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18928, 18929, 18930, 18931, 18932, 18933, 18934, 18935, 18936, 18937, 18938 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1179.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18939, 18940, 18941, 18942, 18943, 18944, 18945, 18946, 18947, 18948, 18949 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1180.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18950, 18951, 18952, 18953, 18954, 18955, 18956, 18957, 18958, 18959, 18960.were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1181.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18961, 18962, 18963, 18964, 18965, 18966, 18967, 18968, 18969, 18970, 18971 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1182.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18972, 18973, 18974, 18975, 18976, 18977, 18978, 18979, 18980, 18981, 18982 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1183.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18983, 18984, 18985, 18986, 18987, 18988, 18989, 18990, 18991, 18992, 18993 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1184.

The probes having the nucleotide sequence represented by SEQ ID NOS: 18994, 18995, 18996, 18997, 18998, 18999, 19000, 19001, 19002, 19003, 19004 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1185.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19005, 19006, 19007, 19008, 19009, 19010, 19011, 19012, 19013, 19014, 19015 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1186.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19016, 19017, 19018, 19019, 19020, 19021, 19022, 19023, 19024, 19025, 19026 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1187.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19027, 19028, 19029, 19030, 19031, 19032, 19033, 19034, 19035, 19036, 19037 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1188.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19038, 19039, 19040, 19041, 19042, 19043, 19044, 19045, 19046, 19047, 19048 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1189.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19049, 19050, 19051, 19052, 19053, 19054, 19055, 19056, 19057, 19058, 19059 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1190.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19060, 19061, 19062, 19063, 19064, 19065, 19066, 19067, 19068, 19069, 19070 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1191.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19071, 19072, 19073, 19074, 19075, 19076, 19077, 19078, 19079, 19080, 19081 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1192.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19082, 19083, 19084, 19085, 19086, 19087, 19088, 19089, 19090, 19091, 19092 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1193.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19093, 19094, 19095, 19096, 19097, 19098, 19099, 19100, 19101, 19102, 19103 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1194.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19104, 19105, 19106, 19107, 19108, 19109, 19110, 19111, 19112, 19113, 19114 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1195.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19115, 19116, 19117, 19118, 19119, 19120, 19121, 19122, 19123, 19124), 19125 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1196.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19126, 19127, 19128, 19129, 19130, 19131, 19132, 19133, 19134, 19135, 19136 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1197.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19137, 19138, 19139, 19140, 19141, 19142, 19143, 19144, 19145, 19146, 19147 were selected from the ORFs,having the nucleotide sequence represented by SEQ ID
NO: 1198.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19148, 19149, 19150, 19151, 19152, 19153, 19154, 19155, 19156, 19157, 19158 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1199.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19159, 19160, 19161, 19162, 19163, 19164, 19165, 19166, 19167, 19168, 19169 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1200.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19170, 19171, 19172, 19173, 19174, 19175, 19176, 19177, 19178, 19179, 19180 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1201.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19181, 19182, 19183, 19184, 19185, 19186, 19187, 19188, 19189, 19190, 19191 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1202.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19192, 19193, 19194, 19195, 19196, 19197, 19198, 19199, 19200, 19201, 19202 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1203.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19203, 19204, 19205, 19206, 19207, 19208, 19209, 19210, 19211, 19212, 19213 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1204.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19214, 19215, 19216, 19217, 19218, 19219, 19220, 19221, 19222, 19223, 19224 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1205.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19225, 19226, 19227, 19228, 19229, 19230, 19231, 19232, 19233, 19234, 19235 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1206.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19236, 19237, 19238, 19239, 19240, 19241, 19242, 19243, 19244, 19245, 19246 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1207.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19247, 19248, 19249, 19250, 19251, 19252, 19253, 19254, 19255, 19256, 19257 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1208.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19258, 19259, 19260, 19261, 19262, 19263, 19264, 19265, 19266, 19267, 19268 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1209.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19269, 19270, 19271, 19272, 19273, 19274, 19275, 19276, 19277, 19278, 19279 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1210.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19280, 19281, 19282, 19283, 19284, 19285, 19286, 19287, 19288, 19289, 19290 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1211.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19291, 19292, 19293, 19294, 19295, 19296, 19297, 19298, 19299, 19300, 19301 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1212.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19302, 19303, 19304, 19305, 19306, 19307, 19308, 19309, 19310, 19311, 19312 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1213.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19313, 19314, 19315, 19316, 19317, 19318, 19319, 19320, 19321, 19322, 19323 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1214.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19324, 19325, 19326, 19327, 19328, 19329, '19330, 19331, 19332, 19333, 19334 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1215.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19335, 19336, 19337, 19338, 19339, 19340, 19341, 19342, 19343, 19344, 19345 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1216.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19346, 19347, 19348, 19349, 19350, 19351, 19352, 19353, 19354, 19355, 19356 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1217.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19357, 19358, 19359, 19360, 19361, 19362, 19363, 19364, 19365, 19366, 19367 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1218.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19368, 19369, 19370, 19371, 19372, 19373, 19374, 19375, 19376, 19377, 19378 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1219.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19379, 19380, 19381, 19382, 19383, 19384, 19385, 19386, 19387, 19388, 19389 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1220.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19390, 19391, 19392, 19393, 19394, 19395, 19396, 19397, 19398, 19399, 19400 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1221.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19401, 19402, 19403, 19404, 19405, 19406, 19407, 19408, 19409, 19410, 19411 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1222.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19412, 19413, 19414, 19415, 19416, 19417, 19418, 19419, 19420, 19421, 19422 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1223.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19423, 19424, 19425, 19426, 19427, 19428, 19429, 19430, 19431, 19432, 19433 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1224.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19434, 19435, 19436, 19437, 19438, 19439, 19440, 19441, 19442, 19443, 19444 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1225.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19445, 19446, 19447, 19448, 19449, 19450, 19451, 19452, 19453, 19454, 19455 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1226.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19456, 19457, 19458, 19459, 19460, 19461, 19462, 19463, 19464, 19465, 19466 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1227.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19467, 19468, 19469, 19470, 19471, 19472, 19473, 19474, 19475, 19476, 19477 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1228.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19478, 19479, 19480, 19481, 19482, 19483, 19484, 19485, 19486, 19487, 19488 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1229.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19489, 19490, 19491, 19492, 19493, 19494, 19495, 19496, 19497, 19498, 19499 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1230.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19500, 19501, 19502, 19503, 19504, 19505, 19506, 19507, 19508, 19509, 19510 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1231.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19511, 19512, 19513, 19514, 19515, 19516, 19517, 19518, 19519, 19520, 19521 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1232.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19522, 19523, 19524, 19525, 19526, 19527, 19528, 19529, 19530, 19531, 19532 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1233.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19533, 19534, 19535, 19536, 19537, 19538, 19539, 19540, 19541, 19542, 19543 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1234.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19544, 19545, 19546, 19547, 19548, 19549, 19550, 19551, 19552, 19553, 19554 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1235.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19555, 19556, 19557, 19558, 19559, 19560, 19561, 19562, 19563, 19564, 19565 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1236.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19566, 19567, 19568, 19569, 19570, 19571, 19572, 19573, 19574, 19575, 19576 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1237.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19577, 19578, 19579, 19580, 19581, 19582, 19583, 19584, 19585, 19586, 19587 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: .1238.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19588, 19589, 19590, 19591, 19592, 19593, 19594, 19595, 19596, 19597, 19598 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1239.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19599, 19600, 19601, 19602, 19603, 19604, 19605, 19606, 19607, 19608, 19609 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1240.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19610, 19611, 19612, 19613, 19614, 19615, 19616, 19617, 19618, 19619, 19620 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1241.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19621, 19622, 19623, 19624, 19625, 19626, 19627, 19628, 19629, 19630, 19631 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1242.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19632, 19633, 19634, 19635, 19636, 19637, 19638, 19639, 19640, 19641, 19642 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1243.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19643, 19644, 19645, 19646, 19647, 19648, 19649, 19650, 19651, 19652, 19653 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1244.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19654, 19655, 19656, 19657, 19658, 19659, 19660, 19661, 19662, 19663, 19664 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1245.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19665, 19666, 19667, 19668, 19669, 19670, 19671, 19672, 19673, 19674, 19675 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1246.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19676, 19677, 19678, 19679, 19680, 19681, 19682, 19683, 19684, 19685, 19686 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1247.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19687, 19688, 19689, 19690, 19691, 19692, 19693, 19694, 19695, 19696, 19697 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1248.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19698, 19699, 19700, 19701, 19702, 19703, 19704, 19705, 19706, 19707, 19708 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1249.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19709, 19710, 19711, 19712, 19713, 19714, 19715, 19716, 19717, 19718, 19719 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1250.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19720, 19721, 19722, 19723, 19724, 19725, 19726, 19727, 19728, 19729, 19730 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1251.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19731, 19732, 19733, 19734, 19735, 19736, 19737, 19738, 19739, 19740, 19741 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1252.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19742, 19743, 19744, 19745, 19746, 19747, 19748, 19749, 19750, 19751, 19752 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1253.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19753, 19754, 19755, 19756, 19757, 19758, 19759, 19760, 19761, 19762, 19763 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1254.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19764, 19765, 19766, 19767, 19768, 19769, 19770, 19771, 19772, 19773, 19774 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1255.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19775, 19776, 19777, 19778, 19779, 19780, 19781, 19782, 19783, 19784, 19785 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1256.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19786, 19787, 19788, 19789, 19790, 19791, 19792, 19793, 19794, 19795, 19796 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1257.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19797, 19798, 19799, 19800, 19801, 19802, 19803, 19804, 19805, 19806, 19807 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1258.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19808, 19809, 19810, 19811, 19812, 19813, 19814, 19815, 19816, 19817, 19818 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1259.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19819, 19820, 19821, 19822, 19823, 19824, 19825, 19826, 19827, 19828, 19829 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1260.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19830, 19831, 19832, 19833, 19834, 19835, 19836, 19837, 19838, 19839, 19840 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1261.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19841, 19842, 19843, 19844, 19845, 19846, 19847, 19848, 19849, 19850, 19851 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1262.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19852, 19853, 19854, 19855, 19856, 19857, 19858, 19859, 19860, 19861, 19862 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1263.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19863, 19864, 19865, 19866, 19867, 19868, 19869, 19870, 19871, 19872, 19873 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1264.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19874, 19875, 19876, 19877, 19878, 19879, 19880, 19881, 19882, 19883, 19884 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1265.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19885, 19886, 19887, 19888, 19889, 19890, 19891, 19892, 19893, 19894, 19895 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1266.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19896, 19897, 19898, 19899, 19900, 19901, 19902, 19903, 19904, 19905, 19906 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1267.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19907, 19908, 19909, 19910, 19911, 19912, 19913, 19914, 19915, 19916, 19917 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1268.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19918, 19919, 19920, 19921, 19922, 19923, 19924, 19925, 19926, 19927, 19928 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1269.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19929, 19930, 19931, 19932, 19933, 19934, 19935, 19936, 19937, 19938, 19939 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1270.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19940, 19941, 19942, 19943, 19944, 19945, 19946, 19947, 19948, 19949, 19950 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1271.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19951, 19952, 19953, 19954, 19955, 19956, 19957, 19958, 19959, 19960, 19961 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1272.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19962, 19963, 19964, 19965, 19966, 19967, 19968, 19969, 19970, 19971, 19972 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1273.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19973, 19974, 19975, 19976, 19977, 19978, 19979, 19980, 19981, 19982, 19983 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1274.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19984, 19985, 19986, 19987, 19988, 19989, 19990, 19991, 19992, 19993, 19994 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1275.

The probes having the nucleotide sequence represented by SEQ ID NOS: 19995, 19996, 19997, 19998, 19999, 20000, 20001, 20002, 20003, 20004, 20005 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1276.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20006, 20007, 20008, 20009, 20010, 20011, 20012, 20013, 20014, 20015, 20016 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1277.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20017, 20018, 20019, 20020, 20021, 20022, 20023, 20024, 20025, 20026, 20027 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1278.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20028, 20029, 20030, 20031, 20032, 20033, 20034, 20035, 20036, 20037, 20038 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1279.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20039, 20040, 20041, 20042, 20043, 20044, 20045, 20046, 20047, 20048, 20049 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1280.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20050, 20051, 20052, 20053, 20054, 20055, 20056, 20057, 20058, 20059, 20060 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1281.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20061, 20062, 20063, 20064, 20065, 20066, 20067, 20068, 20069, 20070, 20071 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1282.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20072, 20073, 20074, 20075, 20076, 20077, 20078, 20079, 20080, 20081, 20082 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1283.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20083, 20084, 20085, 20086, 20087, 20088, 20089, 20090, 20091, 20092, 20093 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1284.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20094, 20095, 2.0096, 20097, 20098, 20099, 20100, 20101, 20102, 20103, 20104 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1285.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20105, 20106, 20107, 20108, 20109, 20110, 20111, 20112, 20113, 20114, 20115 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1286.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20116, 20117, 20118, 20119, 20120, 20121, 20122, 20123, 20124, 20125, 20126 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1287.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20127, 20128, 20129, 20130, 20131, 20132, 20133, 20134, 20135, 20136, 20137 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1288.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20138, 20139, 20140, 20141, 20142, 20143, 20144, 20145, 20146, 20147, 20148 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1289.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20149, 20150, 20151, 20152, 20153, 20154, 20155, 20156, 20157, 20158, 20159 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1290.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20160, 20161, 20162, 20163, 20164, 20165, 20166, 20167, 20168, 20169, 20170 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1291.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20171, 20172, 20173, 20174, 20175, 20176, 20177, 20178, 20179, 20180, 20181 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1292.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20182, 20183, 20184, 20185, 20186, 20187, 20188, 20189, 20190, 20191, 20192 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1293.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20193, 20194, 20195, 20196, 20197, 20198, 20199, 20200, 20201, 20202, 20203 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1294.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20204, 20205, 20206, 20207, 20208, 20209, 20210, 20211, 20212, 20213, 20214 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1295.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20215, 20216, 20217, 20218, 20219, 20220, 20221, 20222, 20223, 20224, 20225 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1296.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20226, 20227, 20228, 20229, 20230, 20231, 20232, 20233, 20234, 20235, 20236 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1297.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20237, 20238, 20239, 20240, 20241, 20242, 20243, 20244, 20245, 20246, 20247 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1298.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20248, 20249, 20250, 20251, 20252, 20253, 20254, 20255, 20256, 20257, 20258 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1299.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20259, 20260, 20261, 20262, 20263, 20264, 20265, 20266, 20267, 20268, 20269 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1300.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20270, 20271, 20272, 20273, 20274, 20275, 20276, 20277, 20278, 20279, 20280 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1301.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20281, 20282, 20283, 20284, 20285, 20286, 20287, 20288, 20289, 20290, 20291 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1302.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20292, 20293, 20294, 20295, 20296, 20297, 20298, 20299, 20300, 20301, 20302 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1303.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20303, 20304, 20305, 20306, 20307, 20308, 20309, 20310, 20311, 20312, 20313 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1304.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20314, 20315, 20316, 20317, 20318, 20319, 20320, 20321, 20322, 20323, 20324 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1305.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20325, 20326, 20327, 20328, 20329, 20330, 20331, 20332, 20333, 20334, 20335 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1306.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20336, 20337, 20338, 20339, 20340, 20341, 20342, 20343, 20344, 20345, 20346 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1307.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20347, 20348, 20349, 20350, 20351, 20352, 20353, 20354, 20355, 20356, 20357 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1308.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20358, 20359, 20360, 20361, 20362, 20363, 20364, 20365, 20366, 20367, 20368 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1309.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20369, 20370, 20371, 20372, 20373, 20374, 20375, 20376, 20377, 20378, 20379 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1310.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20380, 20381, 20382, 20383, 20384, 20385, 20386, 20387, 20388, 20389, 20390 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1311.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20391, 20392, 20393, 20394, 20395, 20396, 20397, 20398, 20399, 20400, 20401 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1312.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20402, 20403, 20404, 20405, 20406, 20407, 20408, 20409, 20410, 20411, 20412 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1313.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20413, 20414, 20415, 20416, 20417, 20418, 20419, 20420, 20421, 20422, 20423 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1314.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20424, 20425, 20426, 20427, 20428, 20429, 20430, 20431, 20432, 20433, 20434 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1315.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20435, 20436, 20437, 20438, 20439, 20440, 20441, 20442, 20443, 20444, 20445 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1316.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20446, 20447, 20448, 20449, 20450, 20451, 20452, 20453, 20454, 20455, 20456 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1317.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20457, 20458, 20459, 20460, 20461, 20462, 20463, 20464, 20465, 20466, 20467 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1318.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20468, 20469, 20470, 20471, 20472, 20473, 20474, 20475, 20476, 20477, 20478 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1319.

The probes having the nucleotide sequence represented by SEQ II) NOS: 20479, 20480, 20481, 20482, 20483, 20484, 20485, 20486, 20487, 20488, 20489 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1320.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20490, 20491, 20492, 20493, 20494, 20495, 20496, 20497, 20498, 20499, 20500 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1321.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20501, 20502, 20503, 20504, 20505, 20506, 20507, 20508, 20509, 20510, 20511 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1322.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20512, 20513, 20514, 20515, 20516, 20517, 20518, 20519, 20520, 20521, 20522 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1323.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20523, 20524, 20525, 20526, 20527, 20528, 20529, 20530, 20531, 20532, 20533 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1324.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20534, 20535, 20536, 20537, 20538, 20539, 20540, 20541, 20542, 20543, 20544 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1325.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20545, 20546, 20547, 20548, 20549, 20550, 20551, 20552, 20553, 20554, 20555 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1326.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20556, 20557, 20558, 20559, 20560, 20561, 20562, 20563, 20564, 20565, 20566 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1327.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20567, 20568, 20569, 20570, 20571, 20572, 20573, 20574, 20575, 20576, 20577 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1328.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20578, 20579, 20580, 20581, 20582, 20583, 20584, 20585, 20586, 20587, 20588 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1329.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20589, 20590, 20591, 20592, 20593, 20594, 20595, 20596, 20597, 20598, 20599 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1330.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20600, 20601, 20602, 20603, 20604, 20605, 20606, 20607, 20608, 20609, 20610 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1331.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20611, 20612, 20613, 20614, 20615, 20616, 20617, 20618, 20619, 20620, 20621 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1332.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20622, 20623, 20624, 20625, 20626, 20627, 20628, 20629, 20630, 20631, 20632 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1333.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20633, 20634, 20635, 20636, 20637, 20638, 20639, 20640, 20641, 20642, 20643 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1334.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20644, 20645, 20646, 20647, 20648, 20649, 20650, 20651, 20652, 20653, 20654 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1335.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20655, 20656, 20657, 20658, 20659, 20660, 20661, 20662, 20663, 20664, 20665 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1336.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20666, 20667, 20668, 20669, 20670, 20671, 20672, 20673, 20674, 20675, 20676 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1337.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20677, 20678, 20679, 20680, 20681, 20682, 20683, 20684, 20685, 20686, 20687 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1338.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20688, 20689, 20690, 20691, 20692, 20693, 20694, 20695, 20696, 20697, 20698 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1339.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20699, 20700, 20701, 20702, 20703, 20704, 20705, 20706, 20707, 20708, 20709 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1340.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20710, 20711, 20712, 20713, 20714, 20715, 20716, 20717, 20718, 20719, 20720 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1341.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20721, 20722, 20723, 20724, 20725, 20726, 20727, 20728, 20729, 20730, 20731 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1342.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20732, 20733, 20734, 20735, 20736, 20737, 20738, 20739, 20740, 20741, 20742 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1343.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20743, 20744, 20745, 20746, 20747, 20748, 20749, 20750, 20751, 20752, 20753 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1344.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20754, 20755, 20756, 20757, 20758, 20759, 20760, 20761, 20762, 20763, 20764 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1345.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20765, 20766, 20767, 20768, 20769, 20770, 20771, 20772, 20773, 20774, 20775 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1346.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20776, 20777, 20778, 20779, 20780, 20781, 20782, 20783, 20784, 20785, 20786 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1347.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20787, 20788, 20789, 20790, 20791, 20792, 20793, 20794, 20795, 20796, 20797 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1348.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20798, 20799, 20800, 20801, 20802, 20803, 20804, 20805, 20806, 20807, 20808 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1349.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20809, 20810, 20811, 20812, 20813, 20814, 20815, 20816, 20817, 20818, 20819 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1350.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20820, 20821, 20822, 20823, 20824, 20825, 20826, 20827, 20828, 20829, 20830 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1351.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20831, 20832, 20833, 20834, 20835, 20836, 20837, 20838, 20839, 20840, 20841 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1352.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20842, 20843, 20844, 20845, 20846, 20847, 20848, 20849, 20850, 20851, 20852 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1353.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20853, 20854, 20855, 20856, 20857, 20858, 20859, 20860, 20861, 20862, 20863 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1354.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20864, 20865, 20866, 20867, 20868, 20869, 20870, 20871, 20872, 20873, 20874 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1355.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20875, 20876, 20877, 20878, 20879, 20880, 20881, 20882, 20883, 20884, 20885 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1356.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20886, 20887, 20888, 20889, 20890, 20891, 20892, 20893, 20894, 20895, 20896 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1357.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20897, 20898, 20899, 20900, 20901, 20902, 20903, 20904, 20905, 20906, 20907 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1358.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20908, 20909, 20910, 20911, 20912, 20913, 20914, 20915, 20916, 20917, 20918 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1359.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20919, 20920, 20921, 20922, 20923, 20924, 20925, 20926, 20927, 20928, 20929 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1360.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20930, 20931, 20932, 20933, 20934, 20935, 20936, 20937, 20938, 20939, 20940 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1361.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20941, 20942, 20943, 20944, 20945, 20946, 20947, 20948, 20949, 20950, 20951 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1362.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20952, 20953, 20954, 20955, 20956, 20957, 20958, 20959, 20960, 20961, 20962 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1363.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20963, 20964, 20965, 20966, 20967, 20968, 20969, 20970, 20971, 20972, 20973 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1364.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20974, 20975, 20976, 20977, 20978, 20979, 20980, 20981, 20982, 20983, 20984 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1365.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20985, 20986, 20987, 20988, 20989, 20990, 20991, 20992, 20993, 20994, 20995 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1366.

The probes having the nucleotide sequence represented by SEQ ID NOS: 20996, 20997, 20998, 20999, 21000, 21001, 21002, 21003, 21004, 21005, 21006 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1367.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21007, 21008, 21009, 21010, 21011, 21012, 21013, 21014, 21015, 21016, 21017 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1368.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21018, 21019, 21020, 21021, 21022, 21023, 21024, 21025, 21026, 21027, 21028 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1369.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21029, 21030, 21031, 21032, 21033, 21034, 21035, 21036, 21037, 21038, 21039 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1370.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21040, 21041, 21042, 21043, 21044, 21045, 21046, 21047, 21048, 21049, 21050 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1371.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21051, 21052, 21053, 21054,. 21055, 21056, 21057, 21058, 21059, 21060, 21061 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1372.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21062, 21063, 21064, 21065, 21066, 21067, 21068, 21069, 21070, 21071, 21072 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1373.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21073, 21074, 21075, 21076, 21077, 21078, 21079, 21080, 21081, 21082, 21083 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1374.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21084, 21085, 21086, 21087, 21088, 21089, 21090, 21091, 21092, 21093, 21094 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1375.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21095, 21096, 21097, 21098, 21099, 21100, 21101, 21102, 21103, 21104, 21105 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1376.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21106, 21107, 21108, 21109, 21110, 21111, 21112, 21113, 21114, 21115, 21116 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1377.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21117, 21118, 21119, 21120, 21121, 21122, 21123, 21124, 21125, 21126, 21127 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1378.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21128, 21129, 21130, 21131, 21132, 21133, 21134, 21135, 21136, 21137, 21138 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1379.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21139, 21140, 21141, 21142, 21143, 21144, 21145, 21146, 21147, 21148, 21149 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1380.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21150, 21151, 21152, 21153, 21154, 21155, 21156, 21157, 21158, 21159, 21160 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1381.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21161, 21162, 21163, 21164, 21165, 21166, 21167, 21168, 21169, 21170, 21171 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1382.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21172, 21173, 21174, 21175, 21176, 21177, 21178, 21179, 21180, 21181, 21182 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1383.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21183, 21184, 21185, 21186, 21187, 21188, 21189, 21190, 21191, 21192, 21193, 21194, 21195, 21196, 21197, 21198, 21199, 21200, 21201, 21202, 21203, 21204 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 1384.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21205, 21206, 21207, 21208, 21209, 21210, 21211, 21212, 21213, 21214, 21215 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1385.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21216, 21217, 21218, 21219, 21220, 21221, 21222, 21223, 21224, 21225, 21226 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1386.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21227, 21228, 21229, 21230, 21231, 21232, 21233, 21234, 21235, 21236, 21237 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1387.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21238, 21239, 21240, 21241, 21242, 21243, 21244, 21245, 21246, 21247, 21248 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1388.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21249, 21250, 21251, 21252, 21253, 21254, 21255, 21256, 21257, 21258, 21259 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1389.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21260, 21261, 21262, 21263, 21264, 21265, 21266, 21267, 21268, 21269, 21270=were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1390.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21271, 21272, 21273, 21274, 21275, 21276, 21277, 21278, 21279, 21280, 21281 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1391.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21282, 21283, 21284, 21285, 21286, 21287, 21288, 21289, 21290, 21291, 21292 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1392.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21293, 21294, 21295, 21296, 21297, 21298, 21299, 21300, 21301, 21302, 21303 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1393.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21304, 21305, 21306, 21307, 21308, 21309, 21310, 21311, 21312, 21313, 21314 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1394.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21315, 21316, 21317, 21318, 21319, 21320, 21321, 21322, 21323, 21324, 21325 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1395.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21326, 21327, 21328,' 21329, 21330, 21331, 21332, 21333, 21334, 21335, 21336 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1396.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21337, 21338, 21339, 21340, 21341, 21342, 21343, 21344, 21345, 21346, 21347 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1397.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21348, 21349, 21350, 21351, 21352, 21353, 21354, 21355, 21356, 21357, 21358 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1398.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21359, 21360, 21361, 21362, 21363, 21364, 21365, 21366, 21367, 21368, 21369 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1399.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21370, 21371, 21372, 21373, 21374, 21375, 21376, 21377, 21378, 21379, 21380 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1400.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21381, 21382, 21383, 21384, 21385, 21386, 21387, 21388, 21389, 21390, 21391 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1401.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21392, 21393, 21394, 21395, 21396, 21397, 21398, 21399, 21400, 21401, 21402 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1402.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21403, 21404, 21405, 21406, 21407, 21408, 21409, 21410, 21411, 21412, 21413 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1403.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21414, 21415, 21416, 21417, 21418, 21419, 21420, 21421, 21422, 21423, 21424 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1404.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21425, 21426, 21427, 21428, 21429, 21430, 21431, 21432, 21433, 21434, 21435 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1405.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21436, 21437, 21438, 21439, 21440, 21441, 21442, 21443, 21444, 21445, 21446 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1406.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21447, 21448, 21449, 21450, 21451, 21452, 21453, 21454, 21455, 21456, 21457 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1407.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21458, 21459, 21460, 21461, 21462, 21463, 21464, 21465, 21466, 21467, 21468 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1408.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21469, 21470, 21471, 21472, 21473, 21474, 21475, 21476, 21477, 21478, 21479 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1409.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21480, 21481, 21482, 21483, 21484, 21485, 21486, 21487, 21488, 21489, 21490 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1410.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21491, 21492, 21493, 21494, 21495, 21496, 21497, 21498, 21499, 21500, 21501 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1411.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21502, 21503, 21504, 21505, 21506, 21507, 21508, 21509, 21510, 21511, 21512 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1412.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21513, 21514, 21515, 21516, 21517, 21518, 21519, 21520, 21521, 21522, 21523 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1413.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21524, 21525, 21526, 21527, 21528, 21529, 21530, 21531, 21532, 21533, 21534 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1414.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21535, 21536, 21537, 21538, 21539, 21540, 21541, 21542, 21543, 21544, 21545 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1415.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21546, 21547, 21548, 21549, 21550, 21551, 21552, 21553, 21554, 21555, 21556 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1416.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21557, 21558, 21559, 21560, 21561, 21562, 21563, 21564, 21565, 21566, 21567 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1417.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21568, 21569, 21570, 21571, 21572, 21573, 21574, 21575, 21576, 21577, 21578 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1418.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21579, 21580, 21581, 21582, 21583, 21584, 21585, 21586, 21587, 21588, 21589 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1419.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21590, 21591, 21592, 21593, 21594, 21595, 21596, 21597, 21598, 21599, 21600 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1420.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21601, 21602, 21603, 21604, 21605, 21606, 21607, 21608, 21609, 21610, 21611 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1421.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21612, 21613, 21614, 21615, 21616, 21617, 21618, 21619, 21620, 21621, 21622 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1422.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21623, 21624, 21625, 21626, 21627, 21628, 21629, 21630, 21631, 21632, 21633 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1423.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21634, 21635, 21636, 21637, 21638, 21639, 21640, 21641, 21642, 21643, 21644 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1424.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21645, 21646, 21647, 21648, 21649, 21650, 21651, 21652, 21653, 21654, 21655 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1425.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21656, 21657, 21658, 21659, 21660, 21661, 21662, 21663, 21664, 21665, 21666 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1426.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21667, 21668, 21669, 21670, 21671, 21672, 21673, 21674, 21675, 21676, 21677 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1427.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21678, 21679, 21680, 21681, 21682, 21683, 21684, 21685, 21686, 21687, 21688 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1428.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21689, 21690, 21691, 21692, 21693, 21694, 21695, 21696, 21697, 21698, 21699 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1429.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21700, 21701, 21702, 21703, 21704, 21705, 21706, 21707, 21708, 21709, 21710 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1430.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21711, 21712, 21713, 21714, 21715, 21716, 21717, 21718, 21719, 21720, 21721 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1431.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21722, 21723, 21724, 21725, 21726, 21727, 21728, 21729, 21730, 21731, 21732 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1432.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21733, 21734, 21735, 21736, 21737, 21738, 21739, 21740, 21741, 21742, 21743 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1433.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21744, 21745, 21746, 21747, 21748, 21749, 21750, 21751, 21752, 21753, 21754 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1434.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21755, 21756, 21757, 21758, 21759, 21760,' 21761, 21762, 21763, 21764, 21765 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1435.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21766, 21767, 21768, 21769, 21770, 21771, 21772, 21773, 21774, 21775, 21776 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1436.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21777, 21778, 21779, 21780, 21781, 21782, 21783, 21784, 21785, 21786, 21787 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1437.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21788, 21789, 21790, 21791, 21792, 21793, 21794, 21795, 21796, 21797, 21798 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1438.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21799, 21800, 21801, 21802, 21803, 21804, 21805, 21806, 21807, 21808, 21809 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1439.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21810, 21811, 21812, 21813, 21814, 21815, 21816, 21817, 21818, 21819, 21820 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1440.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21821, 21822, 21823, 21824, 21825, 21826, 21827, 21828, 21829, 21830, 21831 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1441.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21832, 21833, 21834, 21835, 21836, 21837, 21838, 21839, 21840, 21841, 21842 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1442.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21843, 21844, 21845, 21846, 21847, 21848, 21849, 21850, 21851, 21852, 21853 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1443.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21854, 21855, 21856, 21857, 21858, 21859, 21860, 21861, 21862, 21863, 21864 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1444.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21865, 21866, 21867, 21868, 21869, 21870, 21871, 21872, 21873, 21874, 21875 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1445.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21876, 21877, 21878, 21879, 21880, 21881, 21882, 21883, 21884, 21885, 21886 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1446.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21887, 21888, 21889, 21890, 21891, 21892, 21893, 21894, 21895, 21896, 21897 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1447.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21898, 21899, 21900, 21901, 21902, 21903, 21904, 21905, 21906, 21907, 21908 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1448.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21909, 21910, 21911, 21912, 21913, 21914, 21915, 21916, 21917, 21918, 21919 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1449.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21920, 21921, 21922, 21923, 21924, 21925, 21926, 21927, 21928, 21929, 21930 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1450.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21931, 21932, 21933, 21934, 21935, 21936, 21937, 21938, 21939, 21940, 21941 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1451.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21942, 21943, 21944, 21945, 21946, 21947, 21948, 21949, 21950, 21951, 21952 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1452.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21953, 21954, 21955, 21956, 21957, 21958, 21959, 21960, 21961, 21962, 21963 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1453.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21964, 21965, 21966, 21967, 21968, 21969, 21970, 21971, 21972, 21973, 21974 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1454.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21975, 21976, 21977, 21978, 21979, 21980, 21981, 21982, 21983, 21984, 21985 were,selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1455.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21986, 21987, 21988, 21989, 21990, 21991, 21992, 21993, 21994, 21995, 21996 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1456.

The probes having the nucleotide sequence represented by SEQ ID NOS: 21997, 21998, 21999, 22000, 22001, 22002, 22003, 22004, 22005, 22006, 22007 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1457.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22008, 22009, 22010, 22011, 22012, 22013, 22014, 22015, 22016, 22017, 22018 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1458.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22019, 22020, 22021, 22022, 22023, 22024, 22025, 22026, 22027, 22028, 22029 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1459.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22030, 22031, 22032, 22033, 22034, 22035, 22036, 22037, 2'2038, 22039, 22040 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1460.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22041, 22042, 22043, 22044, 22045, 22046, 22047, 22048, 22049, 22050, 22051 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1461.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22052, 22053, 22054, 22055, 22056, 22057, 22058, 22059, 22060, 22061, 22062 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1462.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22063, 22064, 22065, 22066, 22067, 22068, 22069, 22070, 22071, 22072, 22073 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1463.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22074, 22075, 22076, 22077, 22078, 22079, 22080, 22081, 22082, 22083, 22084 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1464.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22085, 22086, 22087, 22088, 22089, 22090, 22091, 22092, 22093, 22094, 22095 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1465.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22096, 22097, 22098, 22099, 22100, 22101, 22102, 22103, 22104, 22105, 22106 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1466.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22107, 22108, 22109, 22110, 22111, 22112, 22113, 22114, 22115, 22116, 22117 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1467.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22118, 22119, 22120, 22121, 22122, 22123, 22124, 22125, 22126, 22127, 22128 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1468.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22129, 22130, 22131, 22132, 22133, 22134, 22135, 22136, 22137, 22138, 22139 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1469.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22140, 22141, 22142, 22143, 22144, 22145, 22146, 22147, 22148, 22149, 22150 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1470.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22151, 22152, 22153, 22154, 22155, 22156, 22157, 22158, 22159, 22160, 22161 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1471.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22162, 22163, 22164, 22165, 22166, 22167, 22168, 22169, 22170, 22171, 22172 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1472.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22173, 22174, 22175, 22176, 22177, 22178, 22179, 22180, 22181, 22182, 22183 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1473.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22184, 22185, 22186, 22187, 22188, 22189, 22190, 22191, 22192, 22193, 22194 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1474.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22195, 22196, 22197, 22198, 22199, 22200, 22201, 22202, 22203, 22204, 22205 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1475.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22206, 22207, 22208, 22209, 22210, 22211, 22212, 22213, 22214, 22215, 22216 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1476.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22217, 22218, 22219, 22220, 22221, 22222, 22223, 22224, 22225, 22226, 22227 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1477.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22228, 22229, 22230, 22231, 22232, 22233, 22234, 22235, 22236; 22237, 22238 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1478.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22239, 22240, 22241, 22242, 22243, 22244, 22245, 22246, 22247, 22248, 22249 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1479.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22250, 22251, 22252, 22253, 22254, 22255, 22256, 22257, 22258, 22259, 22260 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1480.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22261, 22262, 22263, 22264, 22265, 22266, 22267, 22268, 22269, 22270, 22271 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1481.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22272, 22273, 22274, 22275, 22276, 22277, 22278, 22279, 22280, 22281, 22282 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1482.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22283, 22284, 22285, 22286, 22287, 22288, 22289, 22290, 22291, 22292, 22293 were selected from the.
ORFs having the nucleotide sequence represented by SEQ ID
NO: 1483.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22294, 22295, 22296, 22297, 22298,.22299, 22300, 22301, 22302, 22303, 22304 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1484.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22305, 22306, 22307, 22308, 22309, 22310, 22311, 22312, 22313, 22314, 22315 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1485.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22316, 22317, 22318, 22319, 22320, 22321, 22322, 22323, 22324, 22325, 22326 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1486.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22327, 22328, 22329, 22330, 22331, 22332, 22333, 22334, 22335, 22336, 22337 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1487.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22338, 22339, 22340, 22341, 22342, 22343, 22344, 22345, 22346, 22347, 22348 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1488.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22349, 22350, 22351, 22352, 22353, 22354, 22355, 22356, 22357, 22358, 22359 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1489.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22360, 22361, 22362, 22363, 22364, 22365, 22366, 22367, 22368, 22369, 22370 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1490.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22371, 22372, 22373, 22374, 22375, 22376, 22377, 22378, 22379, 22380, 22381 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1491. 1 The probes having the nucleotide sequence represented by SEQ ID NOS: 22382, 22383, 22384, 22385, 22386, 22387, 22388, 22389, 22390, 22391, 22392 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1492.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22393, 22394, 22395, 22396, 22397, 22398, 22399, 22400, 22401, 22402, 22403 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1493.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22404, 22405, 22406, 22407, 22408, 22409, 22410, 22411, 22412, 22413, 22414 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1494.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22415, 22416, 22417, 22418, 22419, 22420, 22421, 22422, 22423, 22424, 22425 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1495.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22426, 22427, 22428, 22429, 22430, 22431, 22432, 22433, 22434, 22435, 22436 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1496.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22437, 22438, 22439, 22440, 22441, 22442, 22443, 22444, 22445, 22446, 22447 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1497.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22448, 22449, 22450, 22451, 22452, 22453, 22454, 22455, 22456, 22457, 22458 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1498.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22459, 22460, 22461, 22462, 22463, 22464, 22465, 22466, 22467, 22468, 22469 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1499.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22470, 22471, 22472, 22473, 22474, 22475, 22476, 22477, 22478, 22479, 22480 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1500.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22481, 22482, 22483, 22484, 22485, 22486, 22487, 22488, 22489, 22490, 22491 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1501.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22492, 22493, 22494, 22495, 22496, 22497, 22498, 22499, 22500, 22501, 22502 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1502.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22503, 22504, 22505, 22506, 22507, 22508, 22509, 22510, 22511, 22512, 22513 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1503.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22514, 22515, 22516, 22517, 22518, 22519, 22520, 22521, 22522, 22523, 22524 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1504.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22525, 22526, 22527, 22528, 22529, 22530, 22531, 22532, 22533, 22534, 22535 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1505.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22536, 22537, 22538, 22539, 22540, 22541, 22542, 22543, 22544, 22545, 22546 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1506.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22547, 22548, 22549, 22550, 22551, 22552, 22553, 22554, 22555, 22556, 22557 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1507.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22558, 22559, 22560, 22561, 22562, 22563, 22564, 22565, 22566, 22567, 22568 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1508.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22569, 22570, 22571, 22572, 22573, 22574, 22575, 22576, 22577, 22578, 22579 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1509.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22580, 22581, 22582, 22583, 22584, 22585, 22586, 22587, 22588, 22589, 22590 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1510.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22591, 22592, 22593, 22594, 22595, 22596, 22597, 22598, 22599, 22600, 22601 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1511.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22602, 22603, 22604, 22605, 22606, 22607, 22608, 22609, 22610, 22611, 22612 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1512.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22613, 22614, 22615, 22616, 22617, 22618, 22619, 22620, 22621, 22622, 22623 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1513.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22624, 22625, 22626, 22627, 22628, 22629, 22630, 22631, 22632, 22633, 22634 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1514.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22635, 22636, 22637, 22638, 22639, 22640, 22641, 22642, 22643, 22644, 22645 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1515.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22646, 22647, 22648, 22649, 22650, 22651, 22652, 22653, 22654, 22655, 22656 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1516.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22657, 22658, 22659, 22660, 22661, 22662, 22663, 22664, 22665, 22666, 22667 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1517.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22668, 22669, 22670, 22671, 22672, 22673, 22674, 22675, 22676, 22677, 22678 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1518.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22679, 22680, 22681, 22682, 22683, 22684, 22685, 22686, 22687, 22688, 22689 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1519.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22690, 22691, 22692, 22693, 22694, 22695, 22696, 22697, 22698, 22699, 22700 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1520.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22701, 22702, 22703, 22704, 22705, 22706, 22707, 22708, 22709, 22710, 22711 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1521.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22712, 22713, 22714, 22715, 22716, 22717, 22718, 22719, 22720, 22721, 22722 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1522.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22723, 22724, 22725, 22726, 22727, 22728, 22729, 22730, 22731, 22732, 22733 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1523.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22734, 22735, 22736, 22737, 22738, 22739, 22740, 22741, 22742, 22743, 22744 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1524.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22745, 22746, 22747, 22748, 22749, 22750, 22751, 22752, 22753, 22754, 22755 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1525.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22756, 22757, 22758, 22759, 22760, 22761, 22762, 22763, 22764, 22765, 22766 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1526.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22767, 22768, 22769, 22770, 22771, 22772, 22773, 22774, 22775, 22776, 22777 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1527.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22778, 22779, 22780, 22781, 22782, 22783, 22784, 22785, 22786, 22787, 22788 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1528.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22789, 22790, 22791, 22792, 22793, 22794, 22795, 22796, 22797, 22798, 22799 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1529.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22800, 22801, 22802, 22803, 22804, 22805, 22806, 22807, 22808, 22809, 22810 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1530.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22811, 22812, 22813, 22814, 22815, 22816, 22817, 22818, 22819, 22820, 22821 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1531.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22822, 22823, 22824, 22825, 22826, 22827, 22828, 22829, 22830, 22831, 22832 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1532.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22833, 22834, 22835, 22836, 22837, 22838, 22839, 22840, 22841, 22842, 22843 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1533.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22844, 22845, 22846, 22847, 22848, 22849, 22850, 22851, 22852, 22853, 22854 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1534.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22855, 22856, 22857, 22858, 22859, 22860, 22861, 22862, 22863, 22864, 22865 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1535.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22866, 22867, 22868, 22869, 22870, 22871, 22872, 22873, 22874, 22875, 22876 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1536.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22877, 22878, 22879, 22880, 22881, 22882, 22883, 22884, 22885, 22886, 22887 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1537.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22888, 22889, 22890, 22891, 22892, 22893, 22894, 22895, 22896, 22897, 22898 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1538.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22899, 22900, 22901, 22902, 22903, 22904, 22905, 22906, 22907, 22908, 22909 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1539.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22910, 22911, 22912, 22913, 22914, 22915, 22916, 22917, 22918, 22919, 22920 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1540.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22921, 22922, 22923, 22924, 22925, 22926, 22927, 22928, 22929, 22930, 22931 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1541.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22932, 22933, 22934, 22935, 22936, 22937, 22938, 22939, 22940, 22941, 22942 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1542.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22943, 22944, 22945, 22946, 22947, 22948, 22949, 22950, 22951, 22952, 22953 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1543.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22954, 22955, 22956, 22957, 22958, 22959, 22960, 22961, 22962, 22963, 22964 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1544.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22965, 22966, 22967, 22968, 22969, 22970, 22971, 22972, 22973, 22974, 22975 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1545.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22976, 22977, 22978, 22979, 22980, 22981, 22982, 22983, 22984, 22985, 22986 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1546.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22987, 22988, 22989, 22990, 22991, 22992, 22993, 22994, 22995, 22996, 22997 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1547.

The probes having the nucleotide sequence represented by SEQ ID NOS: 22998, 22999, 23000, 23001, 23002, 23003, 23004, 23005, 23006, 23007, 23008 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1548.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23009, 23010, 23011, 23012, 23013, 23014, 23015, 23016, 23017, 23018, 23019 were selected from the ORFs having the nucleotide sequence represented by SEQ ID, NO: 1549.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23020, 23021, 23022, 23023, 23024, 23025, 23026, 23027, 23028, 23029, 23030 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1550.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23031, 23032, 23033, 23034, 23035, 23036, 23037, 23038, 23039, 23040, 23041 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1551.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23042, 23043, 23044, 23045, 23046, 23047, 23048, 23049, 23050, 23051, 23052 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1552.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23053, 23054, 23055, 23056, 23057, 23058, 23059, 23060, 23061, 23062, 23063 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1553.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23064, 23065, 23066, 23067, 23068, 23069, 23070, 23071, 23072, 23073, 23074 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1554.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23075, 23076, 23077, 23078, 23079, 23080, 23081, 23082, 23083, 23084, 23085 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1555.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23086, 23087, 23088, 23089, 23090, 23091, 23092, 23093, 23094, 23095, 23096 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1556.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23097, 23098, 23099, 23100, 23101, 23102, 23103,~23104, 23105, 23106, 23107 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1557.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23108, 23109, 23110, 23111, 23112, 23113, 23114, 23115, 23116, 23117, 23118, 23119, 23120, 23121, 23122, 23123, 23124, 23125, 23126,-23127, 23128, 23129 were selected from the ORFs having the nucleotide sequence represented by SEQ ID NO: 1558.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23130, 23131, 23132, 23133, 23134, 23135, 23136, 23137, 23138, 23139, 23140 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1559.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23141, 23142, 23143, 23144, 23145, 23146, 23147, 23148, 23149, 23150, 23151 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1560.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23152, 23153, 23154, 23155, 23156, 23157, 23158, 23159, 23160, 23161, 23162 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1561.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23163, 23164, 23165, 23166, 23167, 23168, 23169, 23170, 23171, 23172, 23173 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1562.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23174, 23175, 23176, 23177, 23178, 23179, 23180, 23181, 23182, 23183, 23184 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1563.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23185, 23186, 23187, 23188, 23189, 23190, 23191, 23192, 23193, 23194, 23195 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1564.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23196, 23197, 23198, 23199, 23200, 23201, 23202, 23203, 23204, 23205, 23206 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1565.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23207, 23208, 23209, 23210, 23211, 23212, 23213, 23214, 23215, 23216, 23217 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1566.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23218, 23219, 23220, 23221, 23222, 23223, 23224, 23225, 23226, 23227, 23228 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1567.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23229, 23230, 23231, 23232, 23233, 23234, 23235, 23236, 23237, 23238, 23239 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1568.

The probes having the nucleotide sequence represented by SEQ ID NOS: 23240, 23241, 23242, 23243, 23244, 23245, 23246, 23247, 23248, 23249, 23250 were selected from the ORFs having the nucleotide sequence represented by SEQ ID
NO: 1569.

DEMANDE OU BREVET VOLUMINEUX

LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:

NOTE POUR LE TOME / VOLUME NOTE:

Claims (44)

1. A method for analyzing gene of an industrial yeast comprising (a) analyzing nucleotide sequence of the genome sequence of the industrial yeast; and (c-1) selecting a gene of the industrial yeast encoding an amino acid sequence having 70 to 97% identity to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or (c-2) selecting a gene of the industrial yeast consisting of a nucleotide sequence having 60 to 94%
identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae.
2. The analyzing method according to Claim 1, comprising, (b) comparing the genome sequence of the industrial yeast with the genome sequence of Saccharomyces cerevisiae after the step (a) and before the step (c-1) or (c-2).
3. The analyzing method according to Claim 1 or 2, comprising (d) carrying out functional analysis of the selected gene after the step (c-1) or (c-2).
4. The analyzing method according to Claim 3, which comprises screening genes involved in increase of productivity and/or improvement in flavor in the production of an alcohol or an alcoholic beverage by the functional analysis of the step (d).
5. The analyzing method according to Claim 3 or 4, wherein the functional analysis is performed by disruption of a gene or overexpression of a gene.
6. The analyzing method according to any of Claims 1-5, wherein the industrial yeast is a brewing yeast.
7. The analyzing method according to Claim 6, wherein the brewing yeast is a beer yeast.
8. The analyzing method according to Claim 7, wherein the beer yeast is a bottom fermenting yeast.
9. A gene of the industrial yeast encoding an amino acid sequence having 70 to 97% identity to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or consisting of a nucleotide sequence having 60 to 94%
identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae, which is obtained by the analyzing method according to any one of Claims 1-8.
10. A gene library comprising one or more of genes of the industrial yeast each of which encodes an amino acid sequence having 70 to 97% identity to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or consists of a nucleotide sequence having 60 to 94%
identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae, which is obtained by the analyzing method according to any one of Claims 1-8.
11. The gene library according to Claim 10, wherein the gene of the industrial yeast is comprised in, consists of or has any nucleotide sequence selected from SEQ ID
NOs:33 to 6236, SEQ ID NOs:166154 to 166181, SEQ ID
NOs:166490 to 167042 and SEQ ID NOs:173125 to 174603.
12. A DNA array comprising one or more of DNAs, wherein each DNA is selected from at least one group of (1) to (4):

(1) DNA consisting of a nucleotide sequence of an open reading frame of the genome sequence of an industrial yeast which encodes an amino acid sequence having 70 to 97%
identity to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or a nucleotide sequence complementary to the above nucleotide sequence, or a nucleotide sequence of continuous 10 or more nucleotides selected from the above nucleotide sequences;

(2) DNA consisting of a nucleotide sequence of the genome sequence of an industrial yeast other than from open reading frames which consists of a nucleotide sequence having 60 to 94% identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae, or a nucleotide sequence complementary to the above nucleotide sequence, or a nucleotide sequence of continuous 10 or more nucleotides selected from the above nucleotide sequences;

(3) DNA having a nucleotide sequence of any of SEQ ID
NOs:166490 to 167042, or DNA having a nucleotide sequence of any of SEQ ID NOs:167043 to 173124;and (4) DNA having a nucleotide sequence of any of SEQ ID
NOs:173125 to 174603, or DNA having a nucleotide sequence of any of SEQ ID NOs:174604 to 190810.
13. The DNA array according to Claim 12 comprising DNAs wherein at least one DNA is selected from every group of (1) to (4).
14. The DNA array according to Claim 12 or 13, wherein the DNAs of (1) is comprised in, consists of or has any nucleotide sequence selected from SEQ ID NOs:33 to 6236, SEQ ID NOs:166154 to 166181, SEQ ID NOs:6237 to 75336 and SEQ ID NOs:166182 to 166489.
15. The DNA array according to any one of Claims 12-14, which further comprises, in addition to at least one group of DNAs selected from (1) to (4), DNAs of the following (5) and/or (6),:

(5) DNA consisting of a nucleotide sequence of an open reading frame of the genome sequence of an industrial yeast which encodes an amino acid sequence having identity of more than 97% to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or a nucleotide sequence complementary to the above nucleotide sequence, or a nucleotide sequence of continuous 10 or more nucleotides selected from the above nucleotide sequences; and (6) DNA consisting of a nucleotide sequence of the genome sequence of an industrial yeast other than from open reading frames which consists of a nucleotide sequence having identity of more than 94% to the nucleotide sequence of the gene of Saccharomyces cerevisiae, or a nucleotide sequence complementary to the above nucleotide sequence, or a nucleotide sequence of continuous 10 or more nucleotides selected from the above nucleotide sequences, and optionally comprises DNAs of the following (5') and/or (6'):

(5') DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (5), or a nucleotide sequence complementary to the above nucleotide sequence; and (6') DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (6), or a nucleotide sequence complementary to the above nucleotide sequence.
16. The DNA array according to Claim 15, wherein the DNAs of (5) has a nucleotide sequence of any one of SEQ ID
NOs:75337 to 82784, or SEQ ID NOs:82785 to 166153.
17. The DNA array according to any one of Claims 12-16, which comprises, in addition to at least one group of DNAs selected from (1) to (4), DNAs selected from at least one of (7) to (10):

(7) DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (1), or a nucleotide sequence complementary to the above nucleotide sequence;

(8) DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (2), or a nucleotide sequence complementary to the above nucleotide sequence;

(9) DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (3), or a nucleotide sequence complementary to the above nucleotide sequence; and (10) DNA consisting of a nucleotide sequence which contains mismatch of 1 or more base(s) to the DNA of (4), or a nucleotide sequence complementary to the above nucleotide sequence.
18. The DNA array according to Claim 17, which comprises, in addition to at least one group of DNAs selected from (1) to (4), DNAs selected from at least one of (7-1) to (10-1):

(7-1) DNA consisting of a nucleotide sequence which contains mismatch of 1 base to the DNA of (1), or a nucleotide sequence complementary to the above nucleotide sequence;

(8-1) DNA consisting of a nucleotide sequence which contains mismatch of 1 base to the DNA of (2), or a nucleotide sequence complementary to the above nucleotide sequence;

(9-1) DNA consisting of a nucleotide sequence which contains mismatch of 1 base to the DNA of (3), or a nucleotide sequence complementary to the above nucleotide sequence; and (10-1) DNA consisting of a nucleotide sequence which contains mismatch of 1 base to the DNA of (4), or a nucleotide sequence complementary to the above nucleotide sequence.
19. The DNA array according to any one of Claims 12-18, which comprises at least one group of DNAs selected from (1) to (4), at least one group of DNAs selected from (7) to (10), DNAs of (5) and/or (6) and DNAs of (5') and/or (6').
20. The DNA array according to any one of Claims 12-19, wherein the DNAs are oligonucleotides consisting of 10-30 nucleotides.
21. Use of the DNA array according to any one of Claims 12-20 for an analyzing method of genes of an industrial yeast.
22. A method for classifying an industrial yeast comprising (a) hybridizing genomic DNA prepared from the industrial yeast to the DNA array of any one of Claims 15-20; and (b) calculating hybridization ratio to any of (1) to (4), and hybridization ratio to (5) and/or (6).
23. The method for classification according to Claim 22, wherein the DNA array of Claim 19 is used, and percentage of genes which hybridize to DNAs of (1) and/or (2), but not to DNAs of (7) and/or (8) is determined as hybridization ratio to any of (1) to (4), and percentage of genes which hybridize to DNAs of (5) and/or (6), but not to DNAs of (5') and/or (6') is determined as-hybridization ratio to any of (5) and/or (6).
24. A method for detecting nucleotide polymorphism in genome of an industrial yeast comprising (a) hybridizing genomic DNA prepared from the industrial yeast to the DNA array of any one of Claims 17-20; and (b) selecting a gene wherein hybridization intensity to the DNAs of any of (7) to (10) is higher than hybridization intensity to the DNAs of any of (1) to (4).
25. A method for screening a useful strain of industrial yeast, comprising (a) hybridizing genomic DNA prepared from the industrial yeast strain to the DNA array of any one of Claims 12-20;
and (b) determining the industrial yeast strain as useful when the strain contain 1 or more genes wherein hybridization intensity thereof is 1.5 times higher, or 2/3 or less compared to an average hybridization intensity to the DNAs of any of (1) to (4).
26. A method for screening a gene of an industrial yeast, comprising (a) hybridizing genomic DNA prepared from the industrial yeast strain to the DNA array of any one of Claims 12-20;
and (b) selecting a gene wherein hybridization intensity thereof is 1.5 times higher, or 2/3 or less compared to an average hybridization intensity to the DNAs of any of (1) to (4).
27. A method for screening a gene of an industrial yeast, comprising (a-1) hybridizing genomic DNA, cDNA or cRNA prepared from the industrial yeast to the DNA array of any one of Claims 12-20;

(a-2) independently from the step (a-1), hybridizing genomic DNA, cDNA or cRNA prepared from another indystrial yeast to the DNA array of any one of Claims 12-20; and (b) selecting a gene wherein hybridization intensity thereof to the DNAs of any of (1) to (4) at the step (a-1) is significantly different from hybridization intensity thereof at the step (a-2).
28. A method for screening a gene of an industrial yeast, comprising (a-1) hybridizing cDNA or cRNA prepared from the industrial yeast to the DNA array of any one of Claims 12-20;

(a-2) independently from the step (a-1), hybridizing cDNA
or cRNA prepared from the industrial yeast to the DNA array of any one of Claims 12-20, wherein the industrial yeast of (a-2) has been cultured in a different condition from the culture condition for the industrial yeast of (a-1); and (b) selecting a gene wherein hybridization intensity thereof to the DNAs of any of (1) to (4) at the step (a-1) is significantly different from hybridization intensity thereof at the step (a-2).
29. A gene obtained by the screening method of any one of Claims 26-28.
30. The gene according to Claim 9 or 29 characterized in that concentration of sulfite in a culture medium of an industrial yeast increases when the gene is expressed in the yeast.
31. A nucleic acid encoding a polypeptide of any one of the following i) and ii):

i) a polypeptide having the amino acid sequence represented by SEQ ID NO:3, and ii) a polypeptide having an amino acid sequence wherein one or more amino acid residue(s) is deleted from, substituted for and/or added to the amino acid sequence represented by SEQ ID NO:3, and having an activity to increase concentration of sulfite in a culture medium of an industrial yeast when the gene is expressed in the yeast.
32. The nucleic acid according to Claim 31, which is selected from the following a) and b):

(a) a nucleic acid having the nucleotide sequence represented by SEQ ID NO:1; and (b) a nucleic acid having a nucleotide sequence which hybridizes to the nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:1 under a stringent condition, and encodes a polypeptide having an activity to increase concentration of sulfite in a culture medium of an industrial yeast when the gene is expressed in the yeast.
33. A recombinant vector containing the gene of Claim 9 or Claims 29-30, or the nucleic acid of Claims 31-32.
34. A transformant comprising the recombinant vector of Claim 33.
35. The transformant according to Claim 34, which is a yeast of genus Saccharomyces.
36. A polypeptide of any one of the following i) and ii):

I) a polypeptide having the amino acid sequence represented by SEQ ID NO:3; and ii) a polypaptide having an amino acid sequence wherein one or more amino acid residue(s) is deleted from, substituted for and/or added to the amino acid sequence represented by SEQ ID N:3, and having an activity to increase concentration of sulfite in a culture medium of an industrial yeast when the gene is expressed in the yeast.
37. The polypeptide according to Claim 36, which is encoded by a nucleic acid selected from the following a) and b):

(a) a nucleic acid having the nucleotide sequence represented by SEQ ID NO:1; and (b) a nucleic acid having a nucleotide sequence which hybridizes to the nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID No.1 under a stringent condition, and encodes a polypeptide having an activity to increase concentration of sulfite in a culture medium of an industrial yeast when the gene is expressed in the yeast.
38. A method for producing an alcohol or an alcoholic beverage, using the transformant of Claim 34 or 35.
39. A breeding method of yeast which is suitable for the production of an alcohol or an alcoholic beverage, characterized in that, expression of the gene of Claim 9 or Claims 29-30, or the nucleic acid of Claim 31-32 is controlled.
40. The breeding method according to Claim 39, wherein the yeast belongs to the genus Saccharomyces.
41. Yeast obtained by the breeding method of Claim 39 or 40.
42. A method for producing an alcohol or an alcoholic beverage using the yeast mentioned in Claim 41.
43. An alcohol or an alcoholic beverage which is produced by the producing method of Claim 42.
44. A method for analyzing gene of an industrial yeast comprising (c-1) selecting a gene of the industrial yeast encoding an amino acid sequence having 70 to 97% identity to an amino acid sequence encoded by the gene of Saccharomyces cerevisiae, or (c-2) selecting a gene of the industrial yeast consisting of a nucleotide sequence having 60 to 94%
identity to the nucleotide sequence of the gene of Saccharomyces cerevisiae.
CA002621202A 2004-09-02 2005-08-30 Method for analyzing genes of industrial yeasts Abandoned CA2621202A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2004/002873 2004-09-02
PCT/IB2004/002873 WO2006024892A1 (en) 2004-09-02 2004-09-02 Method for analyzing genes of industrial yeasts
PCT/IB2005/002908 WO2006024951A2 (en) 2004-09-02 2005-08-30 Method for analyzing genes of industrial yeasts

Publications (1)

Publication Number Publication Date
CA2621202A1 true CA2621202A1 (en) 2006-03-09

Family

ID=34958564

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002621202A Abandoned CA2621202A1 (en) 2004-09-02 2005-08-30 Method for analyzing genes of industrial yeasts

Country Status (7)

Country Link
EP (1) EP1784507A2 (en)
JP (1) JP2008511305A (en)
KR (1) KR20070083594A (en)
CN (1) CN101052729B (en)
AU (1) AU2005278901A1 (en)
CA (1) CA2621202A1 (en)
WO (2) WO2006024892A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007099692A1 (en) * 2006-02-28 2007-09-07 Suntory Limited Catalase gene and use thereof
AU2006289718B2 (en) * 2004-09-02 2010-12-23 Suntory Holdings Limited Branched-chain amino acid aminotransferase gene and use thereof
WO2007020989A1 (en) * 2005-08-12 2007-02-22 Suntory Limited Sulfate adenyltransferase gene and use thereof
AU2006285606A1 (en) * 2005-09-01 2007-03-08 Suntory Holdings Limited Tryptophan transporter gene and use thereof
JP2007228956A (en) * 2006-02-28 2007-09-13 Suntory Ltd Method for identifying useful protein originated from yeast for brewing
JP5218949B2 (en) * 2006-10-18 2013-06-26 国立大学法人名古屋大学 D-serine dehydratase and use thereof
JP5158944B2 (en) * 2007-03-02 2013-03-06 アサヒビール株式会社 Yeast strain analysis by yeast genome analysis
ES2464740T3 (en) 2009-06-01 2014-06-03 Amyris, Inc. Method to generate a genetically modified microbe
EP2438157A1 (en) * 2009-06-01 2012-04-11 Amyris, Inc. Genetically modified microbes producing isoprenoids
US9487838B2 (en) 2010-12-28 2016-11-08 Qiagen Hamburg Gmbh Oligonucleotide probe for the detection of adenovirus
WO2015002916A1 (en) * 2013-07-03 2015-01-08 Butamax Advanced Biofuels Llc Post-transcriptional regulation of biosynthetic pathways
JP7113682B2 (en) * 2017-08-25 2022-08-05 サントリーホールディングス株式会社 Method for improving yeast sulfite production ability
CN117126898B (en) * 2023-10-26 2023-12-22 内蒙古阜丰生物科技有限公司 Process for preparing valine by biotechnology

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2518046C (en) * 2003-03-04 2013-12-10 Suntory Limited Screening method for genes of brewing yeast

Also Published As

Publication number Publication date
AU2005278901A1 (en) 2006-03-09
EP1784507A2 (en) 2007-05-16
WO2006024951A3 (en) 2006-06-22
WO2006024892A1 (en) 2006-03-09
KR20070083594A (en) 2007-08-24
CN101052729A (en) 2007-10-10
WO2006024951A2 (en) 2006-03-09
JP2008511305A (en) 2008-04-17
CN101052729B (en) 2011-09-14

Similar Documents

Publication Publication Date Title
US7365164B2 (en) Screening method for genes of brewing yeast
US20060046253A1 (en) Method for analyzing genes of industrial yeasts
CA2621202A1 (en) Method for analyzing genes of industrial yeasts
JP4537094B2 (en) Screening method for yeast genes for brewing
Magalhaes et al. Maltose and maltotriose utilisation by group I strains of the hybrid lager yeast Saccharomyces pastorianus
Dietvorst et al. Maltotriose utilization in lager yeast strains: MTT1 encodes a maltotriose transporter
US6248519B1 (en) Detection of fermentation-related microorganisms
Vidgren et al. Characterization and functional analysis of the MAL and MPH loci for maltose utilization in some ale and lager yeast strains
Monerawela et al. Loss of lager specific genes and subtelomeric regions define two different Saccharomyces cerevisiae lineages for Saccharomyces pastorianus Group I and II strains
Hauser et al. Whole genome analysis of a wine yeast strain
Katou et al. QTL mapping of sake brewing characteristics of yeast
US20060099612A1 (en) Method for analyzing genes of industrial yeasts
Den Abt et al. Genomic saturation mutagenesis and polygenic analysis identify novel yeast genes affecting ethyl acetate production, a non-selectable polygenic trait
EP2132318B1 (en) Compositions and methods for reducing h2s levels in fermented beverages
AU2009275655A1 (en) Novel methods of differentiating yeast strains and/or determining genetic stability of yeast strains, and uses thereof
Kimura et al. Polymorphism of the MPR1 gene required for toxic proline analogue resistance in the Saccharomyces cerevisiae complex species
Sampaio et al. Taxonomy, diversity, and typing of brewing yeasts
CN108913755B (en) Multiple primers, kit and detection method for detecting fermentation conditions affecting expression quantity of saccharomyces cerevisiae protease A gene
Blondin et al. Genome of Saccharomyces cerevisiae and related yeasts
Mendes-Ferreira et al. Functional genomics in wine yeast: DNA arrays and next generation sequencing
CA2599862C (en) Dna array and method for analysis of gene expression of brewing yeast
Class et al. Patent application title: YEAST ALLELES INVOLVED IN MAXIMAL ALCOHOL ACCUMULATION CAPACITY AND TOLERANCE TO HIGH ALCOHOL LEVELS Inventors: Johan Thevelein (Blanden, BE) Annelies Goovaerts (Putte, BE) Françoise Dumortier (Blanden, BE) Maria Remedios Foulquie-Moreno (Brussel, BE) Steve Swinnen (Zichem, BE) Thiago Martins Pais (Sinop, BR)
Pérez-Ortín et al. DNA arrays
Martínez genomics and transcriptomics in

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130607